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Abstract 
Duchenne muscular dystrophy (DMD) is a genetic disease that occurs in males due 
to the absence of the dystrophin (427 kDa) protein. Patients have severe skeletal 
muscle weakness that extends to the striated muscles of breathing. Maximal 
inspiratory pressures are low in DMD and the diaphragm is severely compromised. 
Respiratory disturbances occur in patients, particularly during sleep, such as apnoea 
and hypoventilation. Comprehensive studies on the control of breathing in DMD 
and animal models of the dystrophinopathies are lacking. We examined the 
integrated respiratory control system in a pre-clinical model of DMD – the mdx 
mouse. Since inflammation is a major pathological feature of DMD, we assessed the 
potential of a combined anti-inflammatory and anti-stress interventional strategy in 
ameliorating respiratory deficits in mdx mice.  
 
Young (8-week-old) wild-type and mdx mice were studied. We assessed ventilation 
and metabolism during normoxia and in response to physiological gas challenges. 
Respiratory stability and ventilatory capacity were determined. Diaphragm EMG 
activity and inspiratory pressure generating capacity was examined in 
anaesthetised spontaneously breathing mice in vivo. Diaphragm muscle structure 
and force-generating capacity were assessed. Carotid body afferent activity was 
determined ex vivo. Monoamine concentrations, density of activated astrocytes 
and microglia, and pro-inflammatory gene expression was determined in the spinal 
cord (C3-C5), containing the phrenic motor nucleus. Interventional studies 
consisted of a combinational treatment of a neutralizing interleukin-6-receptor (xIL-
6R) antibody and urocortin 2 (Ucn2, corticotrophin releasing factor receptor 2 
agonist), or saline for 2 weeks. Following treatment, ventilation and metabolism, as 
well as diaphragm and upper airway (sternohyoid) muscle form and function, and 
inflammatory status were determined. 
 
During normoxia, mdx mice hypoventilated (decreased ventilatory equivalent for 
carbon dioxide), due to decreased tidal volume with no evidence of perturbed 
respiratory rhythm. Carotid sinus nerve responses to hyperoxia were blunted in 
mdx, suggesting hypoactivity (sensory deficit). Mdx mice retained a remarkable 
 xiv 
capacity to increase ventilation during hypercapnic hypoxic breathing despite 
profound diaphragm muscle weakness and major structural remodelling. Peak 
inspiratory oesophageal pressure generation was preserved during basal breathing 
and was greater during augmented breaths in mdx compared to wild-type mice, 
probably due to recruitment of accessory muscles of breathing. EMG recordings 
assessing neural drive to the diaphragm in anaesthetised vagotomised mice, 
revealed enhanced neural drive to the diaphragm in mdx mice during 
chemoactivation (near maximal drive) compared with wild-type. Monoamine 
concentrations were elevated in the C3-C5 spinal cord of mdx mice, and the density 
of activated immune cells and pro-inflammatory gene expression was unchanged, 
indicating no evidence of neuroinflammation. xIL-6R and Ucn2 co-treatment in mdx 
mice completely restored ventilation during normoxia and significantly improved 
diaphragm and sternohyoid muscle force- and power-generating capacity. 
Combinational therapy restored myosin heavy chain complement in diaphragm and 
sternohyoid muscles.  
 
We conclude that respiratory control is altered in young mdx mice, such that 
considerable deficits arising from dystrophin lack are adequately compensated, 
limiting ventilatory deficits. We reason that compensatory neuroplasticity in 
accessory motor pathways preserves ventilatory capacity in mdx mice despite 
profound diaphragm muscle weakness. Interventional studies indicate that 
strategies aimed at preserving muscle fibre complement and promoting muscle 
fibre quality in mdx respiratory muscles can alleviate breathing and muscle 
functional deficits. These data may have relevance to the development of 
interventional strategies designed to alleviate respiratory dysfunction in the human 
dystrophinopathies. 
 
 
 1 
Chapter 1. The control of breathing in Duchenne muscular 
dystrophy 
 
  
 2 
Abbreviations: AHI, apnoea-hypopnoea index; ATP, adenosine triphosphate; BDNF, 
brain-derived neurotrophic factor; CIAP, cellular inhibitor of apoptosis; CNS, central 
nervous system; CRF, corticotrophin-releasing factor; CRFR, CRF-receptor; CO2, carbon 
dioxide; DAPC, dystrophin associated protein complex; DGC, dystrophin-glycoprotein 
complex; DMD, Duchenne muscular dystrophy; FEV1, forced expired volume in one 
second; FVC, forced vital capacity; GRMD, golden retriever model of muscular 
dystrophy; gp130, glycoprotein 130; IL, interleukin; IL-6R, IL-6-receptor; xIL-6R, 
neutralising IL-6R; MyHC, myosin heavy chain; MRI, magnetic resonance imaging; NIV, 
non-invasive ventilation; NIPPV, non-invasive positive pressure ventilation; NSAID, non-
steroidal anti-inflammatory drug; NTS, nucleus tractus solitarius; OSA, obstructive sleep 
apnoea; PaCO2, partial pressure of arterial CO2; Pdi, trans-diaphragmatic pressure; 
PEEP, positive end expiratory pressure; Pgas, gastric pressure; PO2, partial pressure of 
oxygen; Poes, oesophageal pressure; REM, rapid eye movement; SDB, sleep-disordered 
breathing; TALENS, transcript activator-like effector nuclease; TNF-D, tumour necrosis 
factor-alpha. 
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1.1 Control of breathing in neuromuscular disease 
 
1.1.1 The control of breathing  
Breathing is an active neuro-mechanical process essential for life. Adequate ventilation 
is required to maintain blood oxygenation levels to facilitate the metabolic demands of 
the body. The respiratory system is an integrated system involving a number of 
components including the central nervous system (CNS), motor nerves, skeletal 
musculature and the lungs and conducting airways. The function of the respiratory 
control network is to maintain respiratory homeostasis in response to physiological 
perturbations, which occur in health and disease. Respiratory insufficiency or failure 
can result from inadequate gas exchange by the respiratory system due to major 
deficits at one or more sites of the respiratory control network. 
 
1.1.1.1 The neural control of breathing 
Breathing is a state-dependent process consisting of an inspiratory phase which 
involves active contraction of the respiratory pump muscles (diaphragm and external 
intercostal muscles) followed by a passive expiratory phase. A third phase, termed 
post-inspiration, is also evident, characterised by lengthening contraction of the 
diaphragm and adduction of the laryngeal muscles, which slows expiratory airflow (Del 
Negro et al., 2018). Expiration can have an active component (active expiration) under 
certain conditions (e.g. during exercise), in which the abdominal and internal 
intercostal muscles are recruited to facilitate ventilation. The central drive to breathe 
originates from distinct sites within the brainstem where central pattern is generated 
by a complex diffuse neural network, originating from the rhythm-generating sites of 
the pre-Bötzinger complex and the parafacial respiratory group (Feldman & Del Negro, 
2006; Smith et al., 2009; Feldman et al., 2013). Neurons found in the pre- Bötzinger 
complex display activity in phase with inspiration. Neuronal axons from this complex 
project to motor neurons which innervate respiratory pump and airway resistance 
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muscles, in addition to other ponto-medullary and supra-pontine sites (Del Negro et 
al., 2018).  
 
The end effectors of breathing are the respiratory pump muscles. The phrenic motor 
nucleus is located in the ventral horn of the cervical spinal cord and contains a 
heterogeneous group of motor neurons which provide efferent motor input to the 
diaphragm muscle. Phrenic motor neurons receive excitatory input from medullary 
bulbospinal neurons. The intercostal muscles are controlled by motor neurons located 
in the thoracic spinal cord. Neuromotor control of the diaphragm is achieved by 
phrenic motor units, which consist of a phrenic motor neuron and the corresponding 
diaphragm muscle fibres it innervates. Axon terminals of the phrenic nerve terminate 
at the neuromuscular junction, where motor outflow is transduced into mechanical 
contraction of diaphragm myofibres. This is facilitated by release of the excitatory 
neurotransmitter acetylcholine at the motor end plate.   
 
Although neural drive to the respiratory muscles is an automatic process, motor output 
is influenced by sensory information relayed to the respiratory centres of the 
brainstem. Chemoreceptors relay sensory information regarding the gaseous 
composition and acid-base status of blood. Peripheral chemoreceptors located at the 
aortic arch and carotid body detect the partial pressure of oxygen (PO2) in arterial 
blood (Prabhakar & Peng, 2004; Teppema & Dahan, 2010; Kumar & Prabhakar, 2012; 
Prabhakar & Peng, 2017). The carotid body is the principal oxygen sensor in the body 
located at the bifurcation of the common carotid artery, relaying chemoafferent 
information to the brainstem. The carotid body has a key role in eliciting the initial 
ventilatory and arterial blood pressure response to hypoxaemia (decreased PO2 of 
arterial blood). The carotid body receives sensory innervation from a branch of the 
glossopharyngeal nerve, the carotid sinus nerve. Peripheral chemoreceptor tissue is 
composed of type I (glomus) cells, which are of neural origin, and type II sustentacular 
(glia-like) cells. Sensory discharge from the carotid body is modest during normoxia 
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(~100 mmHg PO2), but increases rapidly with even a slight decrease in arterial PO2. 
Central chemoreceptors are located throughout the CNS and are sensitive to changes 
in the hydrogen ion concentration (pH) of brain extracellular fluid. In addition to the 
sensory chemoreceptor control of breathing, sensory information is also received from 
the respiratory muscles (muscle spindles), the lungs (pulmonary stretch receptors) and 
receptors located in the upper airway (temperature, irritant and mechanical 
receptors). 
 
1.1.1.2 Respiratory plasticity 
Neuroplasticity is a term which describes nervous system changes that occur in 
response to natural stimuli (e.g. learning or aging/ development) and as a result of the 
development of pathological conditions (Fuller & Mitchell, 2017). Plasticity is now 
recognised as a fundamental property of the integrated system controlling breathing 
(Feldman et al., 2003). Respiratory neuroplasticity can be defined as a persistent 
change in a neural control system (morphology and/or function) based on a prior 
experience (Johnson & Mitchell, 2002; Mitchell & Johnson, 2003). Environmental and 
physiological stressors can challenge the respiratory control system’s ability to 
maintain homeostasis, such as during exercise, swallowing, speech and at altitude 
(among other challenges). Modifications within the neural network controlling 
breathing as a result of such challenges can be considered adaptive plastic changes 
which are necessary to maintain adequate blood oxygenation and pH regulation. 
Respiratory plasticity can occur a result of (but is not limited to) changes in 
physiological gases such as oxygen and carbon dioxide or due to experiences during 
sensitive stages of development in utero or during the post-natal period, which can 
have long-lasting effects on ventilatory control into adulthood (Mitchell & Johnson, 
2003). 
 
The first evidence of plasticity within the respiratory control system was demonstrated 
by Elridge, Millhorn and colleagues during studies of electrical stimulation of the 
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carotid sinus nerve resulting in long-lasting elevations in phrenic nerve activity 
(Eldridge & Millhorn, 1986). This was later termed phrenic long-term facilitation and is 
now a well-described exemplar of respiratory motor plasticity (Fuller et al., 2000; 
Devinney et al., 2013). In addition to motor facilitation of the diaphragm, sensory 
facilitation of the carotid body has also been documented (Peng et al., 2003; 
Prabhakar, 2011; Roy et al., 2017), as well as plasticity within the complex circuitry of 
the brainstem in response to, for example, chronic hypoxia (Dwinell et al., 2000; Powell 
et al., 2000; Wilkinson et al., 2010) and chronic intermittent hypoxia (Almado et al., 
2012; Moraes et al., 2012). 
 
Respiratory plasticity induced as a result of hypoxia (oxygen deficiency) has been well 
studied in recent years. Hypoxia can modulate multiple sites of the respiratory control 
network and evoke increased sensory (Peng et al., 2003) and motor nerve output (Bach 
& Mitchell, 1996). Hypoxia, such as that experienced at high altitude, can evoke robust 
plasticity in carotid chemoafferent neurons (Vizek et al., 1987; Nielsen et al., 1988). 
Ventilatory acclimatisation to chronic hypoxia consists of a progressive increase in 
ventilation beyond the acute response during prolonged periods of low oxygen (Powell 
et al., 1998). In addition to increased chemoafferent discharge, brainstem plasticity can 
occur in the nucleus tractus solitaries (NTS), where projections from chemoafferent 
neurons of the carotid body terminate, resulting in a change in the central neural 
integration of chemoafferent inputs (Dwinell & Powell, 1999). Such changes can result 
in a progressive increase in ventilation for sustained periods (hours to days) following 
removal of the initial hypoxic stimulus (Powell et al., 1998). 
 
Sensory long-term facilitation of the carotid chemoreceptors has been well studied by 
Prabhakar and colleagues (Kumar & Prabhakar, 2012). Carotid chemoafferent neuron 
activity is increased following intermittent hypoxia and the sensitivity of these neurons 
to an additional hypoxic stimulus is potentiated (Peng et al., 2003; Kumar & Prabhakar, 
2012). In addition to the carotid chemoreceptors, plasticity is observed following 
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intermittent hypoxia at chemoafferent integration sites in the NTS (Kline et al., 2007; 
Kline, 2010). These alterations in sensory function have been shown to be dependent 
on reactive oxygen species formation by NADPH oxidase (Peng et al., 2009), 
transcriptional regulation of hypoxia-inducible factors (Peng et al., 2006b) and 
serotonergic signalling (Peng et al., 2006a) at the level of the carotid body. 
 
Studies by Mitchell and colleagues have demonstrated that hypoxia-induced spinal 
plasticity can evoke phrenic long-term facilitation, in the absence of sensory long-term 
facilitation (Fuller et al., 2000; Devinney et al., 2013). Plasticity within spinal pathways 
to phrenic motor neurons accounts for elements of this facilitation (Devinney et al., 
2013; Fields & Mitchell, 2015). In addition to the motor pathway to the diaphragm, 
studies support a capacity for motor facilitation of pathways to the inspiratory 
intercostal (Fregosi & Mitchell, 1994), hypoglossal (ElMallah et al., 2016; Wilkerson et 
al., 2017) and laryngeal (Bautista et al., 2012) nerves. Studies examining mechanisms of 
phrenic long-term facilitation have identified a number of essential mediators, some of 
which include: spinal serotonin release and spinal serotonin receptor (type 2) 
activation (Baker-Herman & Mitchell, 2002); synthesis of brain derived neurotrophic 
factor (BDNF) and activation of TrkB receptor (Baker-Herman et al., 2004); ERK MAPK 
activity (Wilkerson & Mitchell, 2009); and reactive oxygen species formation from the 
NADPH oxidase complex (MacFarlane et al., 2009; MacFarlane et al., 2014).  
 
1.1.1.3 Compensatory plasticity in breathing 
The neural network controlling breathing must adapt adequately to maintain breathing 
during a broad range of environmental and physiological challenges that occur during 
health and disease, throughout life. Disorders affecting any component of the 
respiratory system have the potential to disrupt breathing. Central nervous system 
disorders including myelin disorders, motor neuron loss (such as in amyotrophic lateral 
sclerosis) and cervical spinal cord lesions in spinal cord injury, are known to disrupt 
neural pathways important for breathing. Interestingly, some patients can maintain 
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ventilatory capacity despite severe nervous system pathology (such as motor neuron 
loss in amyotrophic lateral sclerosis). Rodent models of motor neuron loss indicate a 
remarkable capacity for respiratory plasticity within the respiratory control system, 
which can compensate for such deficits (Nichols et al., 2013; Nichols et al., 2014; Seven 
et al., 2018). Similarly, recovery of inspiratory muscle activity has been reported in 
models of cervical spinal cord injury (Fuller et al., 2008; Sandhu et al., 2009; Dougherty 
et al., 2012).  
 
A number of mechanisms have been proposed which can operate at sites within the 
system to maintain ventilatory capacity, these include: 1) an alteration in central 
respiratory drive; 2) plasticity at motor neuronal pools such as the phrenic motor 
nucleus; 3) plasticity at the neuromuscular junction; 4) respiratory muscle plasticity and 
altered contribution of respiratory muscles to breathing (e.g recruitment of accessory 
muscles of breathing) (Johnson & Mitchell, 2013).  
 
1.1.2 Duchenne muscular dystrophy (DMD) 
Respiratory failure is a common feature of many neuromuscular diseases and is one of 
the leading causes of death in boys with Duchenne muscular dystrophy (DMD) (Bye et 
al., 1990; Shneerson, 1996; Syabbalo, 1998b; Yiu & Kornberg, 2008). DMD is a 
devastating genetic disease where patients lack the structural protein dystrophin 
(Muntoni et al., 2003; Nowak & Davies, 2004; Yiu & Kornberg, 2008). Dystrophin is the 
protein product of the gene defective in DMD (Hoffman et al., 1987) and is the largest 
described human gene (Muntoni et al., 2003). Full-length dystrophin is rod-shaped 
(427 kDa) and contains four major domains: amino-terminal domain (connects to 
actin), flexible rod domain, cysteine-rich domain (connects cytoskeleton to 
extracellular matrix) and a carboxy-terminal domain (Hoffman et al., 1987; Koenig et 
al., 1988). The protein is expressed in skeletal, cardiac and smooth muscle and the CNS 
(Hoffman et al., 1987; Lidov, 1996; Muntoni et al., 2003).  
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Dystrophin interacts with a group of proteins which collectively form the dystrophin-
glycoprotein complex (DGC), or commonly termed the dystrophin associated protein 
complex (DAPC) (Blake et al., 2002; Ehmsen et al., 2002; Kanagawa & Toda, 2006; 
Ervasti, 2007). Dystrophin has a structural role in muscle where it provides mechanical 
support by linking cytoskeletal actin to the sub-sarcolemmal face functioning to 
prevent stretch-induced damage during muscle contraction (Koenig et al., 1988; Ervasti 
& Campbell, 1991; Ozawa et al., 1999; Allen & Whitehead, 2011). In the absence of 
dystrophin, muscle fibres are at risk of contraction-induced injury due to intracellular 
mechanical destabilisation. Serum creatine kinase is markedly increased in patients, 
suggesting poor muscle integrity (Petrof et al., 1993a; Petrof, 1998; Ozawa et al., 1999; 
Yiu & Kornberg, 2008, 2015).  
 
Skeletal muscle weakness is progressive in DMD and initially affects the distal limb 
musculature, eventually resulting in loss of ambulation when boys are in their teens 
(Yiu & Kornberg, 2008). Pathological features of dystrophic muscles include muscle 
fibre degeneration and necrosis with mononuclear cell infiltration, increased variability 
of muscle fibre size and an increased number of muscle fibres in the regenerative 
phase (Yiu & Kornberg, 2015). Branched muscle fibres are often observed in dystrophic 
muscle and lipid accumulation and fibrosis are prominent in muscles where functional 
fibres are lost (Chan & Head, 2011). Magnetic resonance imaging (MRI) in DMD 
patients indicates a loss of muscle contractile content and an increase in the lipid 
content of DMD muscle, which is dependent on disease progression (Forbes et al., 
2014; Lott et al., 2014; Willcocks et al., 2014; Vohra et al., 2015). 
 
1.1.3 Pulmonary function in DMD 
Since the respiratory system is implicated in DMD, clinicians have examined pulmonary 
function in patients in order to predict survival and mortality and inform when assisted 
ventilation is required to sustain gas exchange. Pulmonary function tests examining 
lung function and volumes in DMD boys have consistently reported that forced vital 
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capacity (FVC) is significantly lower than predicted values (Baydur et al., 1990; Mohr & 
Hill, 1990; Kirk et al., 2000; De Bruin et al., 2001; Bersanini et al., 2012; Canapari et al., 
2015). Once FVC peaks in the early-to-mid teens in DMD, there is a progressive decline 
in FVC with increasing age at a rate of approximately 5% of predicted values per year 
(Baydur et al., 1990; Phillips et al., 2001; Roberto et al., 2011; Khirani et al., 2014; 
Mayer et al., 2015; Meier et al., 2017). Given the progressive nature of the disease, 
when vital capacity falls below one litre in DMD boys, it is believed to be a strong 
predictor of subsequent mortality (Phillips et al., 2001). Truncal fat mass, as measured 
by dual X-ray absorptimetry, was shown to have a significant inverse relationship with 
FVC in DMD subjects (Canapari et al., 2015). Recent data from MRI studies in 
ambulatory DMD boys indicates that DMD patients breathe at lower lung volumes than 
healthy subjects, although FVC may be within the normal range (Mankodi et al., 2017). 
Curvature of the spine can impact on lung capacity and scoliosis is known to occur in 
DMD boys, which further impacts on lung volumes and ventilatory capacity (Rodillo et 
al., 1988; LoMauro et al., 2014; Yiu & Kornberg, 2015). Pulmonary function testing is a 
useful tool for monitoring disease progression and clinical outcome measures in 
patients.  
 
1.1.4 Respiratory muscle weakness in DMD 
The thoracic diaphragm is the principal inspiratory pump muscle, phasically active 
throughout life. The diaphragm is a dome-shaped skeletal muscle that separates the 
thoracic cavity from the abdomen, receiving neural innervation from the phrenic 
nerve, originating at the cervical spinal cord. Rhythmic diaphragm muscle contraction 
increases the volume of the thoracic cavity, in turn decreasing intra-thoracic pressure 
facilitating inflation of the lungs and thus allowing gas exchange to occur. Trans-
diaphragmatic pressure (Pdi) is a surrogate measure for contractile strength of the 
diaphragm muscle in vivo. Pdi is the difference between gastric pressure (Pgas) 
(reflects abdominal muscle strength) and oesophageal pressure (Poes) (reflects 
intrapleural pressure, dynamically generated by inspiratory muscles) (Syabbalo, 
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1998a).  Khirani et al. (2014) measured Pdi during maximal sniff behaviours in DMD 
patients and reported that values for Pdi were low compared with predicted values of 
normal subjects (Khirani et al., 2014). Pdi declined steadily after 10 years of age at an 
average rate of ~4 cmH2O per year (Khirani et al., 2014), revealing a progressive 
impairment of diaphragm mechanical function. These data describe progressive 
inspiratory muscle weakness in DMD boys, which undoubtedly has implications for the 
control of breathing in DMD and adequate ventilatory performance. In addition to 
inspiratory muscle weakness, expiratory muscle strength is also compromised in DMD. 
Pgas during cough was measured in DMD boys and reported to be low compared with 
predicted values and found to decline at a rate of ~6 cmH2O per year (Khirani et al., 
2014). The authors describe this expiratory muscle weakness to present, perhaps even 
prior to inspiratory muscle weakness during the first decade of life. Consistent with 
these data, a similar study found that reductions in expiratory muscle strength were 
found to precede inspiratory muscle dysfunction in DMD boys (Hahn et al., 1997), 
further suggesting an early involvement of expiratory muscles in DMD. Chest wall 
motion during spontaneous breathing in wakefulness and supine position is an 
important indicator of the degree of respiratory muscle impairment in DMD (Lo Mauro 
et al., 2010). 
 
MRI studies of the diaphragm muscle in young DMD boys reported that diaphragm 
length, contractility and motion were not significantly different from healthy subjects 
(Mankodi et al., 2017). In contrast, chest wall motion was reduced in patients 
compared with healthy subjects (Mankodi et al., 2017), with likely consequences for 
ventilatory reserve capacity. These findings are surprising in the context of the current 
literature which describes altered diaphragm muscle mechanics in DMD boys (Beck et 
al., 2006; Khirani et al., 2014). Perhaps overt diaphragm muscle pathology had not yet 
manifested in these DMD boys given their relatively young age (~8 years of age). 
Thickening of the diaphragm muscle has been described in DMD, along with reduced 
diaphragm muscle strength (De Bruin et al., 1997; Beck et al., 2006). In addition to the 
 12 
contribution of the inspiratory muscles to eupnoeic (basal) breathing in DMD boys, the 
abdominal muscles have been shown to contribute to tidal volume generation, which 
may be a compensatory mechanism to sustain ventilation (LoMauro et al., 2014). Rapid 
shallow breathing is observed in some patients and may also be considered an 
adaptive mechanism aimed at reducing the work of breathing, thus delaying 
diaphragm muscle fatigue (Lo Mauro et al., 2010). Strength training of the inspiratory 
muscles in DMD patients has been shown to improve respiratory muscle functional 
parameters such as Poes and Pdi during the early stages of DMD (Wanke et al., 1994).  
 
1.1.5 Respiratory disturbances in DMD 
Sleep can provide a significant challenge for the respiratory control system, particularly 
in conditions where respiratory function may already be compromised, such as in 
neuromuscular diseases (Cerveri et al., 1993). Sleep can naturally result in reductions in 
resting ventilation and responsiveness to chemoreceptor challenges such as hypoxia 
and hypercapnia (Douglas et al., 1982a; Douglas et al., 1982b; Douglas et al., 1982c; 
Worsnop et al., 1998). During sleep there is an absence of the excitatory drive to 
breathe present during wakefulness, and breathing in turn becomes reliant on 
chemoreceptor input (Fink, 1961; Skatrud & Dempsey, 1983; Meza et al., 1998). During 
wakefulness, upper airway muscle hypotonia and negative (sub-atmospheric) pressure 
generated during diaphragmatic contraction increases upper airway resistance, in turn 
increasing the mechanical load placed on the upper airway musculature and activation 
of airway mechanoreceptors occurs, resulting in a reflex increase in pharyngeal dilator 
muscle activity to offset the negative pressure and prevent airway collapse (Fogel et 
al., 2001). This reflex physiological response is dampened during sleep and as such 
individuals are at risk of sleep-related breathing disturbances such as airway collapse. 
 
Sleep-disordered breathing (SDB) is a general term describing breathing difficulties 
during sleep and can include respiratory pause (apnoea), inadequate ventilation 
(hypopnoea) or respiratory depression (hypoventilation). Apnoeas can be obstructive 
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or central in nature. Obstructive apnoeas are a result of collapse of the upper airway, 
whereas central apnoeas are due to diminished neural drive to the upper airway 
(White, 2005). Children with neuromuscular disease appear to be at a greater risk of 
developing SDB compared with healthy subjects. Indeed, SDB is a well-recognised 
feature of DMD (Yiu & Kornberg, 2015; LoMauro et al., 2017).  
 
Obstructive sleep apnoea (OSA) is a common form of SDB characterised by recurrent 
collapse of the upper airway, resulting in a pathological cycle of oxygen desaturation 
(hypoxaemia) and re-oxygenation events (Ryan & Bradley, 2005; Eckert & Malhotra, 
2008; Sankri-Tarbichi, 2012; White & Younes, 2012).  OSA is common in DMD boys as 
young as seven years of age (Hill et al., 1992; Khan & Heckmatt, 1994; Mellies et al., 
2003c; Suresh et al., 2005; Sawnani et al., 2015). It is unclear why patients with DMD 
are at such risk of developing OSA. Some risk factors for the occurrence of OSA in the 
general population include age, sex, airway anatomy and obesity (Schwab et al., 1995; 
Wellman et al., 2004). Obesity is reported in DMD boys (Zanardi et al., 2003), with 
body mass index increased compared with healthy subjects. Since dystrophin is 
expressed in skeletal muscle, is it plausible to speculate that the skeletal musculature 
of the upper airway is weakened in DMD, rendering the upper airway to a greater risk 
of collapse during sleep. This may be one explanation for the increased incidence of 
OSA in DMD, notwithstanding the other complex mechanisms influencing airway 
control including central respiratory gain (Dempsey et al., 2010) and factors affecting 
motor drive to the upper airway (Castele et al., 1985; Mifflin, 1990; Badr, 1996; Funk et 
al., 1997; Jordan, 2001). 
 
The severity of sleep apnoea is scored clinically by the apnoea-hypopnea index (AHI); 
the number of apnoeas and hypopnoeas per hour of sleep, as a result of upper airway 
collapse. Smith et al. (1989) reported the AHI of DMD patients to be 12.6 events/hr 
(Smith et al., 1989a). Later, Bersanini et al. (2012) reported the average AHI of 11 DMD 
patients during sleep to be 18 events/hr (Bersanini et al., 2012). Based on the AHI 
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scale, both studies suggest DMD boys suffer from moderate sleep apnoea. Central 
apnoeas have also been recorded in DMD boys during sleep (Manni et al., 1989). 
Sawnani et al. (2015) observed a reduced FVC (80% of predicted values) in DMD 
patients and reported 64% of patients to be suffering from OSA, 37% had central sleep 
apnoea and 17% had hypoventilation (Sawnani et al., 2015). Co-morbidities can 
manifest as a result of OSA including daytime hypersomnolence and headache, both of 
which are observed in DMD boys with SDB (Barbé et al., 1994). In addition, 
hypertension, neurocognitive impairment and cardiac dysfunction often present as a 
result of OSA. 
 
Despite diaphragm muscle weakness in DMD, minute ventilation can be normal in boys 
during wakefulness, with irregular ventilation prominent during sleep (Smith et al., 
1989b). As patients reach the second decade of life, hypoventilation during sleep 
presents (Smith et al., 1989b, a; Hukins & Hillman, 2000; Kirk et al., 2000; Suresh et al., 
2005; Sawnani et al., 2015). Hypoventilation has been shown to occur during all sleep 
stages in DMD boys (Smith et al., 1989b). During non-rapid eye movement sleep (non-
REM), the diaphragmatic contribution to breathing was found to be lower in DMD 
compared with predicted values and this was correlated with the magnitude of oxygen 
desaturation during REM sleep (Smith et al., 1989b), suggesting impaired force-
generating capacity of the diaphragm muscle with resultant hypoventilation and blood-
gas disturbance. Protriptyline is an anti-cholinergic drug which can suppress REM sleep. 
The effects of protriptylline on oxygen desaturation and disordered breathing were 
assessed in DMD patients and found to effectively reduce sleep hypoxaemia and 
disordered breathing (reduced AHI) (Smith et al., 1989a).  
 
1.1.6 Blood-gas homeostasis in DMD 
Disrupted blood-gas homeostasis can occur in DMD due to apnoeic events and 
hypoventilation. Arterial oxygen desaturations appear to be common, with DMD boys 
experiencing bouts of hypoxaemia during sleep (Smith et al., 1988; Manni et al., 1989; 
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Smith et al., 1989b, a; Hill et al., 1992; Barbé et al., 1994; Khan & Heckmatt, 1994; 
Melacini et al., 1996; Hukins & Hillman, 2000; Bersanini et al., 2012). Khan et al. (1994) 
report that oxygen desaturations were more frequent with increasing age in DMD 
(Khan & Heckmatt, 1994), consistent with the highly progressive nature of the disease. 
Simultaneously, nocturnal hypercapnia occurs due to the retention of CO2 as a result of 
sleep-related hypoventilation (Baydur et al., 1990; Mohr & Hill, 1990; Melacini et al., 
1996; Kirk et al., 2000; Bersanini et al., 2012). Elevations in PaCO2 were associated with 
decreased maximum inspiratory pressure in patients (Hahn et al., 1997). Although vital 
capacity levels can be low in DMD, patients can remain normocapnic once vital 
capacity remains > 1,820ml (Toussaint et al., 2007).  
 
The causes and consequences of OSA and nocturnal hypoventilation in DMD remain to 
be elucidated. OSA and hypoventilation can be multifactorial and can occur due to 
decreased ventilatory drive from the CNS, poor chemical control of breathing during 
sleep or altered respiratory mechanics. Since prominent weakness of the inspiratory 
and expiratory muscles is observed in DMD, worsened respiratory mechanics is likely a 
major contributor. However, whether chemoreceptor control of breathing or 
ventilatory drive is altered in DMD remains to be determined. Nocturnal 
hypoventilation and OSA results in hypoxaemia and hypercapnia during sleep and in 
some cases diurnal hypercapnia presents. Studies in animal models have clearly 
demonstrated the adaptive and maladaptive consequences of hypoxia on the 
integrated respiratory control system, in addition to its effects on autonomic control 
and metabolic and cardiovascular function (O'Halloran et al., 2002; Peng et al., 2003; 
Prabhakar et al., 2005; Dick et al., 2007; Edge et al., 2010; Terada & Mitchell, 2011; 
Edge et al., 2012; Lucking et al., 2014; Souza et al., 2015, 2016). In the light of these 
data, the potential consequences of hypoxaemia in DMD, a disease where the 
respiratory system is already compromised, could prove catastrophic for the control of 
breathing.  
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1.1.7 Non-ventilatory behaviours in DMD 
The respiratory system contributes to many non-ventilatory functions including 
coughing, sneezing and airway clearance manoeuvres. Patients with DMD can have 
inefficient cough due to reduced lung volumes and chest wall compliance and muscle 
weakness of the expiratory and inspiratory musculature (Kravitz, 2009; LoMauro et al., 
2014). Poor cough efficiency in DMD is associated with reduced operating lung and 
chest wall volume as a result of inspiratory muscle weakness (LoMauro et al., 2014). 
Such inefficiencies make patients at risk of respiratory infections and aspiration 
(Aloysius et al., 2008; Toussaint et al., 2016).  
 
1.1.8 Assisted ventilation in DMD 
Current respiratory management strategies for DMD include non-invasive ventilation 
(NIV) (Arens & Muzumdar, 2010; Yiu & Kornberg, 2015; Birnkrant et al., 2016), lung 
volume recruitment and systemic steroids (Katz et al., 2004). Non-invasive positive 
pressure ventilation (NIPPV) has been shown to have the most beneficial effects on 
ventilation in patients with neuromuscular disease compared with negative pressure 
ventilation, which can contribute to upper airway obstruction, reduced chest wall 
movements and oxygen desaturation (Ellis et al., 1987; Hill et al., 1992). Suresh et al. 
(2015) reported a significant improvement in the AHI of DMD boys following non-
invasive ventilation (Suresh et al., 2005). Long-term NIV in DMD patients has the 
capacity to normalise nocturnal gas exchange and improve diurnal gas exchange and 
sleep quality (Mellies et al., 2003b), along with improving side-effects of SDB such as 
morning headaches, mood, concentration and daytime sleepiness (Mellies et al., 
2003a). In comparison, a randomised trial of NIPPV in DMD patients found that NIPPV 
did not improve respiratory function, suggesting that the use of NIPPV should be 
avoided in DMD patients with FVC values between 20 and 50% of predicted values 
(Raphael et al., 1994).  
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Currently no cure exists for DMD; steroidal treatment with glucocorticoids is the 
current strategy adopted to treat patients (Yiu & Kornberg, 2015). Steroid therapy in 
boys with DMD has the capacity to stabilise or delay loss of lung function, independent 
of ambulatory state (Machado et al., 2012). Similarly, chronic glucocorticoid use can 
partially preserve respiratory muscle strength and lung volumes in DMD (Buyse et al., 
2013).  
 
Due to the progressive decline in respiratory function in DMD and chronic disruption to 
blood gas homeostasis, in some severe cases, patients require invasive procedures 
such as tracheostomy to facilitate adequate ventilation (Mohr & Hill, 1990; Baydur et 
al., 2000). Since the use of NIV strategies for DMD patients in combination with 
corticosteroid therapy, there has been a concomitant increase in life expectancy. Lung 
inflation training using a positive end-expiratory pressure (PEEP) valve in 
tracheotomised DMD patients for four months significantly increased maximum PEEP 
lung inflation capacity (Matsumura et al., 2012). A holistic approach to improving 
pulmonary function in DMD boys via yoga breathing exercises has been demonstrated 
to significantly increase FVC and forced expiratory volume (FEV1) (Rodrigues et al., 
2014). 
 
1.1.9 Cardiovascular function in DMD 
Cardiac function has now become the major determinant of survival in patients using 
assisted ventilation (Melacini et al., 1996; Birnkrant et al., 2016). Patients with 
advanced DMD show abnormal electrocardiograms, left ventricular wall abnormalities, 
left ventricular dilation with decreased ejection fraction and pulmonary hypertension 
(Melacini et al., 1996). Dilated cardiomyopathy and left ventricular dysfunction are the 
most common features of cardiac dysfunction in DMD patients (Fayssoil et al., 2017).  
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1.2 Dystrophin-deficient mdx mouse  
The mdx mouse is a mutant model of DMD which arose from an inbred C57BL10 colony 
of mice (Bulfield et al., 1984). The mdx mouse has a premature stop codon which 
terminates on exon 23 of the dystrophin gene and the mdx mouse subsequently lacks 
the largest dystrophin isoform (427kDa). The model has been extensively studied and 
has greatly contributed to understanding of the pathophysiology of DMD (Manning & 
O'Malley, 2015). Dystrophin is absent from skeletal, cardiac and smooth muscle and 
the CNS of mdx mice. A relatively mild phenotype in terms of limb pathology is 
observed in mdx mice compared with human DMD (Lynch et al., 2001). Dystrophic limb 
muscle initially undergoes fibre degeneration and weakness in the first few weeks of 
life (3-8 weeks of age). Thereafter, the limb muscles can recover and compensate for 
the lack of dystrophin by upregulating a protein of similar homology called utrophin. In 
comparison, dystrophic diaphragm muscle from mdx mice exhibits severe mechanical 
dysfunction and muscle weakness during life (Stedman et al., 1991; Petrof et al., 
1993b; Coirault et al., 1999; Coirault et al., 2003). 
 
1.2.1 Dystrophin and the striated muscles of breathing 
Diaphragm muscle weakness presents as early as six weeks of age in the mdx mouse 
(Coirault et al., 2003) and persists throughout life (Stedman et al., 1991; Stevens & 
Faulkner, 2000; Whitehead et al., 2016). The absence of dystrophin in mdx diaphragm 
exposes the sarcolemma to a greater risk of mechanical instability, contraction induced 
injury (Petrof et al., 1993a) and reduced muscle elasticity and fibre length (Stedman et 
al., 1991). Diaphragm muscle fibre degeneration and repair occurs due to muscle fibre 
damage. Centralised myonuclei (indicative of muscle fibre damage and repair) are 
present in mdx diaphragm together with progressive fibrosis (Stedman et al., 1991; 
Gosselin & McCormick, 2004; Gosselin et al., 2007; Ishizaki et al., 2008; Barros 
Maranhão et al., 2015; Gutpell et al., 2015; Smith et al., 2016). Mdx diaphragm 
undergoes inflammation, with an increase in mononuclear cell infiltration. Over time, 
necrotic muscle fibres are replaced by connective tissue and lipid deposits. 
 19 
Structural alterations in myosin heavy chain (MyHC) isoform composition are 
sometimes observed in dystrophic skeletal muscle. Skeletal muscle fibres are 
categorised based on their MyHC isoform composition, which ultimately determines 
the muscle fibres intrinsic contractile properties, resistance to fatigue and metabolic 
enzyme activity. The diaphragm muscle is a mixed muscle comprising all four types of 
MyHC: type I (slow oxidative fibres), type IIa (fast-twitch oxidative-glycolytic) and type 
IIx and IIb (fast-twitch glycolytic fibres). Type II fibres display a progressive increase in 
force production from IIa to IIb, with IIb producing the greatest forces and maintaining 
the least resistance to fatigue (Polla et al., 2004; Schiaffino & Reggiani, 2011).  
 
Dystrophic diaphragm muscle from mdx mice expresses a reduced number of MyHC IIx 
fibres and increased MyHC IIa fibres compared with wild-type (Coirault et al., 1999), 
probably as a result of a lack of maturation of muscle fibres due to ongoing muscle 
damage and repair processes. In addition to diaphragm muscle weakness and altered 
MyHC complement in mdx mice, the total number of cross-bridges per mm2, the 
elementary force per cross-bridge and the peak mechanical efficiency are decreased 
compared with age-matched wild-type mice (Coirault et al., 1999). Bates et al. (2013) 
demonstrated muscle weakness in the diaphragm muscle at the level of intact muscle 
strips, however molecular myosin function and the mechanics of single permeabilized 
muscle cells were not affected (Bates et al., 2013). The number of regenerating muscle 
fibres in mdx diaphragm increase with age, while fibre cross-sectional area, sarcomere 
length and the number of branched fibres are decreased (Henry et al., 2017).  
 
Respiratory muscle training in mdx mice with CO2 breathing increases diaphragm 
muscle force and the expression of the DAPC protein, D-dystrobrevin (Matecki et al., 
2005). Interestingly, there is a paucity of information in relation to the accessory 
muscles of breathing in the mdx mouse model of DMD, namely the intercostal and 
abdominal muscles. Studies indicate the intercostal muscles may present with less 
severe histological changes compared with mdx diaphragm (Stedman et al., 1991; 
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Ishizaki et al., 2008). Studies of the structural and functional consequences of 
dystrophin-deficiency on the accessory muscles of breathing in mdx mice are lacking.  
 
1.2.2 Respiratory function in the mdx mouse 
Although diaphragm muscle weakness is well described in the mdx mouse and is 
observed from a young age, few studies have thoroughly examined the functional 
consequences of dystrophin deficiency on respiratory behaviour and ventilatory 
capacity in mdx mice. Moreover, studies have not tracked ventilatory capacity as a 
function of ageing in mdx mice, despite the fact that the diaphragm muscle undergoes 
a progressive pathology.  
 
Impaired normoxic ventilation was reported in 2- and 6-month-old mdx mice 
(Mosqueira et al., 2013; Burns et al., 2015). At 2 months of age, mdx mice appear to 
have significantly reduced minute ventilation compared with age-matched wild-type 
mice during normoxia (Burns et al., 2015). Mosqueira et al. (2013) reported 
significantly reduced respiratory frequency, tidal volume and minute ventilation during 
normoxic breathing in 6-7 month old mdx mice compared with age-matched wild-type 
mice (Mosqueira et al., 2013). Ishizaki et al. (2008) demonstrated significant reductions 
in respiratory frequency in 2- and 4-month-old mdx mice. Further, Huang et al. (2011) 
concluded that mdx mice have significant reductions in respiratory frequency and tidal 
volume at 3 and 6 months of age (Huang et al., 2011). Markham et al. (2015) report 
that mdx mice at 7 months of age have significantly reduced respiratory frequency and 
minute ventilation compared with wild-type (Markham et al., 2015). 
 
Surprisingly, no study to date has examined indices of respiratory stability in mdx mice 
such as breath-to-breath variability and apnoeic events. Ventilatory capacity in mdx 
mice has been briefly studied by stimulating central chemoreceptors with CO2, 
enhancing neural drive to the diaphragm muscle, thereby driving ventilation. A 
significant blunting of the hypercapnic ventilatory response was observed in 7-month-
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old mdx mice (Gosselin et al., 2003). In comparison, Gayraud et al. (2007) observed no 
differences in ventilation between wild-type and mdx mice during normoxia and 
preservation of hypercapnic breathing at 5 months of age. In older mice (16 months 
old), mdx had higher respiratory frequency and a blunted response to CO2 challenge 
compared with wild-type mice (Gayraud et al., 2007). Some discrepancies are apparent 
in this body of literature. Studies of peripheral chemoreceptor function and 
examination of hypoxic sensitivity in mdx mice are lacking. 
 
1.2.3 Dystrophin and the upper airway 
In addition to diaphragm muscle weakness, the skeletal musculature of the upper 
airway is also compromised by dystrophin deficiency in the mdx mouse (Attal et al., 
2000; Burns & O'Halloran, 2016). Upper airway muscles have a physiological role in 
maintaining upper airway patency during wakefulness and vulnerable periods such as 
sleep. Pharyngeal dilator muscles of the upper airway, such as the genioglossus and 
sternohyoid muscles, are phasically active during respiration and contribute to control 
of upper airway resistance. Attal et al. (2000) hypothesised that the sternohyoid 
muscle from mdx mice would have intrinsic muscle weakness. At six months of age, 
peak tetanic tension was 50% lower for mdx sternohyoid compared with wild-type 
muscle (Attal et al., 2000).  
 
The upper airway muscles are primarily composed of MyHC type II fibres, allowing 
these pharyngeal dilator muscles to generate large forces and produce faster 
contraction times, while concomitantly demonstrating reduced fatigue resistance 
compared with the diaphragm muscle (Dick & van Lunteren, 1990; Van Lunteren & 
Vafaie, 1993; Cantillon & Bradford, 1998, 2000; McGuire et al., 2002; Skelly et al., 
2012). This profound weakness in mdx sternohyoid muscle is associated with a shift in 
the MyHC isoform composition from MyHc IIb to IIx. Mechanical dysfunction has also 
been described in sternohyoid muscle from young mdx mice (eight weeks of age) 
(Burns & O'Halloran, 2016). Alterations in the MyHC composition of dystrophic 
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sternomastoid muscle from mdx mice also occurs with a significant reduction in MyHC 
IIb and an increase in centralised myonuclei (Guido et al., 2010). These data have 
relevance to the control of upper airway patency in DMD. Since obstructive apnoeas 
occur in DMD boys, these data support the hypothesis that weakening of the upper 
airway musculature due to dystrophin-deficiency may contribute to upper airway 
collapse in DMD, and potentially lead to alternating periods of hypoxia and re-
oxygenation due to airway obstruction. Studies of upper airway muscle function are 
lacking in DMD and mdx mice. Adequate upper airway muscle performance is key for 
the homeostatic regulation of breathing. Despite the pronounced muscle weakness 
observed in mdx sternohyoid muscle, studies have not examined the neural control of 
the upper airway in DMD and mdx mice, and it is unclear if motor control of the upper 
airway is compromised by dystrophin deficiency. Indeed, there is a general paucity of 
knowledge in respect of the neural control of breathing in the human 
dystrophinopathies. 
 
1.2.4 Dystrophin and the airways 
In addition to skeletal muscle, dystrophin is expressed in smooth muscle, and of 
relevance to the current review, the smooth muscle of the airways express dystrophin. 
Surprisingly, little work has examined the physiological implications of dystrophin 
deficiency on airway smooth muscle function. Sharma et al. (2014) described the 
consequences of dystrophin lack for airway smooth muscle contraction. Peak airway 
resistance in response to maximal stimulation with methacholine was significantly 
reduced in mdx mice compared with wild-type (Sharma et al., 2014). These data 
indicate that dystrophin’s absence and thus inadequate mechanical linkage between 
the actin cytoskeleton and the DAPC have implications for airway smooth muscle 
function in mdx mice. 
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1.2.5 Dystrophin and the nervous system 
In addition to muscle, dystrophin is expressed in the CNS. The largest isoform of 
dystrophin (Dp427) is absent from the CNS of mdx mice (Nichols et al., 2015; 
Aranmolate et al., 2017). In DMD, cognitive impairment is observed in patents owing to 
a lack of dystrophin expression in the brain (Anderson et al., 2002; Cyrulnik & Hinton, 
2008). In a similar manner, learning and memory deficits are seen in mdx mice 
(Chaussenot et al., 2015; Rae & O'Malley, 2016).  
 
Some consequences of dystrophin absence from the CNS of mdx mice include delayed 
myelination in the cerebral cortex (Aranmolate et al., 2017), decreased neurons in the 
trigeminal sensory nuclear complex (Pinto et al., 2007), increased size of the lateral 
ventricles (Xu et al., 2015), damaged motor pathways (Carretta et al., 2001), decreased 
neuronal projections (Pinto et al., 2008) and a leaky blood-brain-barrier (Goodnough et 
al., 2014). The number of neurons containing the calcium-binding proteins 
parvalbumin and calbindin are increased in the motor and somatosensory cortices of 
mdx mice (Carretta et al., 2001) and an increase in the number of anterior horn 
neurons of the spinal cord has been noted (Papapetropoulos & Bradley, 1972).  
 
Deficits within the peripheral nervous system of dystrophic mice include reduced 
number of axons in the tibial nerve, despite normal fibre diameter and axon packing 
(Harris et al., 1972). Jaros et al. (1983) examined the common peroneal nerve and the 
tibial nerve of dystrophic mice and reported an increase in the number of Schwann cell 
nuclei associated with myelinated axons, decreased inter-nodal length and a reduction 
in the number of myelinated axons (Jaros & Jenkison, 1983).  
 
There is no evidence of utrophin upregulation and compensation in the mdx brain, 
similar to that seen in the limb muscles (Knuesel et al., 2000; Perronnet et al., 2012). 
Biochemically, there is an increase in choline containing compounds in mdx cerebellum 
and hippocampus, and altered glucose metabolism (Rae et al., 2002; Xu et al., 2015). 
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One function of dystrophin in the CNS is the stabilization of neurotransmitter receptors 
such as GABA and acetylcholine receptors (Knuesel et al., 1999; Brünig et al., 2002; 
Pilgram et al., 2010; Parames et al., 2014). Dysfunction of the GABAergic system occurs 
in the brains of mdx mice (Sekiguchi et al., 2009; Vaillend & Chaussenot, 2017), with 
disrupted GABA neurotransmission (Xu et al., 2015), suggesting a removal of central 
inhibition in dystrophic brains. Alterations in antioxidant enzymes are reported in 
dystrophic brains from mdx mice. Superoxide dismutase is increased in the cerebellum, 
prefrontal cortex, hippocampus and striatum, while catalase is reduced in the striatum 
(Comim et al., 2009a). Glutathione is increased in the hippocampus and taurine is 
increased in the pre-frontal cortex (Xu et al., 2015). These data suggest an alteration in 
redox status within the CNS of mdx mice. Neurotrophins are a family of proteins that 
support the survival, development and function of neurons. Studies of neurotrophic 
factors in mdx mice are lacking. Comim et al. (2009) examined BDNF in the pre-frontal 
cortex, cerebellum, hippocampus and striatum of mdx mice. No change in BDNF was 
found in the cerebellum, hippocampus, and cortex, whereas BDNF was reduced in mdx 
striatum and pre-frontal cortex (Comim et al., 2009b).  
 
Of particular relevance to the control of breathing, dystrophin is expressed in the 
brainstem of mice. The effects of dystrophin deficiency on the key cardio-respiratory 
integrating sites and rhythm and pattern generating sites of the brainstem are 
unknown. The brainstem contains the hypoglossal (XII) motor nucleus which provides 
motor control of the upper airway via the hypoglossal nerve; it has not been 
determined if the major motor pathway of the upper airway shows pathological 
features resulting from dystrophin deficiency in mdx mice. Studies examining 
peripheral nerve morphometry in respiratory motor pathways are lacking, despite 
pathological changes reported in the tibial nerve of dystrophic mice.  
 
Dystrophin is expressed at the neuromuscular junction (Huard et al., 1991; Pilgram et 
al., 2010; Pratt et al., 2015a), where it has a scaffolding function for neuronal receptors 
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(Xu & Salpeter, 1997). Remodelling of the neuromuscular junction is observed in 
dystrophic muscle, evidenced by decreased neuromuscular junction occupancy, 
increased nerve branching and increased nerve discontinuity in mdx quadriceps muscle 
(Pratt et al., 2015b). There is an increase in neural transmission variability at the 
neuromuscular junction of mdx diaphragm and disrupted post-synaptic acetylcholine 
receptor clustering (Xu & Salpeter, 1997; Personius & Sawyer, 2006; van der Pijl et al., 
2016). Van der Pijl et al. (2016) reported an increase in the number of acetylcholine 
quanta released per nerve impulse, suggesting a homeostatic increase in the 
neurotransmitter release at the neuromuscular junction in mdx muscle  (van der Pijl et 
al., 2016). Increased nerve branching or sprouting could serve to compensate for 
degenerating neuromuscular junctions and fibres in dystrophic muscle.  
 
1.2.6 Dystrophin and chemoreception 
Dystrophin is expressed in the carotid body of wild-type mice and absent from the 
carotid bodies of mdx mice (Mosqueira et al., 2013). The carotid body is the most 
vascularised tissue in the body and is composed of two types of cells called glomus 
type I (neural crest) and glomus type II (glial cells) cells. Type I cells are electrically 
excitable and become depolarized when there is a decrease in the PO2 of arterial 
blood, an increase in arterial PCO2 or a decrease in the pH of arterial blood. 
Depolarization opens voltage gated calcium channels, increasing intracellular calcium 
concentration, stimulating exocytosis of vesicles which contain a wide variety of 
neurotransmitters. Release of the neurotransmitters ATP, noradrenaline, acetylcholine 
and adenosine (among others), facilitates action potential generation on afferent nerve 
fibres. Type II cells act as supporting cells. The carotid body signals along the carotid 
sinus nerve, which is a branch of the glossopharyngeal nerve, and relays sensory 
afferent information to the NTS of the brainstem.  
 
In muscle, dystrophin is known to have a structural and mechanical function and a cell 
signalling role as part of the DAPC. At this juncture, it is unclear if there is a pivotal role 
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for dystrophin in carotid body function. Dystrophin in the CNS is important for receptor 
localisation and arrangement, particularly for GABA and acetylcholine receptors. 
Perhaps dystrophin has a similar function in the peripheral oxygen sensor, where there 
are abundant neurochemicals. Dystrophin may also have a stabilisation role in the 
cytoskeleton of the peripheral oxygen sensor, affecting synaptic vesicle arrangement 
and trafficking during exocytosis. The consequences of dystrophin deficiency within the 
carotid body are unclear. Investigations are necessary to examine any potential deficits 
within the carotid body of mdx mice, which may have implications for the control of 
breathing and adequate chemoreception during physiological perturbations in arterial 
blood gases. Similarly, the consequences of dystrophin deficiency on central 
chemoreception is unclear. Central chemoreceptors are sensitive to changes in CO2 and 
pH. It is now clear that hypoxaemia and hypercapnia are common features of DMD, 
particularly during sleep, when ventilation is heavily dependent on chemoreceptor 
input. If chemoreception is affected by dystrophin deficiency in mdx mice (and DMD), 
then this would have major implications for the control of breathing.  
  
1.2.7 Dystrophin and neuromechanical control of breathing 
There is a paucity of information pertaining to the neural control of breathing in DMD 
and indeed animal models of DMD, despite respiratory morbidity and mortality being 
dominant features of the disease. Studies are required to understand the extent of 
respiratory system deficits and compensation in DMD and animal models, and to 
characterise temporal changes within the respiratory control network over the course 
of disease progression. Knowledge of fundamental aspects of respiratory control is 
essential in the consideration of respiratory management of patients with DMD. 
Studies should examine the capacity for plasticity within the motor pathway of the 
diaphragm, to potentially compensate for diaphragm functional deficits. A better 
appreciation of the intrinsic compensatory processes (if any) at play in DMD could help 
inform therapeutic strategies. Examination of the motor neuron pools involved in 
breathing and motor unit activity across ventilatory and non-ventilatory behaviours will 
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be important in determining if respiratory muscle activation is altered due to 
dystrophin deficiency. It is clear that neurotransmission in the CNS can be augmented 
in the absence of dystrophin. The neuro-modulators of relevance to breathing should 
be assessed to determine if the neurochemical control of breathing is intact in mdx 
mice. 
 
1.2.8 Other animal models of DMD 
Since the mdx mouse experiences a mild limb muscle phenotype compared with that 
observed in DMD boys, researchers have tried to develop more severe murine models 
by removing utrophin, a protein that purportedly compensates for the lack of 
dystrophin in the limb, thus responsible for the relative sparing of limb muscles in mdx 
mice. The dystrophin/utrophin double knockout mouse (mdx/utrn+/-), which exhibits a 
severe limb muscle pathology and a shortened lifespan, has been widely studied in 
recent years (McDonald et al., 2015). The mdx/utrn+/- mouse experiences cardiac 
damage similar to that of DMD patients (Delfín et al., 2012) and has greater skeletal 
muscle fibrosis compared with mdx mice, with the diaphragm muscle undergoing the 
greatest degree of fibrosis (Gutpell et al., 2015).  
 
A dystrophin deficient rat model of DMD was recently developed using transcript 
activator-like effector nucleases (TALENS) targeting exon 23. This model presents with 
limb and diaphragm muscle necrosis and regeneration, severe fibrosis and adipose 
tissue infiltration, reduced muscle strength and decreased spontaneous motor activity. 
A cardiac phenotype was evident that resembled dilated cardiomyopathy and altered 
diastolic function (Larcher et al., 2014).  
 
A common canine model of DMD is also used by researchers to study DMD and 
potential therapeutics (Howell et al., 1997; Nakamura & Takeda, 2011). Golden 
retriever muscular dystrophy (GRMD) is characterised by progressive skeletal muscle 
weakness and atrophy and cardiac dysfunction. Diaphragm muscle from the GRMD 
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model shows anatomical changes such as increased muscle thickness (Thibaud et al., 
2017). Mead et al. (2014) examined respiratory mechanics in the GRMD model and 
demonstrated a rapid progressive loss of ventilatory capacity in concert with major 
remodelling of the diaphragm muscle (Mead et al., 2014). The mechanics of breathing 
were extensively altered in the GRMD, with the main role of the diaphragm muscle 
becoming the passive elastic storage of energy transferred from the abdominal wall 
muscles, thus allowing the expiratory musculature to participate in the process of 
inspiration (Mead et al., 2014). These data are of major significance and are consistent 
with studies in DMD boys, and indicate accessory muscle compensation by the 
abdominal muscles. Additional research is required to examine the abdominal muscles 
in DMD and their potential role in facilitating breathing in DMD boys and models of 
DMD. Other models of DMD include a porcine model (Klymiuk et al., 2013), feline 
model (Kohn et al., 1993), and further genetic manipulations of mdx mice (Gosselin et 
al., 2003; Willmann et al., 2009; Nitahara-Kasahara et al., 2014; Pelosi et al., 2015b). 
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1.3 Role of inflammation in DMD pathophysiology 
Inflammation is a prominent feature of DMD, secondary to muscle fibre damage. 
Absence of dystrophin in DMD renders the skeletal muscle plasma membrane to a 
greater risk of contraction induced injury during muscle contraction. This mechanical 
damage can result in sarcolemmal tears and fibre damage, which triggers the 
recruitment of inflammatory mediators to the damaged muscle leading to immune cell 
infiltration (Deconinck & Dan, 2007). There is elevated expression of chemokines in 
serum and muscle samples from DMD patients (Pescatori et al., 2007; Abdel-Salam et 
al., 2010; De Paepe et al., 2012) and mdx mice (Porter et al., 2003; Demoule et al., 
2005). Inflammatory chemokines are formed in pathological conditions and have a role 
as chemoattractant molecules, which function to attract monocytes and lymphocytes 
to sites of inflammation.   
 
Similarly, there is heightened expression of pro-inflammatory cytokines in plasma and 
muscle biopsies from DMD boys. As such, systemic and muscle inflammation are 
pathological features of DMD and are major contributing factors in promoting disease 
progression. Cytokine expression studies in DMD report that interleukin-6 (IL-6) is 
significantly increased in DMD serum (Rufo et al., 2011; Cruz-Guzmán et al., 2015), 
along with increased levels of IL-1E and tumour necrosis factor-D (TNF-D) (Cruz-
Guzmán et al., 2015). There is increased mRNA and protein expression of TNF-D and IL-
6 in DMD muscle biopsies (Messina et al., 2011) and increased expression of IL-17 
mRNA (De Pasquale et al., 2012). 
 
1.3.1 Inflammation in mdx mice 
Histological and immuno-histochemical studies of diaphragm muscle from mdx mice 
demonstrate extensive muscle inflammation throughout life. Cytokine concentrations 
are elevated in mdx diaphragm muscle homogenates compared with wild-type 
diaphragm. Such findings indicate that dystrophin deficiency in the diaphragm can 
activate immune cell signalling. In stark contrast, limb muscle from mdx mice exhibits 
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extensive muscle inflammation at an early age (3 to 8 weeks of age), which subsides as 
mice age.  
 
1.3.2 Inflammation and oxidative stress 
There is increasing evidence in support of the link between inflammation and oxidative 
stress in dystrophic muscle. Inflammatory cells such as neutrophils can promote muscle 
damage following injury, while macrophages can also mediate muscle damage through 
the release of free radicals (Tidball, 2005). Elevated levels of free radicals can shift the 
redox balance and cause overt tissue damage and disruption to signalling cascades in 
muscle and other tissues (Tidball & Wehling-Henricks, 2007; Kozakowska et al., 2015). 
Diaphragm muscle weakness in mdx mice is associated with altered redox balance 
(Lawler, 2011; Kim et al., 2013). There is an increase in protein thiol oxidation and 
protein carbonyl content in mdx diaphragm (El-Shafey et al., 2011). The reactive 
oxygen species generating complex, NADPH oxidase, is upregulated in mdx diaphragm 
and is implicated in promoting muscle dysfunction (Loehr et al., 2018). Reactive oxygen 
species production is increased in mdx muscle (Dudley et al., 2006a; Dudley et al., 
2006b; Whitehead et al., 2006; Allen et al., 2010; Kim & Lawler, 2012; Kim et al., 2013). 
Lipofuscin granules, a marker of oxidative stress, are elevated in mdx diaphragm 
(Nakae & Stoward, 2016) and glutathione peroxidase mRNA and protein expression are 
increased in DMD muscle (Messina et al., 2011). Dystrophic diaphragm has significant 
reductions in Nrf2 protein and SIRT1 gene expression, increased dihydroethidium 
(DHE) staining, indicating a pro-oxidant environment, with a concomitant increase in 
pro-inflammatory gene expression (Pelosi et al., 2017). Antioxidant interventions in 
mdx mice have shown improvements in skeletal muscle form and function (Ismail et 
al., 2014; Capogrosso et al., 2016; Burns et al., 2017; Mâncio et al., 2017). 
 
1.3.3 Targeting inflammation as a therapy in DMD 
Curcumin, a potent NF-NB inhibitor, has been examined as a potential therapeutic 
agent in mdx mice. This anti-inflammatory agent was found to improve sarcolemmal 
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integrity, improve grip strength and alleviate structural deficits observed in dystrophic 
muscle (Pan et al., 2008). Moreover, the concentrations of the pro-inflammatory 
cytokines IL-1E and TNF-D were significantly reduced in mdx serum (Pan et al., 2008). 
The cellular inhibitor of apoptosis 1 (cIAP1) protein is a regulator of NF-NB signalling 
pathways. Enwere et al. (2013) examined if loss of cIAP1 in mdx mice would alleviate 
skeletal muscle dysfunction (Enwere et al., 2013). Double mutant cIAP1/mdx mice 
presented with reduced immune cell invasion and decreased cytokine expression in the 
soleus muscle, together with reduced muscle fibre central nucleation compared with 
mdx. Remicade, a TNF blocking agent, showed modest benefits on skeletal muscle 
strength and fibrosis in mdx mice, however inhibition of Akt was observed in mdx mice, 
which negatively influences cardiac function (Ermolova et al., 2014).   
 
Non-steroidal anti-inflammatory drug (NSAID) treatment in mdx mice improved muscle 
morphology and reduced macrophage infiltration and necrosis, but had no beneficial 
effect on isometric force (Serra et al., 2012). Inflammatory cytokines and 
cyclooxygenase-2 expression were decreased following NSAIDs in mdx skeletal muscle. 
The immunosuppressant drug rapamycin was administered to mdx mice to examine its 
effects on dystrophic muscles (Eghtesad et al., 2011). Muscle fibre necrosis was 
significantly reduced in mdx diaphragm and limb muscle following rapamycin 
treatment and the infiltration of CD4+ and CD8+ T cells in skeletal muscle was 
decreased.  
 
1.3.4 Cytokines  
IL-15 is expressed in skeletal muscle and is known to have anabolic effects on muscle. 
Harcourt et al. (2005) demonstrated that four weeks of IL-15 administration in mdx 
mice improved diaphragm muscle strength, decreased collagen infiltration and 
increased muscle fibre cross-sectional area (Harcourt et al., 2005). The anti-
inflammatory cytokine IL-10 is elevated in skeletal muscle from mdx mice and localised 
to the surface of mono-nucleated cells in inflammatory lesions and regenerating 
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muscle fibres and myotubes (Villalta et al., 2011; Pelosi et al., 2017). Ablation of IL-10 
in mdx mice resulted in increased muscle damage in vivo and poor muscular strength. 
The authors concluded that IL-10 has a regulatory role in mdx mice that may be 
executed by decreasing M1 macrophage activation and cyto-toxicity, increasing M2c 
macrophage activation and modulating muscle differentiation. In a similar study, 
ablation of IL-10 in mdx mice resulted in severe cardio-respiratory dysfunction 
(Nitahara-Kasahara et al., 2014). The hearts of mdx mice lacking IL-10 were severely 
affected and exhibited extensive muscle degeneration and myofibre loss and functional 
reductions in percent fractional shortening and percent ejection fraction. Cytokines 
and chemokines were elevated in the diaphragm muscle of these mice and a significant 
reduction in tidal volume was reported compared with mdx mice. These data suggest a 
significant role for IL-10 as an immune-modulator in dystrophic muscle; it appears that 
susceptibility to inflammation in mdx mice is an important feature in the development 
of cardio-respiratory dysfunction. TNF-D deletion in mdx improved diaphragm muscle 
force and increased ventilatory capacity (Gosselin et al., 2003).   
 
1.3.5 Interleukin-6 
IL-6 is a pleiotrophic cytokine with anti- and pro-inflammatory actions in health and 
disease. IL-6 is secreted mainly from macrophages and T cells and plays a critical role in 
inflammation and tissue injury (Fisman & Tenenbaum, 2010). IL-6 signals through the 
IL-6 receptor (IL-6R), of which there are two subtypes, the soluble form (sIL-6R) and the 
transmembrane form (Scheller et al., 2011). IL-6 signalling is complex and involves the 
signal transducing receptor glycoprotein 130 (gp130). The transmembrane IL-6R is 
mainly found in hepatocytes and leukocytes, with low expression in skeletal muscle 
(Keller et al., 2005). The circulating sIL-6R is a ligand binding protein derived from the 
extracellular portion of the IL-6R by proteolytic cleavage or differential IL-6R mRNA 
splicing (Robson-Ansley et al., 2010). IL-6 is released from muscle in response to 
exercise, injury and stress (Welc & Clanton, 2013). In chronic diseases such as DMD, IL-
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6 exerts pro-inflammatory actions. Binding of IL-6 to the IL-6 receptor activates the 
JAK/STAT signalling pathway (Pedersen & Febbraio, 2008). 
 
IL-6 levels are increased in DMD and mdx mice (Rufo et al., 2011; Cruz-Guzmán et al., 
2015; Pelosi et al., 2015a). Blockade of IL-6 signalling in mdx mice using a neutralizing 
IL-R antibody (xIL-6R) (Okazaki et al., 2002) has proved beneficial to muscle physiology 
(Pelosi et al., 2015a; Manning et al., 2016, 2017). IL-6R neutralization improved 
diaphragm force generation (Manning et al., 2017), restoration of gastrointestinal form 
and function (Manning et al., 2016), improved treadmill exercise and decreased 
diaphragm muscle inflammation (Pelosi et al., 2015a). Similarly, blockade of IL-6 in the 
mdx/utrn+/- increased the area of embryonic MyHC-positive fibres, indicating muscle 
fibre regeneration, and reduced fibrosis in quadriceps muscle (Wada et al., 2017). 
Serum creatine kinase was also reduced, indicating improved muscle integrity. 
Although significant improvements in limb muscle were noted, diaphragm and cardiac 
muscle pathology were not improved. Neutralisation of IL-6 in mice with cardio-toxin 
induced muscle damage was shown to promote muscle regeneration (Fujita et al., 
2014). Overexpression of IL-6 in mdx mice results in more severe muscle damage than 
that seen in mdx mice and an upregulation of genes related to antioxidant defence 
mechanisms (Pelosi et al., 2015b; Pelosi et al., 2017). These data suggest a contributing 
role for IL-6 in dystrophic muscle dysfunction. 
 
1.3.6 Anabolic signalling in muscle 
Muscle proteolysis occurs in DMD due to muscle damage and injury, there is increased 
serum creatine kinase due to decreased muscle integrity and activation of autophagy 
signalling pathways. Glucocorticoids are the gold standard treatment in DMD and are 
known to regulate protein metabolism in skeletal muscle, often promoting muscle 
atrophy. Targeting anabolic signalling in dystrophic muscle and supporting protein 
synthesis may be of potential benefit to skeletal muscle physiology.   
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Corticotrophin releasing factor (CRF) is known to have effects on skeletal and cardiac 
muscle signalling. CRF is released from the paraventricular nucleus of the 
hypothalamus in response to stress and hypothalamic-pituitary activation, and drives 
the release of adreno-corticotrophin hormone (ACTH) from the pituitary gland. CRF 
binds to CRF receptors (CRFR), of which there are two subtypes, CRFR1 and CRFR2. 
These are G-protein coupled receptors and CRF maintains high affinity for both CRFR1 
and CRFR2, which on activation, activates adenylyl cyclase and increases cyclic AMP 
formation (Reutenauer-Patte et al., 2012). Skeletal muscle expresses CRFR2 and CRFR2 
agonists have the ability to modulate muscle mass. CRFR2 agonist treatment has been 
shown to promote increases in muscle mass and decrease muscle loss in atrophying 
conditions (Hinkle et al., 2003a; Hinkle et al., 2003b; Hinkle et al., 2004). These effects 
are mediated by activation of anabolic signalling pathways and decreased proteolysis. 
Urocortin-2 is an endogenous peptide highly selective for CRFR2. 
 
CRFR2 agonist treatment in mdx mice prevents diaphragm force loss and reduces 
muscle fibrosis, immune cell infiltration and immune cell-related gene expression 
(Hinkle et al., 2007). Similarly, CRFR2 agonist treatment in mdx mice increased extensor 
digitorum longus and soleus muscle mass (Hall et al., 2007). Urocortin-2 treatment in 
mdx mice increased skeletal muscle mass and reduced creatine kinase levels 
(Reutenauer-Patte et al., 2012). Moreover, urocortin-2 reduced muscle fibre necrosis 
in the diaphragm. In models of myocardial infarction, urocortin-2 improves cardiac 
function and ameliorates cardiac remodelling (Ellmers et al., 2015). In a similar 
manner, urocortin-2 is cardio-protective during ischemia reperfusion injury (Gao et al., 
2015).  
 
Collectively, these data indicate a potential role for Urocotin-2 in stimulating anabolic 
signalling in dystrophic muscle and modulating muscle mass and fibre hypertrophy, 
along with improving muscle integrity.  
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1.3.7 Knowledge gaps addressed in this thesis  
Currently, much remains to be examined in terms of respiratory system control in DMD 
and animal models of the dystrophinopathies. There are many knowledge gaps relating 
to the complete consequences of dystrophin deficiency on the respiratory control 
network. It is unclear if there are neural deficits or compensations in the control of 
breathing as a result of dystrophin deficiency. Dystrophic diaphragm muscle undergoes 
a progressive pathology, but it is unclear the extent to which ventilatory capacity is 
limited by profound diaphragm dysfunction in mdx mice. Given that inflammation is 
such a prominent feature of DMD and pathology in mdx mice, it is important to 
determine if there is evidence of neuroinflammation at sites related to respiratory 
control in mdx mice. Is there a capacity for neuromodulatory compensation in the 
motor pathway of breathing, in order to preserve ventilatory capacity? Can modulation 
of inflammatory-related and stress signalling using a combined anti-inflammatory and 
anti-stress intervention in mdx mice improve respiratory performance? These 
questions and several others posed in this review are addressed in this thesis. 
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1.4 Thesis structure and specific aims 
The overall aim of this thesis was to investigate respiratory system control in a murine 
model of Duchenne muscular dystrophy - the mdx mouse. We sought to explore 
deficits and compensation within the respiratory control network, arising from 
dystrophin deficiency in young (8-week-old) mdx mice. Additionally, we sought to 
elucidate the putative contribution of mediators of inflammation and stress to 
respiratory deficits in mdx mice. 
 
Chapter 2: Sensorimotor control of breathing in the mdx mouse model of Duchenne 
muscular dystrophy. 
 
• Investigate chemo-afferent discharge from the carotid bodies of wild-type and 
mdx mice. 
• Assess ventilation and metabolic activity during normoxia and in response to 
hypoxia in conscious wild-type and mdx mice. 
• Characterise diaphragm muscle form and function in wild-type and mdx. 
• Examine diaphragm EMG activity under basal conditions and in response to 
maximal chemostimulation in anaesthetised wild-type and mdx mice.  
 
 
Chapter 4: Neuromechanical control of breathing in the dystrophin-deficient mdx 
mouse.  
 
• Examine respiratory stability and ventilatory capacity in conscious wild-type and 
mdx mice. 
• Investigate the neuro-mechanical control of breathing in wild-type and mdx 
mice. 
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• Examine the mdx cervical spinal cord (containing the phrenic motor nucleus) for 
evidence of inflammatory remodelling and apoptosis and monoamine 
concentrations compared with wild-type. 
 
 
Chapter 5: Restoration of pharyngeal dilator muscle force in dystrophin-deficient (mdx) 
mice following co-treatment with neutralizing interleukin-6 receptor antibodies and 
urocortin-2. 
 
• Assess the effects of blocking interleukin-6 receptor signalling and stimulating 
corticotrophin releasing factor receptor 2 with urocortin-2 on the form and 
function of wild-type and mdx sternohyoid muscle. 
 
 
Chapter 6: Recovery of respiratory function in mdx mice co-treated with neutralizing 
interleukin-6 receptor antibodies and urocortin-2. 
 
In wild-type and mdx mice, examine the effects of co-administration of neutralizing 
interleukin-6 receptor antibodies and urocortin-2 on: 
 
• Diaphragm muscle force-generating capacity.  
• Ventilation and metabolism in response to acute physiological gas challenges. 
• Diaphragm muscle structure and MyHC isoform composition. 
• Cytokine concentrations in the diaphragm. 
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Cover image shows representative immunofluorescent image of diaphragm muscle 
from a wild-type mouse. Murine diaphragm muscle expresses type I (blue), type IIa 
(red), type IIx (untagged, appearing black) and type IIb (green) myosin heavy chain 
isoforms. Top left shows representative traces for diaphragm raw (red) and integrated 
(blue) EMG activity in an anaesthetised mouse. Bottom right shows original trace of 
diaphragm force-frequency relationship ex vivo (green). 
  
 66 
Key points  
• Respiratory failure is a leading cause of mortality in Duchenne muscular 
dystrophy (DMD), but little is known about the control of breathing in DMD and 
animal models. 
• We show that young (8 weeks of age) mdx mice hypoventilate during basal 
breathing due to reduced tidal volume. Basal CO2 production is equivalent in 
wild-type and mdx mice. 
• We show that carotid bodies from mdx mice have blunted responses to 
hyperoxia, revealing hypoactivity in normoxia. However, carotid body, 
ventilatory and metabolic responses to hypoxia are equivalent in wild-type 
and mdx mice. 
• Our study revealed profound muscle weakness and muscle fibre remodelling in 
young mdx diaphragm suggesting severe mechanical disadvantage in mdx mice 
at an early age. 
• Our study reveals a potentiated neural motor drive to breathe in mdx mice 
during maximal chemoactivation, suggesting compensatory neuroplasticity 
enhancing respiratory motor output to the diaphragm and likely other 
accessory muscles.  
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Abbreviations: AUC, area under the curve; CSA, cross-sectional area; CSN, carotid sinus 
nerve; CT, contraction time; DMD, Duchenne muscular dystrophy; EMG, 
electromyogram; fR, respiratory frequency; FiO2, fractional inspired oxygen 
concentration; Hb, haemoglobin; HCO3-, bicarbonate; Lo, optimum length; MFO, mean 
frequency oscillation; PCO2, partial pressure of CO2; PO2, partial pressure of O2; Pt, 
isometric twitch force; SpO2, arterial O2 percent saturation; TCO2, total CO2; VE, minute 
ventilation; VE/VCO2, ventilatory equivalent for CO2; VE/VO2, ventilatory equivalent for 
O2; VCO2, carbon dioxide production; VO2, oxygen consumption; VT, tidal volume; ½ RT, 
half-relaxation time. 
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Abstract 
Patients with Duchenne muscular dystrophy (DMD) hypoventilate with consequential 
arterial blood gas derangement relevant to disease progression. Whereas deficits in 
DMD diaphragm are recognized, there is a paucity of knowledge in respect of the 
neural control of breathing in dystrophinopathies. We sought to perform an analysis of 
respiratory control in a model of DMD, the mdx mouse. In eight week old male wild-
type and mdx mice, ventilation and metabolism, carotid body afferent activity, and 
diaphragm muscle force-generating capacity, and muscle fibre size, distribution and 
centronucleation were determined. Diaphragm EMG activity and responsiveness to 
chemostimulation was determined. During normoxia, mdx mice hypoventilated, owing 
to a reduction in tidal volume. Basal CO2 production was not different between wild-
type and mdx mice. Carotid sinus nerve responses to hyperoxia were blunted in mdx 
suggesting hypoactivity. However, carotid body, ventilatory and metabolic responses 
to hypoxia were equivalent in wild-type and mdx mice. Diaphragm force was severely 
depressed in mdx mice, with evidence of fibre remodelling and damage. Diaphragm 
EMG responses to chemoactivation were enhanced in mdx mice. We conclude that 
there is evidence of chronic hypoventilation in young mdx mice. Diaphragm 
dysfunction confers mechanical deficiency in mdx resulting in impaired capacity to 
generate normal tidal volume at rest and decreased absolute ventilation during 
chemoactivation. Enhanced mdx diaphragm EMG responsiveness suggests 
compensatory neuroplasticity facilitating respiratory motor output, which may extend 
to accessory muscles of breathing. Our results may have relevance to emerging 
treatments for human DMD aiming to preserve ventilatory capacity.   
 
Keywords: Duchenne muscular dystrophy, mdx, hypoventilation, carotid body, 
diaphragm, EMG 
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2.1 Introduction 
Duchenne muscular dystrophy (DMD) is a fatal X-linked neuromuscular disease 
characterized by dystrophin deficiency. Deficits in this structural protein lead to 
aberrant structural remodelling and damage in skeletal and other muscles (Muntoni et 
al., 2003; Deconinck & Dan, 2007; Ervasti, 2007; Mosqueira et al., 2013b), with 
consequential profound muscle weakness extending to the striated muscles of 
breathing—the final effectors in the respiratory control network. Respiratory 
insufficiency is a hallmark of DMD (Baydur et al., 1990; Bersanini et al., 2012). Whereas 
diaphragm dysfunction is a recognized primary morbid feature in DMD (De Bruin et al., 
1997; Beck et al., 2006; Khirani et al., 2014), there is a paucity of knowledge in respect 
of the neural control of breathing in the human dystrophinopathies. Of note, DMD 
patients hypoventilate with resultant hypoxaemia (Smith et al., 1989a, b; Melacini et 
al., 1996), a symptom which may have particular relevance to muscle pathology and 
disease progression, in the light of data from rodent models revealing hypoxia-induced 
respiratory muscle weakness (McMorrow et al., 2011; Skelly et al., 2012; Shortt et al., 
2014) due to altered redox signalling and overt oxidative stress (Lewis et al., 2015; 
Lewis et al., 2016), which are features of DMD. 
 
Respiratory failure in DMD results in premature death. Yet, the early impact of 
dystrophin deficiency on the respiratory control network is unclear. This knowledge 
gap is significant and has potential relevance to the treatment of DMD. It is not known 
if dystrophin deficiency has consequences for sensorimotor control of breathing. There 
is ample evidence in support of remarkable capacity for plasticity within the respiratory 
control network governing arterial blood gas and pH homeostasis in health and disease 
(Mitchell & Johnson, 2003; Kumar & Prabhakar, 2012; Fuller & Mitchell, 2017). Sensory 
and motor plasticity is context-dependent, with a capacity for adaptive or maladaptive 
outcomes. Compensatory neuroplasticity at one or more sites of the respiratory 
control network could ameliorate respiratory muscle deficits in early stages of DMD. 
Conversely, sensorimotor deficits could exacerbate aberrant respiratory control in 
 70 
DMD and contribute to disease progression. Dystrophin is present in the carotid body 
(Mosqueira et al., 2013a), the primary blood oxygen sensor, but it is unclear if 
dystrophin deficiency affects chemoafferent discharge and as such, the control of 
breathing. Dystrophin is also present in neurons (Lidov, 1996), but it is not known if 
central respiratory motor drive is affected by dystrophinopathies, potentiating or 
ameliorating impaired respiratory mechanics due to respiratory muscle weakness. A 
greater understanding of the control of breathing in DMD is likely to prove important 
to therapeutic strategies, and might offer novel targets in interventional therapies 
particularly early in disease onset before the establishment of overt respiratory 
pathology. 
 
We sought to perform an assessment of respiratory control in a young murine model of 
DMD—the mdx mouse. Whereas, diaphragm dysfunction faithfully recapitulating the 
human condition has been established in the model, assessment of respiratory control, 
especially in young animals, is lacking. We hypothesized that there should be evidence 
of neuroplasticity in the respiratory control network of the mdx mouse. 
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2.2 Methods 
2.2.1 Ethical approval 
Procedures concerning live animals were performed under licence in accordance with 
Irish and European directive 2010/63/EU following approval by University College Cork 
animal research ethics committee. Carotid body recordings were performed in 
accordance with The Canadian Council on Animal Care Guidelines and were approved 
locally by the Animal Care Committee of the Cumming School of Medicine, University 
of Calgary, Canada. 
 
2.2.2 Experimental animals 
Male and female wild-type (C57BL/10ScSnJ) and mdx (C57BL/10ScSn-Dmdmdx/J) mice 
were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and bred at 
University College Cork’s animal housing facility. Eight-week-old male wild-type (n = 53) 
and mdx (n = 52) mice were studied for respiratory and metabolism measurements, ex 
vivo muscle function tests, tissue harvesting for immunohistochemistry, in vivo EMG 
recordings and arterial blood gas analysis. For carotid body-carotid sinus nerve 
preparations, male wild-type (n = 6) and mdx (n = 6) mice were purchased from the 
Jackson Laboratory and transferred to the University of Calgary for subsequent 
experiments at eight weeks of age. Animals were housed conventionally in 
temperature- and humidity-controlled facilities, operating on a 12 h light: 12 h dark 
cycle with food and water available ad libitum. 
 
2.2.3 Respiratory recordings 
Respiratory flow recordings were performed using whole-body plethysmography in 
unrestrained, unanaesthetised mice during quiet rest. Wild-type (n = 13) and mdx (n = 
12) mice were introduced into plethysmograph chambers (Model PLY4211; 
volume=600mL, Buxco Research Systems, Wilmington, NC, USA) and allowed a 60-90 
minute acclimation period until sufficiently settled, with room air passing through each 
chamber (1 L/min). Recordings were typically performed in parallel, with 
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contemporaneous assessment of breathing in one wild-type mouse and one mdx 
mouse using a two chamber set-up. For successive recording sessions, mice were 
assigned to chambers based on genotype in an alternating fashion to avoid any 
potential bias associated with a given chamber. Post hoc analysis of breathing within 
each genotype confirmed no difference in parameters recorded comparing data 
derived from the two chambers.   
 
Experimental protocol: Following the acclimation period, a 20-30-minute baseline 
recording was performed in normoxia. This was followed by a 20-minute hypoxic 
challenge (FiO2 = 0.1; balance N2). Following a 60-minute recovery period in normoxia, 
a 20-30 minute normoxic baseline period was recorded. This was followed by a graded 
hypoxic challenge in which animals were challenged with decreasing levels of inspired 
oxygen: FiO2 = 0.15, 0.12, 0.10, and 0.08 (balance N2) consecutively for 5 minutes each. 
Respiratory parameters including respiratory frequency (fR), tidal volume (VT) and 
minute ventilation (VE) were recorded on a breath-by-breath basis for analysis offline. 
 
 Data analysis: To maximize the recording period for the assessment of ventilatory 
parameters in normoxia, both normoxic bouts were pooled to generate one set of 
baseline (normoxia) data; there was no significant difference for ventilatory 
parameters between the two normoxic periods. Based on the time constant for the 
plethysmograph chambers and that gases were thoroughly mixed before entry to the 
plethysmograph chambers, we assumed complete gas mixing during gas challenges by 
~3 minutes of exposure. For the sustained (20 minute) hypoxic challenge, data are 
shown after 5 minutes of exposure and are presented on a minute-by-minute basis 
thereafter. For the graded hypoxic challenge, measurements were taken during the 5th 
minute of exposure to the given FiO2 challenge. For each of the hypoxic challenges 
(sustained and graded), data during hypoxic exposure were compared with the 
preceding 5 minutes of baseline (FiO2: 0.21). In a separate historical cohort of wild-type 
(n = 10) and mdx (n = 11) mice (Burns et al., 2015), we assessed the ventilatory 
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response to a 10 minute hypercapnic gas challenge (5% CO2, balance O2). VT and VE 
were normalised for body mass (g). 
 
2.2.4 Metabolism measurements 
O2 consumption (VO2) and CO2 production (VCO2) were measured in wild-type (n = 13) 
and mdx (n = 12) mice undergoing the whole-body plethysmography protocol. Airflow 
through the chamber was maintained at 1 L/min. Fractional concentrations of O2 and 
CO2 were measured in air entering and exiting the plethysmograph (O2 and CO2 
analyzer; ADInstruments, Colorado Springs, CO, USA) similar to that previously 
described (Bavis et al., 2010; Bavis et al., 2014).  
 
Data analysis: calculation of VO2 and VCO2 was performed as previously described 
(Haouzi et al., 2009). For the sustained (20 minute) hypoxic challenge data are shown 
after 5 minutes of exposure and are presented on a minute-by-minute basis thereafter. 
For the graded hypoxic challenge, measurements were taken during the 5th minute of 
exposure to the given FiO2 challenge. For each of the hypoxic challenges (sustained and 
graded), data during hypoxic exposure were compared with the preceding 5 minutes of 
baseline (FiO2: 0.21). VO2 and VCO2 were normalised for body mass (g). 
 
2.2.5 Blood gas analysis  
Wild-type (n = 7) and mdx (n = 7) mice were anaesthetised with 5% isoflurane in air. A 
laparotomy was performed and cardiac puncture was performed by advancing a 25G 
needle through the diaphragm and into the apex of the heart for blood sampling for 
analysis. 0.2ml of blood was collected and used to measure pH, the partial pressure of 
O2 (PO2) and CO2 (PCO2), total CO2 (TCO2), bicarbonate concentration [HCO3-], arterial 
saturation (SaO2), sodium ion concentration [Na+], potassium ion concentration [K+], 
haematocrit and haemoglobin concentration [Hb] using a blood gas analyzer (i-Stat; 
Heska, Fort Collins, CO, USA). Animals were killed by cervical dislocation.  
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2.2.6 Arterially perfused ex vivo carotid body-carotid sinus nerve preparation  
At the University of Calgary, wild-type (n = 6) and mdx (n = 6) mice were heavily 
anaesthetised with isoflurane and then decapitated (lower cervical level). The carotid 
bifurcation, including the carotid body-carotid sinus nerve-superior cervical ganglion, 
was quickly isolated en bloc for in vitro perfusion as described previously (Roy et al., 
2012). The carotid bifurcation was then transferred to a dissection dish containing 
physiological saline (in mM: 1 MgSO4, 1.25 NaH2PO4, 4 KCl, 24 NaHCO3, 115 NaCl, 10 
glucose, 12 sucrose, and 2 CaCl2) and equilibrated with hyperoxia (95% O2/5% CO2). 
After 15-20 minutes, the isolated tissue was transferred to a recording chamber with a 
built-in water-fed heating circuit and the common carotid artery was immediately 
cannulated for luminal perfusion with physiological saline equilibrated with 100 mmHg 
PO2 and 36 mmHg PCO2 (balance N2). The carotid sinus nerve was then carefully 
desheathed and the carotid sinus region was bisected. The occipital, internal, and 
external arteries were ligated, and small incisions were made on the internal and 
external carotid arteries to allow perfusate to exit. A peristaltic pump was used to set 
the perfusion rate at ~10 ml/min, which was sufﬁcient to maintain a constant pressure 
of 90-100 mmHg at the tip of the cannula. The perfusate was equilibrated with 
computer-controlled gas mixtures monitored using CO2 and O2 gas analyzers (models 
CA-2A and PA1B, respectively, Sable Systems, Las Vegas, NV, USA); a gas mixture of 100 
mmHg PO2 and 36 mmHg PCO2 (balance N2) was used to start the experiments 
(yielding pH ~7.4). Before reaching the cannula, the perfusate was passed through a 
bubble trap and heat exchanger. The temperature of the perfusate, measured 
continuously as it departed the preparation, was maintained at 37 ± 0.5°C. The efﬂuent 
from the chamber was recirculated.  
 
Chemosensory discharge was recorded extracellularly from the whole desheathed 
carotid sinus nerve, which was placed on a platinum electrode and lifted into a thin 
ﬁlm of parafﬁn oil. A reference electrode was placed close to the bifurcation. Carotid 
sinus nerve activity was monitored using a differential AC ampliﬁer (model 1700, AM 
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Systems) and a secondary ampliﬁer (model AM502, Tektronix, Beaverton, OR). The 
neural activity was ampliﬁed, ﬁltered (300-Hz low cutoff, 5-kHz high cutoff), displayed 
on an oscilloscope, rectiﬁed, integrated (200-ms time constant), and stored on a 
computer using an analogue-to-digital board (Digidata 1322A, Axon Instruments, Union 
City, CA, USA) and data acquisition software (Axoscope 9.0). Preparations were left 
undisturbed for 45 minutes to stabilize before the experimental protocol began.  
 
Experimental protocol: The following protocol was used for all experiments: 1) the 
carotid body was perfused for 5 minutes with normoxia (100 mmHg PO2 and 36 mmHg 
PCO2; balance N2) to determine baseline carotid sinus nerve activity; 2) neural 
responses were obtained by challenging the carotid body for 5 minutes with mild, 
moderate and severe hypoxia (80, 60 & 40 mmHg, respectively) interspersed with 
normoxia; 3) finally a hyperoxic (500 mmHg PO2 and 36 mmHg PCO2; balance N2) 
challenge was given for 5 minutes to examine the sensitivity of the carotid body 
(Dejours test).  
 
Data analysis: Data were analyzed ofﬂine using custom software (written by R.J.A. 
Wilson). Carotid sinus nerve activity was divided into 2 second time bins, and activity in 
each bin was rectiﬁed and summed (expressed as integrated neural discharge). Data 
are shown as absolute carotid sinus nerve discharge frequencies in each of the 
different conditions in the protocol. Neural responses to PO2 challenge were 
determined by comparing absolute discharge frequencies and also responses 
normalised to the hyperoxic condition, and separately to the normoxic condition.  
 
2.2.7 Ex vivo muscle function tests 
Diaphragm muscle function was examined ex vivo under isometric conditions using a 
standardized protocol as previously described (Shortt et al., 2014). Wild-type (n = 7) 
and mdx (n = 7) mice were anaesthetised with 5% isoflurane by inhalation in air and 
euthanized by cervical dislocation. The diaphragm muscle was excised immediately 
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with rib and central tendon attached. Longitudinally arranged bundles were prepared 
for assessment of contractile function and were suspended vertically between two 
platinum plate electrodes. The rib was attached to a fixed hook at one end and the 
central tendon was attached to a force transducer with non-elastic string at the other 
end. Muscle baths contained Krebs solution (in mM: 120 NaCl, 5 KCl, 2.5 Ca2+, 1.2 
MgSO4, 1.2 NaH2PO4, 25 NaHCO3, 11.5 glucose) and ᴅ-tubocurarine (25μM) and were 
equilibrated under hyperoxic conditions (95% O2/ 5% CO2). The optimum length (Lo) 
was determined by adjusting the position of the force transducer, and hence the length 
of the muscle preparations, by use of a micro-positioner between intermittent twitch 
contractions (Burns & O'Halloran, 2016; Burns et al., 2017). Lo was taken as the muscle 
length associated with maximal isometric twitch force in response to single isometric 
twitch stimulation (supramaximal stimulation, 1ms duration). Once Lo was determined, 
the muscle was held at this length for the duration of the protocol.  
 
Experimental protocol: A single isometric twitch was measured. Peak isometric twitch 
force (Pt), contraction time (CT; time to peak force) and half-relaxation time (½ RT; time 
for peak force to decay by 50%) were determined. The force-frequency relationship 
was determined by sequentially stimulating the muscle at 10, 20, 40, 60, 80, 100, 120, 
140, 160 Hz (300ms train duration), allowing a 1 minute interval between stimulation.  
 
Data analysis: Specific force was calculated in N/cm2 of muscle cross-sectional area 
(CSA). The CSA of each strip was determined by dividing the muscle mass (weight in 
grams) by the product of muscle Lo (cm) and muscle density (assumed to be 1.06 
g/cm3). The CT and ½ RT were measured as indices of isometric twitch kinetics. 
Normalisation of diaphragm forces to CSA was principally a means of standardizing the 
ex vivo muscle preparations. It should be noted that tissue, and not muscle fibre CSA 
was estimated with this approach and our data do not provide information on the 
specific force of muscle fibres per se, which might also require consideration of revised 
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muscle density values in mdx. Absolute muscle forces (N) were also assessed and 
compared in our study. 
 
2.2.8 Muscle immunohistochemistry 
Wild-type (n = 8) and mdx (n = 8) mice were anaesthetised with 5% isoflurane by 
inhalation in air and euthanized by cervical dislocation. Diaphragm muscle was excised 
immediately and a section of the hemi-diaphragm was mounted on a block of liver. 
Tissue samples were embedded in optimum cutting temperature (OCT; VWR 
International, Dublin, Ireland) embedding medium, frozen in isopentane (Sigma 
Aldrich, Wicklow, Ireland) cooled in liquid nitrogen and stored at -80oC for subsequent 
structural analysis. Serial transverse muscle sections (10µm) were cryosectioned (Leica 
CM3050; Leica Microsystems, Nussloch, Germany) at -22oC and mounted on polylysine-
coated glass slides (VWR International, Dublin, Ireland). Slides were immersed in PBS 
(0.01 M) containing 1% bovine serum albumin (BSA) for 15 minutes. After 3x5 minute 
PBS washes, slides were immersed in PBS containing 5% normal goat serum (Sigma 
Aldrich, Wicklow, Ireland) for 30 minutes. Slides then underwent a further 3x5 minute 
PBS washes prior to application of the primary antibody (rabbit anti-laminin, 1:500; 
Sigma Aldrich, Wicklow, Ireland), diluted in PBS and 1% BSA. Slides were incubated 
overnight at 4oC in a humidity chamber. After the incubation period, slides were 
washed with PBS for 3x5 minutes before the secondary antibody (FITC-conjugated goat 
anti-rabbit; 1.250, Sigma Aldrich, Wicklow, Ireland), diluted in PBS and 1% BSA, was 
applied. Slides were incubated for 1 hour in the dark at room temperature. To identify 
myonuclei, the nuclear stain Hoechst (Sigma Aldrich, Wicklow, Ireland) was diluted in 
PBS (1:4) and applied to a subset of muscle sections for 10 minutes. Slides were rinsed 
with PBS for 5 minutes, cover-slipped with polyvinyl alcohol mounting medium with 
DABCO® anti-fade (Sigma Aldrich, Wicklow, Ireland).  
 
Data analysis: Muscle sections were viewed at x10 magnification and images captured 
using an Olympus BX51 microscope and an Olympus DP71 camera. For each animal, 3-
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4 images were captured for analysis from multiple muscle sections. For measurements, 
a square test frame of (600 x 600 μm), with inclusion and exclusion boundaries, was 
placed randomly over each image (Shortt et al., 2014). To determine the size 
distribution of muscle fibres within the diaphragm the individual fibre boundaries were 
determined using Imaris software. From this, the fibre cross-sectional area as well as 
Feret’s minimal diameter were determined (Dubach-Powell, 2008). The coefficient of 
variation of muscle fibre minimal Feret’s diameter, was also constructed for wild-type 
and mdx. In a subset of animals (n = 5 per genotype) centrally nucleated muscle fibres 
were identified using ImageJ software on merged laminin and hoescht stained images. 
The proportion of centrally nucleated muscle fibres was expressed relative to the total 
number of myofibres analyzed per image. Data generated from multiple images was 
averaged per animal before computing group means.  
 
2.2.9 Diaphragm EMG activity and responsiveness  
Anaesthesia was induced with 5% isoflurane in 60% O2 (balance N2) followed by 
urethane (1.8 g/kg i.p.). Wild-type (n = 8) and mdx (n = 7) mice were then placed in the 
supine position, gradually weaned off the isoflurane and body temperature was 
maintained at 37oC via a rectal probe and thermostatically-controlled heating blanket 
(Harvard Apparatus, Holliston, MA, USA). Supplemental anaesthetic was administered 
if necessary to maintain a surgical plane of anaesthesia, which was assessed by 
assessment of pedal withdrawal reflex to noxious pinch. A pulse oximeter clip 
(MouseOxTM, Starr Life Sciences Corporation, Oakmount, PA, USA) was placed on the 
thigh of each mouse for the measurement of arterial O2 saturation. A mid-cervical 
tracheotomy was performed to avoid upper airway obstruction. All animals were 
maintained with a bias flow of supplemental O2 (FiO2 = 0.60) unless otherwise stated. 
Concentric needle electrodes (26G; Natus Manufacturing Ltd, Ireland) were inserted 
into the costal diaphragm for the continuous measurement of diaphragm EMG activity 
which was amplified (x5,000), filtered (500Hz low cut-off to 5,000Hz high cut-off) and 
integrated (50ms time constant; Neurolog system, Digitimer Ltd, UK). All signals were 
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passed through an analogue-to-digital converter (r8/30; ADInstruments, Colorado 
Springs, CO, USA) and were acquired using LabChart 7 (ADInstruments, Colorado 
Springs, CO, USA).  
 
Experimental protocol: Spontaneously breathing animals were vagotomized and 
allowed to stabilize for a minimum of 5 minutes before baseline parameters were 
measured. It is established that chemostimulation in spontaneously breathing mice 
elicits a significantly greater phrenic motor response following vagotomy compared 
with vagi intact (Kline et al., 2002). Next, animals were sequentially challenged with 
hypercapnia (5% CO2 and 10% CO2; 2min each), hypoxia (15% O2; 1min), and asphyxia 
(15% O2/5% CO2; 1min) to examine the effects of chemostimulation on diaphragm 
EMG activity. Following completion of diaphragm EMG recordings, animals were 
euthanized via cervical dislocation.  
 
Data analysis: Amplitude and area under the curve (AUC) of integrated respiratory 
EMG activity was analyzed and averaged under steady-state basal conditions, and for 1 
minute of baseline immediately prior to chemostimulation challenges. Amplitude and 
AUC of integrated respiratory EMG activity was analyzed and averaged for the final 15 
breaths (maximal response) of the chemostimulation challenges. Baseline data were 
reported in absolute units. Responses to chemostimulation were expressed as percent 
change from the preceding baseline value. This portrayal of the data was considered 
appropriate given that baseline EMG activity was found to be equivalent in wild-type 
and mdx mice. As such, percent change from baseline is in effect equivalent to ΔEMG 
activity and importantly, a difference in the percent change between groups 
corresponds to a true difference in total EMG activity, important in the context of a 
transduction of neuromuscular-to-mechanical activity. Because we tested the 
hypothesis that diaphragm EMG activity would be altered in mdx mice compared with 
wild-type mice we did not normalise EMG data to a maximum reference value within 
each preparation (e.g. augmented breath or swallow), because such a maximum value 
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could itself be changed in mdx mice resulting from neuroplasticity. Our principal focus 
was the level of EMG activity per se. In 1 mdx and 2 wild-type mice, the EMG response 
to gas challenges was characterized by tachypnoea and reduced EMG amplitude. Since 
our aim was to compare the magnitude of the increase in EMG amplitude (motor 
recruitment) during chemostimulation, we established a priori that trials characterized 
by frequency-only responses to gas challenge (tachypnoea) would be excluded from 
group analysis of the effects of chemostimulation on EMG amplitude and area under 
the curve in wild-type and mdx mice.  
 
2.2.10 Statistical analysis  
Values are expressed as mean ± SD or as box and whiskers plot (median, 25-75% 
centiles and minimum and maximum values). Data were statistically analyzed by Prism 
6.0 (Graphpad Software, San Diego, CA, USA). For measures of baseline ventilation and 
metabolism, basal carotid sinus nerve activity during normoxia and hyperoxia, basal 
diaphragm EMG activity, diaphragm muscle twitch force and contractile kinetics, 
diaphragm muscle fibres, and arterial blood gas analysis, all data for wild-type and mdx 
groups were tested for normal distribution and equal variances and were statistically 
compared using unpaired two-tailed Student’s t tests, with Welch’s correction for 
unequal variances used as appropriate. Ventilatory and metabolic responsiveness to 
hypoxia (separate sustained and graded challenges), carotid sinus nerve activity 
response to hypoxic challenge, diaphragm muscle force-frequency relationship, and 
diaphragm EMG responses to chemostimulation in wild-type and mdx groups were 
statistically compared by repeated measures two-way ANOVA (gas x gene) with 
Bonferroni post hoc test. Data for absolute carotid sinus nerve activity were non-
parametric and therefore were log transformed. P < 0.05 was considered statistically 
signiﬁcant in all tests. 
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2.3 Results 
2.3.1 Baseline ventilation and metabolism 
Representative respiratory flow traces for wild-type and mdx mice during baseline 
(normoxic) ventilation are shown in Fig. 2.1A. Minute ventilation during baseline 
conditions (combined normoxic bouts) was significantly reduced in mdx compared with 
wild-type mice (P = 0.0001; unpaired Student’s t test; Fig. 2.1D). This reduction in 
normoxic VE in mdx mice was the result of a lower VT (P = 0.0003; Fig. 2.1C); fR did not 
differ significantly between groups (P = 0.2612; Fig. 2.1B). Performing this analysis on 
absolute volume data (not normalised for body mass) yielded similar effects for both VE 
and VT (data not shown).  
 
Respiratory and metabolic parameters are shown in Table 2.1. Assessment of O2 
consumption (VO2) and CO2 production (VCO2) revealed minimal differences between 
wild-type and mdx mice. VO2 (normalised to body mass) was significantly reduced for 
mdx (P = 0.0043) compared with wild-type, but not when expressed in absolute terms 
of oxygen consumed (P = 0.6985). No difference was noted for VCO2 between groups 
when analysis was performed on absolute and normalised values. Carbon dioxide 
production, chosen a priori as the preferred index of metabolism, was effectively 
unchanged between wild-type and mdx mice. The ventilatory equivalent for CO2 
(VE/VCO2) was significantly reduced for mdx (P = 0.0243) compared with wild-type 
mice, indicative of hypoventilation in mdx mice. The ratio of VCO2 to VO2 (respiratory 
exchange ratio) was not different between groups. 
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Figure 2.1 Baseline ventilation in conscious mice 
A: representative respiratory flow traces during normoxic ventilation in a wild-type (WT) mouse (black) and mdx mouse (grey); 
inspiration downwards. B, C and D: breathing frequency (B), tidal volume (C) and minute ventilation (D) for WT (n = 13) and mdx (n = 
12) mice during normoxic ventilation. Values (B-D) are expressed as box and whisker plots (median, 25-75% centiles and minimum 
and maximum values) and data were statistically compared by unpaired Student’s t tests with Welch’s correction used where 
appropriate. ***P < 0.001 compared with WT. 
 83 
 
 
 
 
 
 
 
 
 
 
Table 2.1 Baseline ventilation and metabolic measurements 
Definition of abbreviations: VO2, oxygen consumption; VCO2, carbon dioxide 
production; VCO2/VO2, respiratory exchange ratio (RER); VE/VO2, ventilatory equivalent 
for O2; VE/VCO2, ventilatory equivalent for CO2; WT, wild-type. Data are shown as mean 
± SD and were statistically compared using unpaired Student’s t tests.  
 WT 
(n = 13) 
mdx 
(n = 12) 
Student’s t tests 
VO2 (ml/min) 1.6 ± 0.2 1.5 ± 0.3 P = 0.6985 
VO2 (ml/g/min) 0.072 ± 0.01 0.058 ± 0.01 P = 0.0043 
VCO2 (ml/min) 0.86 ± 0.18 0.94 ± 0.25 P = 0.3570 
VCO2 (ml/g/min) 0.040 ± 0.009 0.036 ± 0.009 P = 0.2404 
VCO2/VO2 0.6 ± 0.1 0.6 ± 0.1 P = 0.2228 
VE/VO2 17.5 ± 5.4 13.6 ± 5.5 P = 0.0819 
VE/VCO2 32.4 ± 11.5 22.4 ± 8.8 P = 0.0243 
Body mass (g) 22.0 ± 1.7 26.3 ± 1.4 P < 0.0001 
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2.3.2 Blood gas analysis 
Intra-cardiac blood gas data for wild-type and mdx mice are shown in Table 2.2. 
Haematocrit was significantly lower in mdx (P = 0.0005; unpaired Student’s t test) 
compared with wild-type, but haemoglobin concentration was equivalent between the 
two groups. Significant increases in blood values for [HCO3-] (P = 0.0496), TCO2 (P = 
0.00382), [K+] (P = 0.0078), and [Na+] (P = 0.0442) were observed in mdx compared 
with wild-type.  
 
 WT 
(n = 7) 
mdx 
(n = 7) 
Student’s t tests 
pH 7.37 ± 0.03 7.37 ± 0.01 P = 0.5815 
PCO2 (mmHg) 35.2 ± 4.7 38.3 ± 2.0 P = 0.1248 
PO2 (mmHg) 107.1 ± 13.7 96.7 ± 6.2 P = 0.0920 
HCO3- (mmol/L) 20.0 ± 2.4 22.3 ± 1.4 P = 0.0496 
TCO2 (mmol/L) 21.0 ± 2.4 23.4 ± 1.4 P = 0.0382 
SaO2 (%) 97.9 ± 0.9 97.3 ± 0.8 P = 0.2225 
Na+ (mmol/L) 143.0 ± 1.2 144.1 ± 0.7 P = 0.0442 
K+ (mmol/L) 4.4 ± 0.2 5.0 ± 0.4 P = 0.0078 
Haematocrit (%) 39.7 ± 1.4 36.0 ± 1.5 P = 0.0005 
Hb (g/dl) 13.5 ± 0.5 13.0 ± 2.1 P = 0.5080 
 
Table 2.2 Intra-cardiac blood gas analysis 
Definition of abbreviations: PCO2, partial pressure of CO2; PO2, partial pressure of O2; 
HCO3-, bicarbonate; TCO2, total CO2; SaO2, arterial oxygen saturation; Na+, sodium; K+, 
potassium; Hb, haemoglobin; WT, wild-type. Data are shown as mean ± SD and were 
statistically compared using unpaired Student’s t tests. 
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2.3.3 Carotid sinus nerve discharge 
Figure 2.2 shows representative traces from wild-type (A) and mdx (B) carotid body-
carotid sinus nerve preparations ex vivo. Group data for carotid sinus nerve activity 
(normalised to hyperoxia) for wild-type and mdx preparations during normoxia (100 
mmHg) and in response to a graded hypoxic challenge (80, 60 and 40 mmHg) are 
shown in Fig. 2.2C. Of note during normoxia, carotid sinus nerve activity was ~30% less 
in mdx compared with wild-type preparations (P = 0.0064; unpaired Student’s t test), 
revealing a relative hypoactivity of carotid body afferent discharge in normoxia. Both 
wild-type and mdx preparations responded to decreasing levels of O2 by corresponding 
increases in carotid sinus nerve activity (P < 0.0001; two-way ANOVA); however, no 
significant difference in hypoxic responsiveness was noted between wild-type and mdx 
(gas x gene P = 0.6452). Statistical judgment of the data was equivalent whether 
normalised to hyperoxia or normoxia.  
 
Data for absolute carotid sinus nerve discharge frequencies in each condition are 
shown in Table 2.3. Consistent with the normalised data, there was no statistical 
difference in hypoxic responsiveness between wild-type and mdx preparations (Table 
2.3). The carotid sinus nerve discharge frequency response to hyperoxia (Dejours test) 
was significantly blunted in mdx compared with wild-type (-18.7 ± 7.2 vs. -7.7 ± 3.1 
'impulses per min, unpaired Student’s t test, P = 0.011 for wild-type (n = 6) vs. mdx (n 
= 6) mice), further suggestive of a relative hypoactivity during normoxia in mdx carotid 
body.
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Figure 2.2 Ex vivo carotid sinus nerve discharge 
 
 
 
 
 
A and B: representative recordings of 
integrated carotid sinus nerve (CSN) 
activity ex vivo in a wild-type mouse 
(A) and mdx mouse (B) during 
normoxia (100 mmHg) and mild (80 
mmHg), moderate (60 mmHg) and 
severe (40 mmHg) hypoxia. CSN 
activity was normalised to activity in 
hyperoxia (500 mmHg), illustrated by 
the horizontal dashed line. C: group 
data of CSN activity for wild-type (WT, 
n = 6) and mdx (n = 6) during normoxia 
(100 mmHg) and graded hypoxia (80, 
60, 40 mmHg). Values are expressed as 
box and whisker plots (median, 25-75% 
centiles and minimum and maximum 
values). Data were statistically 
compared by repeated measures two-
way ANOVA (gas x gene). 
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100 mmHg 80 mmHg 60 mmHg 40 mmHg Two-way 
RMANOVA 
Discharge 
frequency 
(impulses/min) 
WT 37.4 ± 20.7 53.2 ± 23.9 82.3 ± 39.9 122.2 ± 73.1 Gas P < 0.001 
Gene P = 0.327 
Gas x gene P = 0.953 
mdx 23.8 ± 11.5 36.2 ± 14.5 54.9 ± 22.4 80.0 ± 39.6 
Δ discharge 
frequency 
(impulses/min) 
WT - 15.8 ± 7.8 44.9 ± 26.2 84.8 ± 59.6 Gas P < 0.001 
Gene P = 0.357 
Gas x gene P = 0.228 
mdx - 12.5 ± 8.1 31.3 ± 16.2 56.3 ± 36.2 
 
Table 2.3 Carotid sinus nerve afferent discharge in normoxia and hypoxia 
Definition of abbreviations: WT, wild-type. Data are shown as mean ± SD and were statistically compared by repeated measures two-
way ANOVA (gas x gene). Responses to hypoxia are expressed as ' impulses per min from baseline (normoxia) values. 
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2.3.4 Ventilatory responsiveness to hypoxia and hypercapnia 
Figure 2.3 shows ventilatory and metabolic data during normoxia and in response to 
graded hypoxia. Minute ventilation was lower in mdx (P = 0.0054; two-way ANOVA) 
compared with wild-type, attributed to a lower tidal volume in mdx mice. VCO2 
decreased in response to hypoxia in wild-type and mdx mice (P < 0.0001). VE/VCO2 
increased for both wild-type and mdx mice with decreasing levels of inspired O2 (P < 
0.0001). No significant difference in VE/VCO2 was observed between wild-type and mdx 
mice in response to graded hypoxia. Fig. 2.4 shows the time course of minute 
ventilation to a 20-minute sustained hypoxic challenge (FiO2 = 0.1; balance N2). 
Ventilation increased rapidly in wild-type and mdx mice at the onset of hypoxia (P < 
0.0001) and then declined towards baseline values (Fig. 2.4). A significantly lower VE in 
mdx compared with wild-type mice was observed during gas challenge (P = 0.03), 
owing to reduced VT in mdx mice (Fig. 2.4). The peak hypoxic ventilatory response was 
not different between strains (delta VE was +1.44 ± 0.80 vs. +0.90 ± 0.70 ml/min/g, 
unpaired Student’s t test, P = 0.07 for wild-type (n = 13) vs. mdx (n = 12); % change 
from baseline was +131.8 ± 52.1% vs. +111.7 ± 69.6%, P = 0.4185). Figure 2.5 shows 
data for VE during baseline and hypercapnic gas challenge. Minute ventilation was 
increased significantly both in wild-type and mdx mice during CO2 exposure. Minute 
ventilation remained significantly lower in mdx compared with wild-type mice during 
hypercapnic breathing, but the ventilatory response to hypercapnia was not different 
between wild-type and mdx mice (delta VE was +1.9 ± 0.8 vs. +1.7 ± 0.6 ml/min/g, 
unpaired Student’s t test, P = 0.5768 for wild-type (n = 10) vs. mdx mice (n = 11); % 
change from baseline was +131 ± 47% vs. +178 ± 80%, P = 0.1194). 
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Figure 2.3 Ventilatory and metabolic responsiveness to graded hypoxia 
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Figure 2.3 A-H: group data for breathing frequency (A), tidal volume (B), minute 
ventilation (C), oxygen consumption (D; VO2), carbon dioxide production (E; VCO2), 
respiratory exchange ratio (F; VCO2/VO2), ventilatory equivalent for oxygen (G; VE/VO2) 
and ventilatory equivalent for carbon dioxide (H; VE/VCO2) for wild-type (WT, n = 13) 
and mdx (n = 12) mice during normoxia (21% inspired O2; balance N2) and graded 
hypoxia (15, 12, 10 and 8% inspired O2; balance N2). Values expressed as box and 
whisker plots (median, 25-75% centiles and minimum and maximum values). Data 
were statistically compared by repeated measures two-way ANOVA (gas x gene) with 
Bonferroni post hoc test. *P < 0.05, **P < 0.01 compared with corresponding WT value. 
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Figure 2.4 Ventilatory and metabolic responsiveness to sustained hypoxia 
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Figure 2.4 A-H: group data (mean ± SD) for breathing frequency (A), tidal volume (B), 
minute ventilation (C), oxygen consumption (D; VO2), carbon dioxide production (E; 
VCO2), respiratory exchange ratio (F; VCO2/VO2), ventilatory equivalent for oxygen (G; 
VE/VO2) and ventilatory equivalent for carbon dioxide (H; VE/VCO2) for wild-type (WT, n 
= 13) and mdx (n = 12) mice during baseline and after 5-20 min of exposure to hypoxia 
(10% O2 inspired oxygen; balance N2). Data were statistically compared by repeated 
measures two-way ANOVA (gas x gene) with Bonferroni post-hoc test. *P < 0.05, **P < 
0.01 compared with corresponding WT value. 
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Figure 2.5 Ventilatory responsiveness to hypercapnia 
A: group data (mean ± SD) for minute ventilation in wild-type (WT, n = 10) and mdx (n = 11) mice during baseline (air) and 
hypercapnia (5% CO2, balance N2). Data were statistically compared using repeated measures two-way ANOVA. B: group data (mean 
± SD) for ventilatory responsiveness to hypercapnia (ΔVE) in WT (n = 10) and mdx (n = 11) mice. Values are expressed as box and 
whisker plots (median, 25-75% centiles and minimum and maximum values). Data were statistically compared by unpaired Student’s 
t tests. 
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2.3.5 Diaphragm muscle function 
Representative original traces for wild-type and mdx diaphragm twitch contraction (A) 
and force-frequency relationship (B) are shown in Fig. 2.6. Isometric twitch force and 
contractile kinetics for wild-type and mdx mice are shown in Table 2.4. Twitch 
contraction time was significantly prolonged in mdx compared with wild-type 
diaphragms (P = 0.0155; unpaired Student’s t test). Twitch force was significantly 
reduced in mdx diaphragm muscle preparations (P = 0.0292). For force-frequency 
relationship, diaphragm specific force was significantly depressed in mdx compared 
with wild-type preparations (P = 0.0002, repeated measures two-way ANOVA). Post-
hoc analysis revealed significant differences between wild-type and mdx diaphragm 
force generation across a broad stimulus range (40-160 Hz). Absolute measurements of 
diaphragm force (N), prior to normalisation to CSA, were significantly depressed in mdx 
compared with wild-type.  
 
 
 
 
 
 
 
 
 
 
 
Table 2.4 Diaphragm muscle twitch force and contractile kinetics 
Definition of abbreviations: CT, contraction time; ½ RT, half-relaxation time; Pt, twitch 
force; WT, wild-type. Data are shown as mean ± SD and were statistically compared 
using unpaired Student’s t tests. 
 WT 
(n = 7) 
mdx 
(n = 7) 
Student’s t tests 
 
CT (ms) 15.4 ± 1.3 18.9 ± 3.0 P = 0.0155 
½ RT (ms) 19.9 ± 3.0 19.1 ± 2.9 P = 0.5975 
Pt (N/cm2) 2.7 ± 0.7 1.8 ± 0.8 P = 0.0292 
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Figure 2.6 Ex vivo diaphragm muscle contractile function 
A and B: original traces of ex vivo diaphragm muscle twitch contraction (A) and force-frequency relationship (B) for wild-type (WT) 
(black) and mdx (grey) preparations. C, group data (mean ± SD; n = 7 for both groups) for diaphragm muscle force-frequency 
relationship ex vivo in WT (open) and mdx (grey) muscle preparations. Data were statistically compared by repeated measures two-
way ANOVA (frequency x gene) followed by Bonferroni post-hoc test. **P < 0.01, ***P < 0.001 compared with corresponding WT 
values.
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2.3.6 Diaphragm muscle fibre size and distribution 
Representative immunofluorescence images from wild-type and mdx diaphragm 
muscle are shown in figure 2.7. Dystrophin deficiency in mdx diaphragm resulted in a 
significant increase in the coefficient of variation of muscle fibre size (P < 0.0001; 
unpaired Student’s t test), as measured by minimal Feret’s diameter (Fig. 2.7C). There 
was a significantly increased proportion of centralized myonuclei, indicative of muscle 
damage in mdx compared with wild-type (P = 0.0005; Fig. 2.7D). A leftward shift in the 
frequency distribution of muscle fibre size was evident in mdx diaphragm, based on 
minimal Feret’s diameter (Fig. 2.7E) or CSA (Fig. 2.7F). 
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Figure 2.7 Diaphragm muscle structure 
A: representative images of diaphragm muscle immunofluorescently labelled for laminin from wild-type (WT) (top left) and mdx (top 
right) mice. B: representative images of diaphragm muscle immunofluorescently labelled for laminin (green) and myonuclei (blue) 
from WT (bottom left) and mdx (bottom right) mice. C: group data for coefficient of variation of diaphragm muscle fibre size as 
measured by minimal Feret’s diameter for WT (n = 8) and mdx (n = 8) mice. D: group data for percentage of fibres with centralized 
myonuclei in diaphragm muscle of WT (n = 6) and mdx (n = 5) mice. Values are expressed as box and whisker plots (median, 25-75% 
centiles and minimum and maximum values). Data were statistically compared by unpaired Student’s t tests. E and F: frequency 
distribution of WT and mdx diaphragm muscle fibre size as measured by minimal Feret’s diameter (E) and cross-sectional area (F). 
***P = 0.0005, ****P < 0.0001 compared with corresponding WT value. 
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2.3.7 Diaphragm EMG responsiveness 
Representative original diaphragm EMG traces during baseline and in response to 
chemostimulation are shown in figure 2.8A. Diaphragm EMG activity was examined in 
wild-type and mdx mice during baseline (60% O2) and in response to chemostimulation 
challenges. Basal diaphragm EMG amplitude and AUC was not different between wild-
type and mdx mice (Fig. 2.8B, inset). Gas challenges typically increased EMG 
responsiveness for both wild-type and mdx for amplitude (P = 0.0202; repeated 
measures two-way ANOVA; Fig. 2.8B) and AUC (P = 0.0531; Fig.  2.8C). For AUC, a 
significant genotype difference was noted (P = 0.0452) and post-hoc analysis revealed 
EMG responsiveness to maximal chemostimulation (asphyxia) was significantly 
enhanced in mdx compared with wild-type mice (P < 0.05; two-way ANOVA with 
Bonferroni post hoc test).  
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Figure 2.8 Diaphragm EMG 
A: representative traces of diaphragm (Dia) muscle raw and integrated (Int.) EMG 
activity for a wild-type (WT) mouse (black) and mdx mouse (grey) during baseline (60% 
inspired O2), hypercapnia (5% and 10% CO2), hypoxia (15% O2) and asphyxia (15% 
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O2/5% CO2). B and C: diaphragm muscle integrated EMG activity expressed as 
amplitude (B) and area under the curve (C) for WT (n = 8) and mdx (n = 7) mice during 
baseline (inset), hypercapnia (5% CO2 and 10% CO2), hypoxia (15% O2) and asphyxia 
(15% O2/5% CO2). Baseline data are reported as absolute units. Note that there was no 
significant difference in baseline data comparing WT and mdx mice. Gas challenges are 
expressed as % change from baseline. All values are presented as box and whisker plots 
(median, 25-75% centiles and minimum and maximum values). Baseline data were 
statistically compared by unpaired Student’s t tests. Gas challenges were statistically 
compared by repeated measures two-way ANOVA with Bonferroni post-hoc test. *P < 
0.05 compared with WT. 
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2.4 Discussion 
The main findings of our study are: 1) young (eight week old) mdx mice 
hypoventilate during basal breathing, owing to reduced tidal volume; 2) intra-
cardiac blood total CO2 and [HCO3-] are elevated in young mdx mice suggesting 
compensated respiratory acidosis; 3) the carotid body response to hyperoxia is 
depressed in young mdx mice; 4) chemosensory, ventilatory, and metabolic 
responses to hypoxia are unaffected in young mdx mice; 5) there is profound 
diaphragm muscle weakness, fibre remodelling and damage in young mdx mice; 6) 
diaphragm EMG responsiveness to chemostimulation is enhanced in young mdx 
mice suggesting compensatory neuroplasticity. 
 
Overall, our study revealed that basal CO2 production was unaffected in mdx mice, 
but mdx mice had a substantial reduction in tidal volume that was not 
compensated for by increased breathing frequency resulting in reduced minute 
ventilation. Thus, mdx mice hypoventilate by 8 weeks of age i.e. inadequate 
ventilation to meet metabolic demand, which is suggested by the data for reduced 
ventilatory equivalent for carbon dioxide (VE/VCO2) in mdx mice. Cardiac puncture 
for blood gas analysis under isoflurane anaesthesia (breathing air) revealed a trend 
towards decreased PO2 and increased PCO2 in mdx, but the changes were modest in 
comparison to the ventilatory data derived by plethysmography. There are at least 
three factors to consider. First, the blood was sampled from anaesthetised animals, 
and anaesthesia has pronounced inhibitory effects on ventilation, though this might 
be expected to potentiate respiratory depression in mdx mice. Second, there may 
be cardio-pulmonary adjustments that compensate for mechanical deficits in young 
mdx mice. Third, the sample size may have been too small to reveal statistical 
significance in some key parameters (PO2 and PCO2) that did change in a manner 
consistent with hypoventilation. Nonetheless, total CO2 and [HCO3-] were 
significantly elevated in mdx mice suggesting the development of a compensated 
respiratory acidosis secondary to chronic hypoventilation. Persistent 
hypoventilation and resultant hypoxaemia, which have been described in mdx mice 
at 6 months of age (Mosqueira et al., 2013a), would be expected to cause increased 
haematocrit and haemoglobin concentration. Of interest, we noted significantly 
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enlarged, darkened spleens in mdx mice, which may have implications for the 
control of circulating red blood cells. It would be interesting to determine if mdx 
mice are chronically hypoxic in early life, as hypoxic stress has the capacity to drive 
plasticity at multiple sites within the respiratory control network.  
 
Sensory inputs from the peripheral chemoreceptors are generally regarded as 
providing a tonic drive to “eupnoeic” breathing. Moreover, while they primarily 
detect hypoxia, their sensitivity is strongly modulated by PaCO2 and they have 
powerful non-linear interactions with central (brainstem) chemoreceptors that also 
detect CO2 concentration (Wilson & Teppema, 2016). Therefore, the relative 
hypoactivity of mdx compared with wild-type carotid bodies might have 
contributed to the resting hypoventilation of mdx mice. Carotid body responses to 
hypoxia (mild, moderate and severe), whether assessed as absolute or normalised 
data, were equivalent in mdx and wild-type mice with no statistical genotype or 
genotype x gas effect. Of note, carotid sinus nerve afferent discharge was less at all 
PO2 levels in mdx preparations, such that chemoafferent drive to the respiratory 
centres was lower in mdx compared with wild-type representing a potentially 
physiologically relevant sensory deficit in the control of breathing. Interestingly, 
ventilatory responsiveness to sustained and graded hypoxia was equivalent in mdx 
and wild-type mice with no genotype effect. Of note, however, ventilation was 
reduced in mdx due to significant reductions in tidal volume at all levels of hypoxic 
ventilation, which may relate to sensory deficit as well as mechanical disadvantage 
in mdx over a range of ventilations compared with wild-type. Metabolism and 
metabolic responses to hypoxia were generally equivalent between wild-type and 
mdx mice. 
 
While our report is the first to characterize respiratory and metabolic parameters in 
young mdx mice and describe that a significant respiratory phenotype presents as 
early as 8 weeks of age, our data are generally consistent with reports of 
hypoventilation in older (6-12 months of age) mdx mice (Huang et al., 2011; 
Mosqueira et al., 2013a). When viewed together, the implication of these findings is 
that respiratory insufficiency presents early in the mdx model, and thus likely 
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impacts on the progression and manifestation of respiratory morbidity typically 
reported in older animals.  
 
Our study confirmed profound diaphragm weakness in mdx mice. Coirault et al. 
(1999) have previously reported reduced strength in mdx diaphragm which was 
associated with a reduction in the number of cross bridges generating contractile 
force and in the elementary force generated per actomyosin interaction. These 
functional changes were associated with changes in myosin isoform composition 
(shift from myosin heavy chain type IIa to IIa). Interestingly, diaphragm mechanical 
dysfunction is present at a young age (6 weeks) when muscle fibre necrosis and/or 
fibrosis remain limited (Coirault et al., 2003). Diaphragm force-generating capacity 
in the present study was depressed across a broad range of stimulation frequencies 
including the range relevant to basal breathing. Respiratory nerve activity in mice 
displays medium frequency oscillations (MFOs) in the range of 20-50Hz (O'Neal et 
al., 2005; ElMallah et al., 2016), which are believed to reflect the underlying motor 
neuron discharge rates (Christakos et al., 1991). The severe weakness in mdx 
diaphragm at this early age appears primarily responsible for the mechanical 
disadvantage manifest in reduced tidal volumes in freely-behaving mice. Force 
increases as a function of stimulation frequency in mdx mice, which provides 
capacity to increase breathing in response to increased neural drive. However, the 
intrinsic weakness in mdx diaphragm is impressive even at this early stage, 
presumably placing a limit on ventilatory capacity. Moreover, force-generating 
capacity remains severely compromised at higher stimulation frequencies.  
 
There are few studies examining the hypoxic ventilatory response in mdx 
(Mosqueira et al., 2013a; Burns et al., 2015). The hypometabolic response to 
hypoxia in mice is such that ventilatory responses to hypoxia are modest. Indeed, 
tidal volume and ventilation do not increase much above baseline in response to 
graded hypoxia, and the ventilatory response to sustained hypoxia is primarily 
driven by increased respiratory frequency. Therefore, it is difficult to discern from 
ventilatory responses to hypoxia if mdx mice are capable of transducing increased 
diaphragm force-generating capacity resulting from motor recruitment to increase 
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ventilation. To examine this further, we assessed hypercapnic ventilatory responses 
in wild-type and mdx mice. Ventilation increased in response to hypercapnic 
challenge, due to increases in respiratory frequency and tidal volume, and the 
response was equivalent in the two groups. The data reveal that mdx mice are 
capable of increasing tidal volume during chemostimulation. Although, ventilation 
remains significantly lower in mdx compared with wild-type mice during 
hypercapnic breathing, the ventilatory response to hypercapnia is not different 
between the two groups of mice. This reveals an interesting feature of respiratory 
control in the young mdx mouse, namely that a considerable reserve in ventilatory 
capacity prevails, which presumably extends to accessory muscles of breathing 
given the profound weakness noted in the diaphragm muscle. Analysis of fibre size 
and distribution in diaphragm muscle revealed considerable fibre remodelling and 
evidence of centronucleation, which is a hallmark of fibre necrosis. Diaphragm 
muscle structure of mdx mice has been well described with muscle fibres 
undergoing inflammatory cell infiltration, fibrosis and necrosis (Gayraud et al., 
2007; Ishizaki et al., 2008; Huang et al., 2011).  In addition to structural 
abnormalities in mdx resulting in loss of function, there is growing evidence 
implicating oxidative stress in dystrophic diaphragm pathology (Kim & Lawler, 2012; 
Kim et al., 2013).  
 
In anaesthetised mice, we examined respiratory neural drive to the diaphragm 
under baseline conditions and in response to chemostimulation with hypoxia, 
hypercapnia, and asphyxia. Baseline diaphragm EMG activity was equivalent in wild-
type and mdx mice (although respiratory frequency was higher in mdx mice), but 
since anaesthetised animals breathed 60% oxygen under baseline conditions, it is 
likely that carotid body chemoafferent input was depressed in our studies such that 
putative differences in peripheral control of breathing between mdx and wild-type 
(i.e. sensory deficit suggested by carotid body preparations) would not have 
contributed to the EMG findings. We further acknowledge the recognized 
limitations in respect of comparisons of EMG activity between animals. Whether 
dystrophin deficiency affects central respiratory motor outflow in normoxia was not 
established in our studies; however, given the significance of this observation, it is 
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worthy of future investigation. Chemoactivation of diaphragm EMG activity was 
enhanced in mdx, with EMG activity considerably potentiated under maximal 
chemostimulation with asphyxia. The potentiated response, which revealed a true 
increase in absolute EMG activity, reveals compensatory plasticity in mdx either in 
the central brainstem respiratory network and/or at the level of the phrenic motor 
nucleus. Potentiated motor outflow in response to chemostimulation may serve to 
facilitate increased ventilation by providing greater neural drive via phrenic motor 
neurons to diaphragm, facilitating the transduction of neuromuscular-to-
mechanical events during chemostimulation challenge. Perhaps in this manner the 
potentiated output facilitates equivalent increases in ventilation (delta VE) during 
chemostimulation despite the mechanical disadvantage presenting in mdx mice.  
 
However, it is important to recognize that the force-generating capacity of the mdx 
diaphragm is severely compromised. It is evident from analysis of force-frequency 
relationship in mdx diaphragm that increased frequency of stimulation results in 
little gain in force. As such, there may be little mechanical advantage to increased 
activation of the diaphragm, which suggests that activation of accessory muscles of 
breathing may be especially important in mdx (and DMD) to support increased tidal 
volume during respiratory stimulation. We acknowledge that aberrant motor unit 
potentials in dystrophic mdx muscle (Han et al., 2006) could have contaminated 
diaphragm EMG recordings such that comparisons between wild-type and mdx may 
not be entirely appropriate in respect of the issue of neuroplasticity, an issue 
further complicated by potential changes at the neuromuscular junction (Pratt et 
al., 2015). Recordings of phrenic motor discharge are required to definitively 
determine if central respiratory drive is elevated in mdx and this is an area worthy 
of future study. Assessment of motor drive in accessory pathways contributing to 
ventilation is also worthy of pursuit. It would also be very interesting to 
characterize motor unit potentials in respiratory EMGs of young mdx mice. 
 
Limitations 
Whole-body plethysmography provides an estimate of tidal volume, which is 
dependent on a number of assumptions (Mortola & Frappell, 1998; Stephenson & 
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Gucciardi, 2002). The calculation depends on knowledge of chamber temperature 
and humidity, and animal airway temperatures. Whereas the former were 
measured in our studies (~22oC), animal body temperature, a surrogate for alveolar 
temperature, was estimated (37.5oC) for both groups in our study for the purpose 
of the calculation of tidal volume. This additional limitation raises concern over the 
accuracy of our estimation of tidal volume, important to address since we report 
that tidal volume was significantly different between wild-type and mdx mice. 
Direct airflow measurement with a pneumotachometer or assessment of breathing 
using head-out plethysmography would provide accurate measures of tidal 
volumes, worthy of pursuit into the future, but it is recognized that these 
techniques are not without limitations associated with anaesthesia and restraint, 
respectively. Of note for the present study, errors in body temperature could 
conceivably have accounted for a substantive proportion of the difference reported 
between wild-type and mdx mice (Mortola & Frappell, 1998). We determined that 
basal CO2 production was equivalent in both groups, but we assumed for the 
purpose of tidal volume calculation that body temperature was also equivalent, 
which we acknowledge is an assumption of major significance in the calculation of 
tidal volume. Body temperature likely decreased during the hypoxic challenges. 
Indeed, we report a significant decrease in CO2 production during both sustained 
and graded hypoxia. Whereas, the hypometabolic response (decreased CO2 
production) was equivalent in wild-type and mdx mice, we assumed (because we 
did not measure) that the presumed hypothermic response was also equivalent 
between wild-type and mdx mice. Our assumption does not account for potential 
differences in body temperature between wild-type and mdx mice at rest and/or in 
response to gas challenge. Of interest, a significant difference in resting body 
temperature between wild-type and mdx mice was reported in a previous study 
(Helliwell et al., 1996). However, such a difference if it existed in our study would 
on average have resulted in an under-estimation of the magnitude of the reduction 
in tidal volume in mdx mice compared with wild-type during normoxia. It is also 
probable that our use of a single estimated body temperature for all animals in the 
study introduced errors and thus variability within and not just between groups, 
which might have obscured the genotype effect. It remains possible that a 
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component ---perhaps substantial--- of the difference in tidal volume reported in 
the present study relates to temperature differences between wild-type and mdx 
mice and hence errors related to the assumptions made herein. This issue should 
be addressed in future studies, notwithstanding the inherent limitations of the 
technique of whole-body plethysmography for the estimation of tidal volume even 
with incorporation of body temperature.  
 
We acknowledge the apparent discrepancy in the strength of the conclusions drawn 
from plethysmography and intra-cardiac blood gas analysis, particularly in the light 
of the limitations described above. We have favoured the conclusion that mdx 
animals hypoventilate based on the significant decrease in VE/VCO2 measurements 
derived by plethysmography. Yet, the blood gas data, which are ordinarily taken as 
the gold standard, suggest modest differences in PO2 and PCO2 but with additional 
supporting evidence suggesting a compensated respiratory acidosis. We suggest 
that blood gas data should be viewed cautiously in our study, acknowledging that 
sample size was a limiting factor, but again we emphasize that the magnitude of the 
hypoventilation reported in our study by use of whole-body plethysmography may 
have been over-estimated. Arterial blood gas sampling in conscious mice during 
ventilatory and metabolic assessment by plethysmography represents the gold 
standard for comparisons and would be required to convincingly demonstrate 
hypoventilation in young mdx mice. 
 
Our EMG study suggests compensatory neuroplasticity in respiratory motor output 
in mdx mice in response to chemostimulation. We acknowledge that recordings of 
respiratory motor nerves in reduced preparations, complemented by respiratory 
EMGs in intact spontaneously breathing preparations, extending to 
contemporaneous recordings of respiratory EMGs and breathing across the sleep-
wake cycle would lend further credence to this novel observation. 
 
Relevance to DMD 
Our study in the mdx mouse raises interesting issues of potential relevance to 
human DMD. Dystrophin deficiency results in respiratory insufficiency early in life, 
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which could establish blood gas disturbances with relevance to neuromuscular 
performance. Hypoxia-induced respiratory muscle dysfunction may be an important 
and under-recognised feature of DMD. Dystrophin deficiency may adversely affect 
basal sensory control of breathing, but the preserved capacity for carotid body 
chemoafferents to respond to hypoxia and therefore presumably other stimulants, 
suggests that pharmacotherapies that enhance carotid body activity may have 
some application in the treatment of DMD. It is apparent that dystrophin deficiency 
results in profound diaphragm dysfunction, which appears early in the mouse 
model. The severe mechanical disadvantage presents across a range of 
stimulations, but a preserved capacity to raise ventilation suggests support from 
accessory muscles of breathing, which may have relevance to DMD. Our study 
revealed a potentiated neural drive to breathe in mdx during maximal 
chemoactivation, suggesting compensatory neuroplasticity enhancing respiratory 
motor output to the diaphragm and perhaps other respiratory muscles, which 
should serve to facilitate ventilation in response to challenge. If neuroplasticity is a 
feature of DMD, it may be possible to boost motor facilitation of breathing through 
safe interventions, and in this way preserve or limit deficiencies in respiratory 
capacity.  
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2.5 Translational Perspective 
Duchenne muscular dystrophy (DMD) is an X-linked fatal neuromuscular disease, 
which commonly culminates in respiratory failure. Whereas respiratory muscle 
dysfunction is recognized in DMD, a comprehensive assessment of respiratory 
control is lacking. The dystrophin-deficient mdx mouse has proved to be a useful 
pre-clinical model of DMD, principally because diaphragm muscle dysfunction 
recapitulates features of the human disease. We set out to interrogate sensory and 
motor control of breathing in young mdx mice. We hypothesized that there would 
be evidence of plasticity in the neural control of breathing. Our study reveals that 
mdx mice hypoventilate as early as 8 weeks of age (equivalent to young adult).  We 
revealed evidence of sensory deficit in mdx mice which may partly contribute to 
resting hypoventilation, but sensory responses to oxygen deprivation (hypoxia) are 
normal.  Ventilatory responses to respiratory-relevant chemical activation of 
breathing are normal in mdx mice, revealing ventilatory reserve, although 
ventilation is lower in mdx mice compared with wild-type mice at all levels of 
ventilation. Assessment of diaphragm electromyogram activity revealed enhanced 
motor drive to the respiratory pump muscle during maximum chemoactivation, 
revealing a compensatory phenomenon in neuromechanical control of ventilation 
in mdx mice. Profound diaphragm weakness in young mdx mice suggests that 
enhanced recruitment of accessory muscles of breathing may be especially 
important in facilitating enhanced lung ventilation during chemoactivation.  Our 
novel findings have implications for human DMD. Safe interventional therapies that 
serve to boost breathing may preserve or limit deficiencies in respiratory capacity in 
DMD patients reducing morbidity and mortality. 
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Highlights 
• Dystrophin deficiency in mdx mice results in deficits at multiple sites of the 
respiratory control system. 
• Evidence suggests compensatory neuroplasticity in the motor drive to the 
diaphragm muscle during maximal chemoactivation in mdx mice. 
• Understanding intrinsic physiological compensatory mechanisms in mdx 
mice is important in the context of interventional strategies in animal 
models and human dystrophinopathies. 
 
Abbreviations: DMD, Duchenne muscular dystrophy; EMG, electromyography; LTF, 
long-term facilitation; MyHC, myosin heavy chain; VE/VCO2, ventilatory equivalent 
for carbon dioxide; WT, wild-type.  
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Abstract 
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease associated 
with respiratory-related morbidity and mortality. Herein, we review recent work by 
our group exploring deficits and compensation in the respiratory control network 
governing respiratory homeostasis in a pre-clinical model of DMD, the mdx mouse. 
Deficits at multiple sites of the network provide considerable challenges to 
respiratory control. However, our work has also revealed evidence of compensatory 
neuroplasticity in the motor drive to breathe enhancing diaphragm muscle activity 
during increased chemical drive. The finding may explain the preserved capacity for 
mdx mice to increase ventilation in response to chemoactivation. Given the 
profound dysfunction in the primary pump muscle of breathing, we argue that 
activation of accessory muscles of breathing may be especially important in mdx 
(and perhaps DMD). Notwithstanding the challenges offered by respiratory muscle 
dysfunction, it may be possible to further leverage intrinsic physiological 
mechanisms serving to compensate for weak muscles in attempts to restore or 
preserve ventilatory capacity. We discuss current knowledge gaps and the need to 
better appreciate fundamental aspects of respiratory control in pre-clinical models 
so as to better inform intervention strategies in human DMD. 
 
Keywords: Duchenne muscular dystrophy; diaphragm; electromyogram; mdx 
mouse; neuroplasticity  
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3.1 Duchenne muscular dystrophy (DMD): Respiratory morbidity and mortality 
Dystrophin is a structural protein involved in preventing stretch-induced muscle 
damage during contraction via anchoring the actin cytoskeleton to the sarcolemma 
(Petrof et al., 1993). In the absence of dystrophin, muscle damage occurs, resulting 
in muscle fibre necrosis and extensive muscle weakness. Skeletal muscle function is 
adversely affected in the dystrophinopathies, with attendant muscle fibrosis and 
secondary inflammation. The striated muscles of breathing are implicated in the 
disease with evidence of diaphragm muscle weakness (Khirani et al., 2014), which 
has major implications for the control of breathing in DMD. 
 
Respiratory morbidity and mortality are common features of many neuromuscular 
diseases (Bye et al., 1990). Many boys with DMD experience respiratory 
disturbances during life, while cardio-respiratory failure remains the leading cause 
of death. Pulmonary function peaks when patients are in their mid-teens, although 
forced vital capacity values remain lower than predicted (De Bruin et al., 2001; 
Phillips et al., 2001; Khirani et al., 2014). Thereafter, there is a steady decrease in 
lung volumes with increasing age. Trans-diaphragmatic pressure during sniff 
behaviours are reported to be low in DMD and declined steadily once DMD boys 
reached 10 years of age (Khirani et al., 2014), revealing impaired mechanical 
function of the diaphragm. 
 
Patients with DMD experience disruptions to breathing, particularly during sleep 
(Arens & Muzumdar, 2010). Patients are known to suffer from sleep apnoea and 
both obstructive and central apnoeas have been described with subsequent 
disruptions to arterial blood oxygenation levels (Barbé et al., 1994; Khan & 
Heckmatt, 1994). Evidence suggests that patients have a greater risk of oxygen 
desaturation during sleep with increasing age (Khan & Heckmatt, 1994), which is 
most likely due to obstructive apnoea during the first decade of life (Suresh et al., 
2005). As patients reach the second decade of life, they are at an increased risk of 
hypoventilation during sleep (Smith et al., 1989; Suresh et al., 2005), likely due to 
inadequate diaphragm muscle performance. Patients are known to develop 
scoliosis, further impacting on respiratory function.  
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3.2 The dystrophin-deficient mdx mouse: Diaphragm dysfunction recapitulating 
human DMD 
The mdx mouse is a mutant model of DMD. Dystrophic diaphragm muscle from mdx 
mice exhibits severe mechanical dysfunction and muscle weakness from a young 
age (Coirault et al., 2003). Moreover, mdx diaphragm shows evidence of 
inflammation, centralised myonuclei and fibrosis (Stedman et al., 1991; Coirault et 
al., 2003; Huang et al., 2009). Structural alterations in myosin heavy chain (MyHC) 
isoform composition are observed, with dystrophic diaphragm expressing a reduced 
number of MyHC IIx fibres and increased MyHC IIa fibres (Coirault et al., 1999) 
compared with wild-type, likely related to a lack of maturation of muscle fibres due 
to ongoing damage and repair processes. Few studies have examined the functional 
consequences of dystrophin deficiency on ventilatory capacity in mdx mice. 
Impaired normoxic ventilation was reported in 2 month old and 6 month old mdx 
mice (Mosqueira et al., 2013; Burns et al., 2015). In addition to diaphragm muscle 
weakness, the musculature of the upper airway is also compromised by dystrophin 
deficiency in the mdx mouse (Attal et al., 2000; Burns & O'Halloran, 2016). Muscle 
weakness, inflammation, fibrosis and central nucleation are described in the 
dystrophic sternohyoid muscle, a representative pharyngeal dilator (Burns et al., 
2017a). 
 
3.3 Control of breathing in the mdx mouse: Neural adaptation or maladaptation? 
There is now a large body of evidence revealing a remarkable capacity for plasticity 
at multiple sites within the respiratory control network governing control of arterial 
blood gases and pH (Huey et al., 2003; Mitchell & Johnson, 2003; Bavis et al., 2007; 
Kumar & Prabhakar, 2012; Fuller & Mitchell, 2017). Sensory and motor plasticity is 
context-dependent and can elaborate overt adaptive or maladaptive outcomes 
(Baker et al., 2001; Peng et al., 2003; Prabhakar, 2011; Wilkerson et al., 2017). 
Compensatory neuroplasticity at one or more sites of the integrative network could 
ameliorate respiratory system compromise in DMD. Conversely, deficits in 
sensorimotor control of breathing could further compound respiratory morbidity, 
disrupting respiratory homeostasis potentially establishing a spiral of disability. 
Until recently, the impact of dystrophin deficiency on the neural control of 
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breathing was unclear. We performed the first broad assessment of sensorimotor 
control of breathing in mdx mice (Burns et al., 2017b). We reasoned that there 
would be evidence of neuroplasticity of relevance to respiratory homeostasis at one 
or more sites of the respiratory control network of the mdx mouse.  
 
3.4 Control of breathing in the mdx mouse: Deficits and dysfunction 
We studied young adult male mdx mice given our interest in the early impact of 
dystrophin deficiency on the control of breathing. In mdx mice at 8 weeks of age, 
we confirmed the appearance of profound diaphragm muscle weakness. Isometric 
force-generating capacity of ex vivo diaphragm preparations was depressed by 
~40% compared with age-matched wild-type control diaphragms (Burns et al., 
2017b). Immunohistochemistry performed on diaphragm muscle cross-sections 
revealed a greater abundance of small diameter fibres and increased coefficient of 
variation of muscle fibre size, which together with an increased density of centrally-
nucleated fibres (indicative of myonecrosis) demonstrated considerable muscle 
remodelling in the mdx diaphragm (Burns et al., 2017b). The intrinsic weakness in 
diaphragm is substantial at a young age and would be expected to place 
considerable limits on ventilatory performance. 
 
Indeed, mechanical disadvantage in mdx at 8 weeks of age was suggested by our 
study with evidence, using whole-body plethysmography, of hypoventilation during 
baseline normoxic breathing in mdx mice compared with wild-type mice (Burns et 
al., 2017b). There was a significant decrease in the ventilatory equivalent for carbon 
dioxide (VE/VCO2) in mdx mice, the principal deficit arising from a significant 
reduction in baseline tidal volume. Intra-cardiac blood gas analysis in isoflurane 
anaesthetised mdx mice demonstrated the development of a compensated 
respiratory acidosis.  
 
Dystrophin is expressed in the carotid body (Mosqueira et al., 2013). We explored 
carotid body afferent discharge frequency and responsiveness to hypoxia in 
isolated perfused carotid body-carotid sinus nerve preparations to determine if 
sensory deficit presents and contributes to ventilatory impairment in mdx mice 
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(Burns et al., 2017b). A relative hypoactivity of the carotid body was revealed 
during normoxia, with evidence of a blunted inhibitory response to hyperoxia in 
mdx preparations compared with wild-type preparations. However, the classic 
excitatory chemosensory response to hypoxia was not significantly different 
between mdx and wild-type carotid bodies. The latter finding was consistent with 
observations of equivalent hypoxic ventilatory responses in mdx and wild-type mice 
(Burns et al., 2017b). Since sensory inputs from the peripheral chemoreceptors 
provide tonic drive to eupnoeic breathing, carotid body hypoactivity might 
contribute, at least in part, to resting hypoventilation in mdx.  
 
3.5 Control of breathing in the mdx mouse: Compensation and limitations 
In our recent study (Burns et al., 2017b), we recorded diaphragm EMG activity 
during baseline and in response to chemoactivation of breathing during asphyxic 
challenge. Baseline activity was equivalent between wild-type and mdx mice, but 
the increased EMG activity in response to asphyxia was significantly enhanced in 
mdx mice. The response is suggestive of compensatory neuroplasticity in the motor 
control of breathing. Since chemosensory responses were equivalent between wild-
type and mdx mice, we concluded that increased neural drive was reflective of an 
increased gain in the control system at the level of key integrative sites in the 
brainstem network and/or at the level of the spinal phrenic motor pool innervating 
the diaphragm. 
 
Whereas diaphragm EMG responsiveness was significantly increased in mdx, the 
profound weakness of the major muscle of breathing is such that transduction of 
enhanced neural drive to the mechanical act of breathing is likely severely 
compromised. Yet, of note, mdx mice are capable of increasing ventilation in 
response to increased chemical drive to breathe. In our study, the ventilatory 
response to hypercapnia was equivalent in wild-type and mdx mice (Burns et al., 
2017b). It is established that motor recruitment of the diaphragm in response to 
hypercapnia is submaximal, operating below 30% of the maximum capacity of the 
system (Mantilla et al., 2010; Greising et al., 2013). As such, increased neural drive 
and a right-ward shift of the force-frequency relationship in mdx diaphragm might 
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provide increased diaphragm force-generating capacity, notwithstanding the 
significant deficit in mdx muscle compared with wild-type (Figure 3.1). It is also 
conceivable that increased drive in motor pathways to accessory muscles of 
breathing facilitates tidal breathing in mdx mice. If neuroplasticity extends to 
multiple parallel efferent pathways, arising for example from enhanced central 
respiratory drive to breathe during chemoactivation, recruitment of accessory 
inspiratory muscles of breathing might help to preserve ventilatory capacity in 
response to chemoactivation. Activation of accessory muscles of breathing may be 
especially important in mdx (and perhaps DMD) allowing for greater efficiency in 
neuromechanical coupling compared with outcomes dependent on the 
dysfunctional diaphragm. Interestingly, there is evidence of expiratory muscle 
recruitment to facilitate ventilation in the Golden Retriever model of muscular 
dystrophy (Mead et al., 2014). If compensatory neuroplasticity presents in efferent 
motor pathways in DMD, it may be possible to further boost neural drive to breathe 
and in this way help preserve ventilatory capacity. A major drawback with such an 
approach are the limits afforded by the final effector organs, the respiratory 
muscles, and potential concerns associated with activity-induced damage, since it is 
known that exercise in mdx mice exacerbates muscle dysfunction, including 
diaphragm dysfunction (Selsby et al., 2013). However, harnessing putative plasticity 
in accessory pathways may offer an attractive therapeutic strategy in DMD.  
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Figure 3.1 Diaphragm muscle weakness in dystrophin-deficient mdx mice. 
Schematic representation of diaphragm force-frequency relationship in wild-type 
(WT) and dystrophin-deficient mdx mice. Deficits in force-generating capacity are 
seen in the range relevant to ventilation and airway protective behaviours. 
Enhanced neural drive during chemoactivation has limited capacity to increase 
diaphragm force, compared with wild-type, suggesting that preserved ventilatory 
capacity in mdx during chemostimulation may be especially dependent on 
accessory muscles of breathing. Adapted from data presented in (Burns et al., 
2017b). The bottom schematic, informed by the studies of Sieck and Mantilla 
(Mantilla et al., 2010), illustrates the major motor unit types associated with graded 
force-generating capacity of the in vivo diaphragm. 
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3.6 Control of breathing in the mdx mouse: Knowledge gaps 
There is a surprising dearth of information in respect of the neural control of 
breathing in the dystrophinopathies, notwithstanding that respiratory morbidity 
and mortality are dominant features. More studies are required to understand the 
extent of respiratory system deficit and compensation, and the temporal changes 
over the course of disease progression. Knowledge of fundamental aspects of 
respiratory control is essential in the consideration of respiratory management of 
patients with neuromuscular disease. Moreover, a better appreciation of the 
intrinsic compensatory processes at play in DMD should help inform therapeutic 
strategies. Our study revealed enhanced diaphragm EMG responsiveness in mdx 
mice suggestive of compensatory neuroplasticity. However, in a myopathy model 
such as mdx, EMG recordings may be contaminated by aberrant motor unit 
potentials associated with dynamic degeneration and regeneration of muscle fibres. 
It will be important to establish if increased efferent drive is revealed in phrenic 
neurogram recordings. We are currently exploring this issue with evidence of 
potentiated phrenic neurogram activity in mdx mice in response to maximum 
chemostimulation (Burns et al., unpublished observations). It is unclear whether 
motor activation of accessory muscles is altered in mdx and this represents an 
important gap in the understanding of respiratory control in dystrophin-deficient 
neuromuscular disease. Studies are required to address this issue and determine if 
therapeutic strategies exploiting these pathways represents a viable interventional 
option aimed at increasing ventilatory capacity, with a view to treatment options 
for DMD patients. A summary of the effects of dystrophin-deficiency on respiratory 
control in young adult mdx mice is shown in Figure 3.2. 
 
3.7 Control of breathing in the mdx mouse: Therapeutic intermittent hypoxia to 
boost respiratory drive? 
In recent years, Mitchell and colleagues have pioneered the understanding and 
potential exploitation of mechanisms of motor plasticity to enhance respiratory 
motor output (Fuller & Mitchell, 2017). Manipulating environmental oxygen in the 
form of acute bouts of intermittent hypoxia has the capacity to evoke ventilatory 
long-term facilitation (LTF) in behaving rodents (Edge & O'Halloran, 2015). 
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Furthermore, intermittent hypoxia-induced LTF is well described in motor pathways 
of the diaphragm (Fuller et al., 2000), upper airway (Wilkerson et al., 2017) and 
accessory muscles of breathing such as the intercostal muscles (Navarrete-Opazo & 
Mitchell, 2014). We reason that safe interventions aimed at evoking LTF in the 
motor pathways of breathing may have therapeutic capacity to facilitate breathing 
in mdx mice, as has been elegantly demonstrated in rodent models of motor 
neuron loss (Nichols et al., 2013; Nichols et al., 2015) and spinal cord injury 
(Dougherty et al., 2017). This warrants attention in future studies. 
 
3.8 Conclusion 
Dystrophin-deficiency has detrimental consequences for respiratory control, 
principally owing to respiratory muscle dysfunction. We have revealed a broader 
vista of the deficits that present early in a pre-clinical model of neuromuscular 
disease, the mdx mouse. We also have revealed, for the first time, compensatory 
adjustments in the nervous system control of respiratory muscles in mdx mice 
striving for homeostatic control of breathing. We suggest that it may be possible to 
exploit intrinsic physiological mechanisms serving to boost breathing in the 
development of therapeutic strategies for DMD, through the use of safe 
interventional therapies such as intermittent hypoxia.  
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Figure 3.2   Summary of the effects of dystrophin-deficiency on respiratory control 
in young mdx mice. 
Summary of the deficits and compensation in respiratory control in young adult 
mdx mice. Adapted from data presented in (Burns et al., 2017b).  
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Top image shows immunofluorescent image of spinal cord labelled for green 
fibrillary acidic protein (GFAP, green), NeuN (red) and DAPI (nuclear stain, blue). 
Trace shows diaphragm raw EMG activity in an anaesthetised mouse. Bottom image 
shows astrocytes labelled using GFAP.  
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Key points  
• Respiratory muscle weakness is a major feature of Duchenne muscular 
dystrophy (DMD), but little is known about the neural control of respiratory 
muscles in DMD and animal models. 
• Although extensive diaphragm muscle weakness is apparent in young (8-
week-old) mdx mice, ventilatory capacity in response to maximum 
chemostimulation is preserved, with no evidence of perturbed respiratory 
rhythm.  
• In mdx mice, peak inspiratory oesophageal pressure generation is 
maintained during basal and chemoactivated breathing and peak sub-
atmospheric pressure during augmented breaths is greater compared with 
wild-type mice; diaphragm EMG activity is equivalent between groups.  
• Monoamine concentrations are increased and the density of activated 
astrocytes and microglia and pro-inflammatory gene expression is 
equivalent in the C3-C5 spinal cord of mdx mice compared with wild-type 
mice.  
• Our finding of enhanced inspiratory pressure generation in mdx mice, 
despite substantial diaphragm weakness, suggests enhanced accessory 
respiratory motor drive preserving ventilatory capacity.  
 
  
 134 
 
Abbreviations: ½ RT, half-relaxation time; 5-HT, 5-hydroxytryptamine; ANOVA, 
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Abstract 
Diaphragm dysfunction is recognised in the mdx mouse model of muscular 
dystrophy, however there is a paucity of information concerning neural control of 
the respiratory muscles. In young adult (8 weeks of age) wild-type and mdx mice, 
we sought to assess respiratory rhythm stability, ventilatory capacity, neural 
activation of the diaphragm and inspiratory pressure-generating capacity. In C3-C5 
spinal cord containing the phrenic motor nucleus, monoamine concentrations, the 
density of activated astrocytes and microglia, and pro-inflammatory gene 
expression was assessed. We hypothesised that increased motor recruitment of the 
diaphragm limits ventilatory decline in mdx mice. Poincaré analysis of respiratory 
timing revealed no evidence of perturbed respiratory rhythm in mdx mice, which 
retained a remarkable capacity to enhance ventilation despite substantial 
diaphragm muscle weakness. In mdx mice, peak inspiratory oesophageal pressure 
generation was preserved during basal and chemoactivated breathing and was 
significantly greater during augmented breaths compared with wild-type mice. 
Monoamine concentrations were significantly increased in the cervical spinal cord 
of mdx mice, and the density of activated glial cells and expression of pro-
inflammatory genes was unchanged, revealing no evidence of neuroinflammation, 
but mdx diaphragm EMG activity was not potentiated compared with wild-type 
across the range of ventilatory behaviours. We reason that compensatory 
neuroplasticity in accessory motor pathways preserves ventilatory capacity in mdx 
mice despite profound diaphragm muscle weakness, which may have relevance to 
the development of interventional strategies designed to alleviate respiratory 
insufficiency in the human dystrophinopathies. 
 
 
Keywords: DMD; mdx; plasticity; breathing; spinal cord; oesophageal pressure; 
EMG; diaphragm   
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4.1 Introduction 
Dystrophin is a structural protein found in muscle and the central nervous system 
(Lidov, 1996; Muntoni et al., 2003). Duchenne muscular dystrophy (DMD) is a 
severe neuromuscular disease caused by dystrophin deficiency (Hoffman et al., 
1987; Ervasti, 2007). Respiratory muscle dysfunction is described in DMD patients 
(De Bruin et al., 1997; Beck et al., 2006) with deleterious consequences for 
respiratory system performance (Mayer et al., 2015). Loss of ambulation and 
cardio-respiratory failure are cardinal features of DMD (Yiu & Kornberg, 2008). Life 
expectancy for DMD boys is severely curtailed and there is no cure for the 
devastating disease. 
 
Substantial diaphragm muscle weakness is reported in patients and animal models 
of DMD (Stedman et al., 1991; Khirani et al., 2014). However, there remains an 
incomplete understanding of the neural control of breathing, where further deficits 
or compensation may arise with implications for respiratory performance (Burns et 
al., 2017c). A thorough understanding of the consequences of dystrophin deficiency 
on the neuromechanical control of breathing is essential in the consideration of 
disease progression and therapeutic strategies to combat respiratory insufficiency 
in DMD. 
 
Dystrophin is highly enriched post-synaptically in the central nervous system. In the 
mdx mouse model of DMD, studies indicate reduced cortico-spinal neurons 
(Sbriccoli et al., 1995), damage to motor pathways (Carretta et al., 2001), loss of 
neuronal projections (Pinto et al., 2008), GABAergic dysfunction (Sekiguchi et al., 
2009; Vaillend & Chaussenot, 2017) and cognitive deficits (Chaussenot et al., 2015). 
It is unclear if dystrophin deficiency affects central respiratory rhythm and pattern 
generation and propensity for apnoea, notwithstanding that sleep-disordered 
breathing is common in DMD (Barbé et al., 1994; Suresh et al., 2005; Sawnani et al., 
2015). Clearly, aberrant neural control of breathing could serve to exacerbate 
respiratory morbidity in DMD, compounding mechanical constraints arising from 
respiratory muscle dysfunction.  
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Respiratory neuromechanical coupling in DMD and animal models is understudied. 
A comprehensive understanding of the motor control of the dystrophin deficient 
respiratory musculature is lacking. It is essential to determine if dystrophin 
deficiency is deleterious to the motor control of breathing, or if there is intrinsic 
compensation within the neural control circuits, or perhaps a capacity to evoke 
compensation, with consequences for the mechanics of breathing. Recently we 
described evidence of enhanced motor drive to the mdx diaphragm during 
enhanced chemoactivation of breathing (Burns et al., 2017c), suggesting intrinsic 
compensation in the neural control of ventilation in dystrophin deficient mice. Our 
study revealed hypoventilation during basal breathing in conscious mice, but a 
retained capacity in mdx mice to increase ventilation in response to modest 
chemostimulation (Burns et al., 2017c). However, the extent to which dystrophin 
deficiency affects inspiratory pressure-generating capacity, or if enhanced phrenic 
recruitment of the diaphragm contributes to preservation of mechanical capacity 
during increased ventilatory drive is unclear, but important to establish. It is not 
known if altered neuromodulatory signalling to the phrenic motor neuronal pool 
underpins the expression of evoked motor facilitation of breathing in mdx mice 
(Burns et al., 2017c). 
 
Systemic and muscle inflammation are prominent features of DMD and mdx mice, 
due to muscle fibre damage (Messina et al., 2011; Rufo et al., 2011; Cruz-Guzmán et 
al., 2015). Blood brain barrier function is impaired in mdx mice due to dystrophin 
deficiency (Goodnough et al., 2014). There is mounting evidence that inflammation 
suppresses the expression of respiratory motor facilitation (Huxtable et al., 2011; 
Huxtable et al., 2013; Huxtable et al., 2015) and increased understanding of the 
pivotal role of neuroimmune interactions for the control of breathing (Popa et al., 
2011; MacFarlane et al., 2016; Stokes et al., 2017; Sheikhbahaei et al., 2018). If 
enhanced motor facilitation of the weakened diaphragm is an intrinsic 
compensatory feature in mdx mice to preserve breathing or limit ventilatory 
insufficiency (Burns et al., 2017c), then it is important to discern if there is 
neuroinflammation in the cervical spinal phrenic motor pool, which may suppress 
the capacity for neuroplasticity. 
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We sought to address these knowledge gaps. We assessed respiratory stability in 
conscious mdx mice and determined ventilatory capacity during hypercapnic 
hypoxic breathing. In anaesthetised mice, we sought to determine peak inspiratory 
pressure-generating capacity with contemporaneous measurement of diaphragm 
electromyogram (EMG) activity, to consider neuromechanical coupling. The 
concentrations of neuromodulatory monoamines together with assessment of the 
neuroinflammatory status was determined in cervical spinal cord containing the 
phrenic motor nucleus. Our principal objective was to perform an assessment of 
the neuromechanical control of breathing in the mdx mouse model of DMD. We 
hypothesized that potentiated motor facilitation of the diaphragm during increased 
ventilatory demand limits ventilatory insufficiency in mdx mice.   
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4.2 Methods 
4.2.1 Ethical approval 
Procedures on live animals were performed under licence in accordance with Irish 
and European law following approval by University College Cork animal research 
ethics committee.  
 
4.2.2 Experimental animals 
Male and female wild-type (C57BL/10ScSnJ) and mdx (C57BL/10ScSn-Dmdmdx/J) 
mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA) and bred 
at University College Cork’s animal housing facility. Eight-week-old male wild-type 
(n = 23) and mdx (n = 21) mice were studied for respiratory recordings examining 
breathing stability and subsequent tissue harvesting for immunohistochemistry and 
gene expression analyses. Animals were housed conventionally. In addition, male 
wild-type (n = 18) and mdx (n = 16) mice were purchased directly from the Jackson 
Laboratory for respiratory measurements examining ventilatory capacity, in vivo 
oesophageal pressure and EMG recordings, ex vivo diaphragm muscle function and 
tissue harvesting for monoamine analysis. The latter animals were housed in 
individually ventilated cages in our institution’s animal housing facility. All animals 
were housed in temperature and humidity-controlled rooms, operating on a 12 h 
light/ 12 h dark cycle with food and water available ad libitum. 
 
4.2.3 Whole-body plethysmography 
Whole-body plethysmography was used to assess respiratory flow in unrestrained 
and unanaesthetised mice during quiet rest. Mice were introduced into 
plethysmograph chambers (Model PLY4211; volume 600ml, Buxco Research 
Systems, Wilmington, NC, USA) and allowed 60-90 min to acclimate to the chamber 
environment. Following exploration and grooming behaviours mice settled and 
were studied during quiet rest. Recordings were typically performed in a wild-type 
and mdx mouse contemporaneously in parallel using a pair of plethysmograph 
chambers. 
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4.2.3.1 Respiratory stability 
Experimental protocol: Respiratory flow recordings were performed in wild-type (n 
= 13) and mdx (n = 12) mice during normoxia (21% O2) for 20-30 min to assess 
respiratory stability.  
 
Data analysis: The breath-to-breath (BBn) and subsequent interval (BBn+1) of 200 
breaths were analyzed as previously described (Peng et al., 2011; Souza et al., 
2015). Poincaré plots expressing BBn versus BBn+1 for 200 consecutive breaths were 
plotted for wild-type and mdx mice. Short-term variability (SD1) and long-term 
variability (SD2) were calculated as indices of breathing variability in wild-type and 
mdx mice. The frequency of augmented breaths, defined as an increase in tidal 
volume to at least twice the amplitude observed in a eupnoeic breath, was 
recorded. In addition, the frequency and duration of spontaneous and post-sigh 
apnoeas were determined. An apnoea was defined as a period of breathing 
cessation of at least two missed breaths. A study of ventilatory and metabolic 
responsiveness to hypoxia in these mice was previously reported (Burns et al., 
2017c). 
 
4.2.3.2 Ventilatory responsiveness to chemostimulation 
Experimental protocol: Mice were introduced into plethysmograph chambers as 
described above. Following acclimation and a settling period, a 20-min baseline 
recording was performed in normoxia. This was followed by a graded hypercapnic 
challenge in which animals were challenged with increasing levels of inspired 
carbon dioxide: FiCO2 = 0.02, 0.04 and 0.06 (in 21% O2) consecutively for 5 min 
each. This was immediately followed by maximal chemoreceptor stimulation with 
asphyxia (10% O2/ 6% CO2) for 5 minutes, to examine ventilatory capacity in wild-
type (n = 9) and mdx (n = 7) mice. Mice were subsequently euthanized by urethane 
overdose.  
 
Data analysis: Peak ventilation during graded hypercapnia and asphyxia was 
determined and compared with the preceding baseline normoxic period. 
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Ventilatory responsiveness to chemostimulation was expressed as % change from 
baseline.  
 
4.2.4 Diaphragm EMG and oesophageal pressure recordings 
Anaesthesia was induced with 5% isoflurane in 60% O2 (balance N2) followed by 
urethane (1.7g/kg i.p.). Wild-type (n = 9) and mdx (n = 9) mice were then placed in 
the supine position, gradually weaned from the isoflurane and body temperature 
was maintained at 37oC via a rectal probe and thermostatically-controlled heating 
blanket (Harvard Apparatus, Holliston, MA, USA). Supplemental anaesthetic was 
administered if necessary to maintain a surgical plane of anaesthesia, which was 
assessed by assessment of pedal withdrawal reflex to noxious pinch. A pulse 
oximeter clip (MouseOxTM, Starr Life Sciences Corporation, Oakmount, PA, USA) 
was placed on a shaved thigh of each mouse for the measurement of peripheral 
capillary O2 saturation (SpO2). A mid-cervical tracheotomy was performed. All 
animals were maintained with a bias flow of supplemental O2 (FiO2 = 0.60) under 
baseline conditions. End-tidal carbon dioxide (ETCO2) was measured using a 
MicroCapStar (CWE, Ardmore, PA). To estimate intra-pleural subatmospheric 
pressure generated by the respiratory musculature during inspiration, we measured 
oesophageal pressure using a pressure-tip catheter (Mikro-Tip, Millar Inc., Houston, 
TX, USA), which was positioned in the thoracic oesophagus through the mouth. 
During inspiratory activity, oesophageal recordings displayed phasic 
subatmospheric pressure swings. Concentric needle electrodes (26G; Natus 
Manufacturing Ltd, Ireland) were inserted into the costal diaphragm for the 
continuous measurement of diaphragm EMG activity, which was amplified (x5,000), 
filtered (500Hz low cut-off to 5,000Hz high cut-off) and integrated (50ms time 
constant; Neurolog system, Digitimer Ltd, UK). All signals were passed through an 
analogue-to-digital converter (r8/30; ADInstruments, Colorado Springs, CO, USA) 
and were acquired using LabChart 7 (ADInstruments, Colorado Springs, CO, USA).  
 
Experimental protocol: Following instrumentation, animals were allowed at least 10 
minutes to stabilize before baseline parameters were measured for a period of 10 
minutes. Next, animals were challenged with asphyxia (15% O2/5% CO2; 1min) to 
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examine the effects of chemostimulation on diaphragm EMG activity and 
oesophageal pressure generation. Following the experimental protocol, mice were 
euthanised by decapitation. Diaphragm muscle was excised for ex vivo functional 
analysis (section 4.2.5). Cervical spinal cord was collected for the determination of 
monoamine concentrations (section 4.2.9). 
 
Data analysis: The amplitudes of integrated inspiratory diaphragm EMG activity and 
peak inspiratory subatmospheric oesophageal pressure were analyzed and 
averaged under steady-state basal conditions, and for 1 minute of baseline 
immediately prior to chemostimulation challenges. The amplitude of integrated 
inspiratory diaphragm EMG activity and peak inspiratory subatmospheric 
oesophageal pressure were analyzed and averaged for the final 15 breaths 
(maximal response) of the asphyxic challenge. Baseline EMG data and oesophageal 
pressure are reported in absolute units. Responses to chemostimulation are 
expressed as absolute change from the preceding baseline value. Spontaneous 
augmented breaths (sighs) observed during baseline conditions were analysed and 
compared with the average of the preceding five breaths. Augmented breaths were 
classified as breaths with more than double baseline EMG amplitude a (Mantilla et 
al., 2011; Seven et al., 2014). 
 
4.2.5 Ex vivo diaphragm muscle function 
Diaphragm muscle was excised with rib and central tendon attached. Muscle 
bundles with longitudinally arranged muscle fibres were prepared for functional 
assessment and suspended vertically between two platinum plate electrodes. The 
rib was attached to an immobile hook and the central tendon was attached to a 
dual-mode force transducer (Aurora Scientific Inc.; Aurora, ON, Canada) with non-
elastic string. Diaphragm muscle preparations from wild-type (n = 8) and mdx (n = 
9) mice were studied in a water-jacketed tissue bath at 35oC containing Krebs 
solution (in mM: 120 NaCl, 5 KCl, 2.5 Ca2+, 1.2 MgSO4, 1.2 NaH2PO4, 25 NaHCO3, 
11.5 glucose) and D-tubocurarine (25 Pm) and were continuously aerated with 
hyperoxia (95% O2/ 5% CO2). Muscle optimum length (Lo) was determined by 
adjusting the position of the force transducer, in turn adjusting the length of the 
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muscle preparations, using a micro-positioner between intermittent twitch 
contractions (Burns & O'Halloran, 2016; Burns et al., 2017b). Lo was determined as 
the muscle length which revealed maximal isometric twitch force in response to 
single isometric twitch stimulation (supramaximal stimulation, 1ms duration). 
Preparations remained at Lo for the duration of the protocol. 
 
Experimental protocol: A single isometric twitch contraction was measured. Peak 
isometric twitch force (Pt), contraction time (CT) and half-relaxation time (1/2 RT) 
were determined. Peak isometric force at 100Hz (Po) was determined. The force-
frequency relationship was examined by stimulating the muscle sequentially at 10, 
20, 40, 60, 80, 100, 120, 140 and 160 Hz (300ms train duration). Contractions were 
interspersed by a 1 min interval. Next, an isotonic contraction was elicited in 
preparations at 0% load to examine maximum unloaded muscle shortening and 
velocity of shortening (Burns & O'Halloran, 2016; Burns et al., 2017b). 
 
Data analysis: Muscle force was normalised for muscle cross-sectional area (CSA) 
and expressed as specific force (N/cm2). The CSA of each muscle bundle was 
determined by dividing muscle mass (weight in grams) by the product of muscle Lo 
(cm) and muscle density (assumed to be 1.06 g/cm3). CT and ½ RT were measured 
as indices of isometric twitch kinetics. Total muscle shortening was determined as 
the maximum distance shortened during contraction. Shortening velocity was 
determined as the distance shortened during the initial 30 ms of shortening (Lewis 
et al., 2015). Total muscle shortening was normalised to Lo and expressed in L/Lo. 
Shortening velocity was normalised to Lo and expressed in Lo/s 
 
4.2.6 Tissue collection 
Real time polymerase chain reaction (RT-PCR) analysis: wild-type (n = 7) and mdx (n 
= 6) mice were anaesthetised with 5% isoflurane by inhalation in oxygen and 
euthanized by decapitation. The cervical spinal cord was isolated at the level of C3-
C5 and immediately snap frozen in liquid nitrogen. This region of the spinal cord 
contains the phrenic motor nuclei in the mouse (Qiu et al., 2010).  
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Immunohistochemical experiments: wild-type (n = 3) and mdx (n = 3) mice were 
deeply anaesthetised with 60mg/kg i.p. sodium pentobarbital (Euthatal; Abbeyville 
Veterinary Clinic, Cork, Ireland). Mice were transcardially perfused with saline (100 
ml) followed by perfusion with 4% Paraformaldehyde (PFA). Spinal cord (C3-C5) was 
harvested and post-fixed overnight in 4% PFA at 4°C and then transferred to a 20% 
sucrose solution for cryo-protection for ~72hrs at 4°C. Spinal cords were embedded 
in optimum cutting temperature (OCT; VWR International, Dublin, Ireland) and 
frozen in isopentane (Sigma Aldrich, Wicklow, Ireland) cooled on dry ice. All tissues 
were then stored at -80qC until required for cryo-sectioning.  
 
4.2.7 Spinal cord immunostaining 
Spinal cord samples were removed from the -80°C and allowed to equilibrate at -
22°C in a cryostat (Leica CM3050 S, Leica Biosystems). Samples were orientated to 
enable transverse sections to be obtained. Serial sections of 20 μm thickness were 
obtained starting at C5 and moving in a caudal to rostral fashion were collected and 
mounted on polysine-coated glass slides (VWR International, Dublin, Ireland). 
Sections were collected in series, with 4 sections per slide ensuring a difference of 
100Pm between each tissue section on a given slide. This allowed for a good 
distribution of key nuclei across multiple slides for comparative 
immunohistochemical investigation.  Slides were allowed to dry at room 
temperature for 30 min before being stored at −80°C until required for staining. To 
examine astrocytes and microglia within the putative phrenic motor nucleus, 
sections were double-labelled with the neuronal marker NeuN (Millipore – 
2726770), and glial fibrillary acidic protein (GFAP – DAKO – Z0334) or ionizing 
calcium-binding adaptor molecule 1 (Iba-1 – Wako - LAR1186). GFAP is a pan 
reactive astrocytic marker and Iba-1, is a microglia-specific calcium binding protein. 
Slides were removed from the -80°C and equilibrated at room temperature before 
staining. Transverse sections throughout the extent of C3-C5, were stained from 
wild-type and mdx mice (n = 3 per group). Individual sections were circled using a 
hydrophobic pap pen (Liquid Blocker Super PAP Pen, Ted Palla, Inc). Slides were 
washed with 0.1M PBS twice for 5 min. All sections were then blocked with 3% goat 
serum (Sigma G9023) and 20% Triton® X-100 (Tx-100) (Acrös 215682500) in 0.1M 
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PBS for 1 hour at room temperature. Following a wash with 0.1M PBS 2 x 5 min, 
primary antibodies were applied in a cocktail of (NeuN 1:200 and GFAP 1:1000) or 
(NeuN 1:200 and Iba1 1:800) in 0.1M PBS containing 0.1% Tx-100 (PBT). Negative 
control sections were run in parallel with omission of the primary antibodies.  
Following an overnight incubation at 4oC, slides were washed with PBT 3 x 10 min, 
then dH2O x 5 min before application of specific secondary antibodies, Alexa flour 
594 (1:100; Jackson 115585205) and a Fluorescein isothiocyanate (FITC) conjugated 
goat anti-rabbit IgG (1:500; Sigma F9887) for 90 min in the dark, at room 
temperature. Following a PBST 2 x 5 min wash slides were incubated with DAPI 
(1:500 in 0.1M PBS), washed with PBS (5 min) before cover slipping with 
Fluoromount (Sigma F460).  
 
Image analysis: All slides were viewed and images were digitally captured using an 
Olympus BX51 microscope and an Olympus DP71 and camera. Images were taken 
of each region of interest at x10/x20 magnification. Quantitative analysis of GFAP 
and Iba-1 positive cell numerical density (%) was measured using Image J, by 
analysing cell counts of 8-bit FITC (green) channel, within a 250μm2 discrete area of 
motor nuclei by counting the number of GFAP- or Iba-1 positive cells and expressing 
them as a % of the total nuclei x 100 per area. Only cells which displayed activated 
morphology (astrocytes: 3 or more projections, and microglia: amoeboid in shape) 
were included in the analysis. Multiple images were captured and averaged per 
animal before comparing group means.  
 
4.2.8 Terminal deoxynucleotidyl Transferase (TdT) dUTP Nick-End Labelling assay 
(TUNEL assay) 
To investigate cellular apoptosis in the spinal cord, TUNEL (terminal 
deoxynucleotide transferase-mediated dUTP nick end labelling) staining was 
performed. Transverse sections throughout the C3-C5 region were stained from 
wild-type and mdx mice (n = 3 per group). Slides were removed from the -80°C and 
equilibrated at room temperature before staining using the ApopTag® Peroxidase In 
Situ Apoptosis Detection Kit (Millipore S7100) according to the manufacturer's 
instructions. DNAase-treated slides were used as a positive control (Fig. 4.6B).   
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4.2.9 High performance liquid chromatography (HPLC) 
Monoamines and metabolites important in the neurochemical control of breathing, 
including noradrenaline (NA), 5-hydroxytryptamine (5-HT) and 5-
hydroxyindoleacetic acid (5-HIAA), were quantified using high performance liquid 
chromatography (HPLC), as previously described,  in the cervical spinal cord (C3-C5 
region) of wild-type (n = 9) and mdx (n = 9) mice.  
 
Experimental protocol: Frozen samples were thawed in 500 Pl of chilled 
homogenising buffer spiked with 2ng/20µl of N-Methyl 5-HT (Sigma, UK) as internal 
standard, sonicated for 2 x 4 s bursts (Bandelin Sonoplus HD 2070) and centrifuged 
at 14,000 RPM for 20 mins at 8oC (MIKRO 22 R refrigerated centrifuge). 20 Pl of 
supernatant was injected onto the HPLC system (Electrochemical Detection). The 
mobile phase contained 0.1M citric acid, 0.1M sodium dihydrogen phosphate, 
0.01mM EDTA (Fisher Scientific Ireland), 5.6mM octane-1-sulphonic acid (Sigma) 
and 11% (v/v) HPLC-grade methanol (Fisher Scientific IRELAND), and was adjusted 
to pH 2.8 using 4N sodium hydroxide (Alkem/Reagecon). A reverse-phase column 
(Kinetex 2.6u C18 100 x 4.6mm, Phenomenex, UK) maintained at 30oC was 
employed in the separation (Flow rate 0.9ml/min), the glassy carbon working 
electrode combined with an Ag/AgCL reference electrode (Shimdazu) was operated 
a +0.8V and the chromatograms generated were analysed using Class-VP 5 software 
(Shimadzu, Corporation, Kyoto, Japan). Neurotransmitters and their 
precursors/metabolites were identified by their characteristic retention times as 
determined by standard injections which were run at regular intervals during the 
sample analysis.  
 
Data analysis: The chromatograms were processed using Class 5-VP software 
(Shimadzu Corporation, Kyoto, Japan). Analyte: Internal standard peak height ratios 
were measured and compared with standard injections and results were expressed 
as ng of analyte per g tissue weight. 
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4.2.10 RNA extraction and real-time polymerase chain reaction (RT-PCR) 
RNA was isolated from the spinal cord samples using a Nucleospin RNAII kit 
(Macherey-Nagel GmbH, Germany). RNA quantity and purity was assessed by 
spectrophotometry with a Nanospec (Nanodrop Lite, Thermo Scientific, USA). RNA 
was reverse transcribed into complimentary DNA (cDNA) using a Transcriptor First 
Strand cDNA Synthesis Kit (Roche Products Ireland Ltd) as per manufacturer’s 
instructions. Equal concentrations of cDNA were prepared for reverse transcription 
polymerase chain reaction (PCR) amplification.  cDNA was amplified using Realtime 
ready Catalog or Custom Assays (Roche Diagnostics Ltd) or “Taqman Gene 
Expression Assays” containing forward and reverse primers and a FAM-labelled 
MGB Taqman probe for each gene (Applied Biosystems; Table 4.1) and SensiFASTTM 
Probe Hi-ROX Kit (Bioline). Real-time PCR was completed using an ABI Prism 7300 
instrument (Applied Biosystems). Assay IDs are shown in Table 4.1. Relative mRNA 
expression was normalised to β-actin used as the endogenous control. Relative 
gene expression was calculated using the ΔΔCT method with Applied Biosystems RQ 
software (Applied Biosystems). 
 
Gene title Gene symbol Assay ID Configuration number 
Dystrophin Dmd 317524 1001317524 
Β-actin Actb 307903 Mm00607939_s1 
NF-κB Nfkb1 300085 1001300085 
TNFα Tnf 314800 1001314800 
GFAP Gfap 311752 Mm01253033_m1 
CD11b Itgam 26G09 Mm00434455_m1 
IL-6 Il6 300699 1001300699 
HIF-1α Hif1a 300617 1001300617 
HIF-2α Epas1 314102 1001314102 
iNOS Nos2 300665 1001300665 
 
Table 4.1 Real-time ready catalog and custom assays used for cDNA amplification. 
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4.2.11 Statistical analysis  
Values are expressed as mean r SD or as box and whisker plots (median, 25-75 
percentile, and scatter plot). Data were statistically compared using Prism 6.0 
(Graphpad Software, San Diego, CA, USA). Data were tested for normal distribution 
and equal variances. Data sets which were normally distributed and of equal 
variance were statistically compared using unpaired two-tailed Student’s t test. 
Welch’s correction was applied in the case of unequal variance. Data which were 
not normally distributed were compared using Mann Whitney non-parametric 
tests. Data for diaphragm muscle force-frequency relationship and ventilatory 
responsiveness to chemostimulation were statistically compared by repeated 
measures two-way ANOVA (frequency x gene) with Bonferroni post hoc test. P < 
0.05 was considered statistically significant in all tests.   
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4.3 Results 
4.3.1 Breathing variability 
Figure 4.1 shows Poincaré plots of the breath-to-breath (BBn) and subsequent 
interval (BBn+1) of 200 consecutive breaths for expiratory duration (Te; A and B) and 
total breath duration (Ttot; E and F) in wild-type (A and E; open) and mdx (E and F; 
grey) mice. Assessment of the short-term (SD1) and long-term (SD2) variability of 
breathing indicated no evidence of respiratory instability for Te (Fig. 4.1C and D; SD1 
and SD2, respectively) and Ttot (Fig. 4.1 G and H; SD1 and SD2, respectively) in mdx 
compared with wild-type mice.  
 
Figure 4.1 shows representative respiratory flow traces illustrating a sigh and post-
sigh apnoeas (I) and a spontaneous apnoea (J) in a wild-type mouse during 
normoxia. Analysis of sighs revealed no difference in the frequency of sighs (P = 
0.3106; Mann Whitney test; Fig. 4.1K) between wild-type and mdx mice. Similarly, 
no difference was observed in the frequency of post-sigh apnoeas (P = 0.8157; 
unpaired Student’s t test; Fig. 4.1M) and the duration of post-sigh apnoeas (P = 
0.9460; unpaired Student’s t test; Fig. 4.1N). Analysis of spontaneous apnoeas, 
which were infrequent, showed no difference in the frequency of spontaneous 
apnoeas (P = 0.4881; Mann Whitney test; Fig. 4.1O) and the duration of apnoeas (P 
= 0.1333; Mann Whitney test; Fig. 4.1P). 
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Figure 4.1 Respiratory measurements in conscious mice 
A and B, poincaré plot of breath-to-breath (BBn) and subsequent breath-to-breath (BBn+1) 
interval of expiratory duration (Te) over 200 consecutive breaths for wild-type (A; WT) and mdx 
(B) mice. C and D, group data of short-term (C; SD1) and long-term (D; SD2) variability of 
breathing based on Te for WT (n = 13) and mdx (n = 12) mice. E and F, poincaré plot of BBn and 
BBn+1 of total breath duration (Ttot) over 200 consecutive breaths for WT (E) and mdx (F) mice. G 
and H, group data of SD1 (G) and SD2 (H) based on Ttot for WT and mdx mice. For SD1 and SD2, 
values are expressed as scatter point box and whisker plots (median, 25-75 centile and scatter 
plot). Data were statistically compared by unpaired Student’s t tests or Mann Whitney non-
parametric test. I and J, representative respiratory flow traces showing a sigh (grey shading) and 
post-sigh apnoeas (grey line) in a WT mouse (I) and a spontaneous apnoea (grey line) in a WT 
mouse (J) during normoxia. K, L, M, N, O and P, group data for sigh frequency (K) and amplitude 
(L), post-sigh apnoea frequency (M) and duration (N) and spontaneous apnoea frequency (O) 
and duration (P) occurring during normoxia for WT and mdx mice. Values are expressed as 
scatter point box and whisker plots (median, 25-75 percentile and scatter plot). Data were 
statistically compared by unpaired Student’s t tests or Mann Whitney non-parametric tests. 
 151 
 
4.3.2 Ventilatory responsiveness to hypercapnic hypoxia 
Figure 4.2 shows representative respiratory flow traces for wild-type and mdx mice 
during exposure to baseline air and hypercapnic-hypoxia (asphyxia). 
Chemostimulation with graded hypercapnia and asphyxia resulted in a significant 
increase in minute ventilation (P < 0.0001 (gas); repeated measures two-way 
ANOVA; Fig. 4.2B) for both wild-type and mdx mice, with no difference between 
groups. Ventilatory responsiveness to gas challenge expressed as % change from 
baseline was not different between wild-type and mdx mice (Fig. 4.2C).  
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Figure 4.2 Ventilation in response to chemostimulation in conscious mice 
A, representative respiratory flow traces during normoxia (21% O2) and hypercapnic-
hypoxia (6% CO2/10% O2) in a wild-type (black; WT) and mdx mouse (grey); inspiration 
downwards. B, group data for peak minute ventilation during graded hypercapnia (2, 4 and 
6% CO2) and hypercapnic-hypoxia. C, group data for ventilatory responsiveness to 
chemostimulation (expressed as % change from baseline). Values are expressed as scatter 
point box and whisker plots (median, 25-75 percentile and scatter plot). Data were 
statistically compared by repeated measures two-way ANOVA. 
 
  
 154 
 
4.3.3 Oesophageal pressure and diaphragm EMG activity in vivo  
Representative original recordings of oesophageal pressure and diaphragm EMG 
during baseline conditions (60% O2) and during an augmented breath are shown in 
figure 4.3A. Table 4.2 shows baseline respiratory measurements in wild-type and 
mdx mice. Respiratory frequency was significantly higher in mdx mice compared 
with wild-type (P < 0.0001; unpaired Student’s t test; Table 4.2). There was no 
significant difference in SpO2 and ETCO2 between wild-type and mdx mice (Table 
4.2).  
 
Peak inspiratory oesophageal pressure during baseline was equivalent between 
wild-type and mdx mice (P = 0.2887; unpaired Student’s t test; Fig. 4.3B). Baseline 
diaphragm EMG activity was significantly lower in mdx (P = 0.025; unpaired 
Student’s t test with Welch’s correction; Fig. 4.3C) compared with wild-type. The 
peak inspiratory oesophageal pressure response (' amplitude) to asphyxia revealed 
a trend towards a significant increase in responsiveness in mdx mice compared with 
wild-type (P = 0.08; unpaired Student’s t test with Welch’s correction; Fig. 4.3D); 
diaphragm EMG response to asphyxia (' amplitude) was not different between 
wild-type and mdx (P = 0.27; unpaired Student’s t test with Welch’s correction; Fig. 
4.3E). The magnitude of the change in peak inspiratory oesophageal pressure 
during an augmented breath was significantly greater in mdx (P = 0.0006; unpaired 
Student’s t test; Fig. 4.3F) compared with wild-type mice; the magnitude of the 
change in diaphragm EMG during an augmented breath was equivalent between 
wild-type and mdx mice (P = 0.4341; unpaired Student’s t test; Fig. 4.3G). 
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Figure 4.3 Oesophageal pressure and diaphragm muscle EMG activity in anaesthetised 
mice 
A, representative traces of oesophageal pressure and diaphragm (Dia) muscle raw and 
integrated (Int.) EMG activity for a wild-type (WT) mouse (black) and mdx mouse (grey) 
during baseline (60% inspired O2) and an augmented breath (shaded). B and C, group data 
for oesophageal pressure (B) and diaphragm muscle integrated EMG activity (C) during 
baseline conditions (both expressed as amplitude) for WT (n = 7-9) and mdx (n = 7-9) mice. 
D and E, group data for oesophageal pressure (D) and diaphragm muscle integrated EMG 
activity (E) in response to an asphyxic gas challenge for WT and mdx mice. Both expressed 
as delta values. F and G, group data for oesophageal pressure (F) and diaphragm muscle 
integrated EMG activity (G) during an augmented breath for WT and mdx mice. Values are 
expressed as scatter point box and whisker plots (median, 25-75 percentile and scatter 
plot). Data were statistically compared by unpaired Student’s t tests or Mann Whitney non-
parametric test. *P = 0.025 (Fig. 4.3C), ***P = 0.0006 (Fig. 4.3F) compared with 
corresponding WT values. 
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 WT 
(n = 9) 
mdx 
(n = 9) 
P (Student’s t test) 
fR (bpm) 195.1 ± 10.8 229.6 ± 10.6 < 0.0001 
SpO2 (%) 97.2 ± 1.9 96.5 ± 2.0 0.4069 
ETCO2 (%) 4.4 ± 0.4 4.0 ± 0.4 0.0966 
Body mass (g) 24.9 ± 1.8 25.0 ± 2.3 0.911 
 
Table 4.2 Baseline respiratory parameters in anaesthetised mice 
Definition of abbreviations: fR, respiratory frequency; SpO2, peripheral capillary oxygen 
saturation; ETCO2, end-tidal carbon dioxide; WT, wild-type. Data are shown as mean ± SD 
and were statistically compared using unpaired Student’s t tests. 
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4.3.4 Diaphragm muscle contractile function ex vivo 
Figure 4.4 shows representative original traces for wild-type (black) and mdx (grey) 
diaphragm twitch (A) and tetanic (B) contractions, force-frequency relationship (C) 
and maximal unloaded shortening (D). Twitch kinetics (CT and ½ RT) and isotonic 
contractile parameters (Smax and Vmax) are shown in Table 4.3. Twitch contraction 
time was significantly increased in mdx compared with wild-type diaphragm (P = 
0.027; unpaired Student’s t test). Twitch half-relaxation time and isotonic 
contractile parameters were not significantly different between wild-type and mdx 
diaphragm preparations. Diaphragm twitch (P = 0.0241; unpaired Student’s t test; 
Fig. 4.4E, Pt) and tetanic force (P < 0.0001; unpaired Student’s t test with Welch’s 
correction; Fig. 4.4E, Po) were both significantly depressed in mdx compared with 
wild-type. For the force-frequency relationship, diaphragm specific force was 
significantly lower in mdx compared with wild-type preparations (P = 0.0003 
(genotype); repeated measures two-way ANOVA; Fig. 4.4F). Post hoc analysis 
revealed significant force depression in mdx across a broad range of stimulation 
frequencies (60-160 Hz).  
 
 WT 
(n = 8) 
mdx 
(n = 9) 
P (Student’s t test) 
CT (ms) 17.3 ± 2.3 20.3 ± 2.6 0.027 
½ RT (ms) 19.6 ± 6.9 23.2 ± 4.3 0.2177 
Smax (L/Lo) 0.36 ± 0.07 0.30 ± 0.13 0.3252 
Vmax (Lo/s) 4.1 ± 1.1 3.3 ± 1.9 0.3373 
 
Table 4.3 Ex vivo diaphragm muscle contractile kinetics 
Definition of abbreviations: CT, contraction time; ½ RT, half-relaxation time; Smax, peak 
shortening; Vmax, peak shortening velocity; Lo, optimum length. Data are shown as mean ± 
SD and were statistically compared using unpaired Student’s t tests. 
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Figure 4.4 Ex vivo diaphragm muscle contractile function 
A, B, C, and D, original traces of ex vivo diaphragm muscle twitch contraction (A), tetanic 
contraction (B), force-frequency relationship (C) and maximum unloaded shortening (D) for 
wild-type (WT; black) and mdx (grey) preparations. E, group data for diaphragm muscle 
twitch (Pt) and tetanic (Po) force in WT (n = 8) and mdx (n = 9) mice. Tetanic force was 
measured following stimulation at 100 Hz ex vivo. Values are expressed as scatter point box 
and whisker plots (median, 25-75 percentile and scatter plot). Data were statistically 
compared by unpaired Student’s t tests. *P < 0.05, ***P < 0.001 compared with 
corresponding WT value. F, group data (mean ± SD) for diaphragm muscle force-frequency 
relationship ex vivo in WT (open) and mdx (grey) preparations. Data were statistically 
compared by repeated measures two-way ANOVA (frequency x gene) followed by 
Bonferroni post hoc test. **P < 0.0 ***P < 0.001 compared with corresponding WT value.  
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4.3.5 Cervical spinal cord immune cell density 
Figure 4.5 shows representative images for wild-type and mdx C3-C5 spinal cords 
immuno-fluorescently labelled with GFAP (a pan reactive astrocytic marker; Fig. 
4.5A) and Iba-1 (a microglia-specific calcium binding protein; Fig. 4.5B). Circles 
identify the putative phrenic motor nucleus. There was no significant difference in 
GFAP positive cell counts (numerical density %) (P = 0.1497; unpaired Student’s t 
test; Fig. 4.5C) between wild-type and mdx spinal cords. Similarly, there was no 
significant difference in IBA-1 positive cell counts (P = 0.0823; unpaired Student’s t 
test; Fig. 4.5D), between wild-type and mdx spinal cords. Figure 4.6A shows spinal 
cord sections examined for cellular apoptosis using TUNEL assay. The ventral horn 
of the C3-C5 spinal cord, which contains the phrenic motor nucleus was devoid of 
brown apoptotic bodies in wild-type and mdx sections (0.16 ± 0.2% versus 0.09 ± 
0.2% TUNEL positive cell counts, unpaired Student’s t test, P = 0.6499 for wild-type 
versus mdx (n=3 each) mice).  
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Figure 4.5 Cervical spinal cord immunohistochemistry  
A and B, representative images of the ventral horn of the spinal cord (C3-C5 region) of wild-
type (WT) and mdx mice immuno-fluorescently labelled for glial fibrillary acidic protein (A; 
GFAP, green) or ionizing calcium-binding adaptor molecule (B; Iba-1, green), NeuN 
(neuronal marker, red) and DAPI (nuclear stain, blue). Circles identify the putative phrenic 
motor nucleus. C and D, group data (mean ± SD) for GFAP (C) and IBA-1 (D) positive cells in 
the putative phrenic motor nucleus of WT and mdx mice. Data were statistically compared 
by unpaired Student’s t tests. 
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Figure 4.6 Cervical spinal cord TUNEL assay 
A, representative images of terminal deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL) in the ventral horn of C3-5 region of the spinal cord for wild-type (WT) and mdx 
mice. Images from WT and mdx are devoid of brown apoptotic bodies. Circles identify the 
putative phrenic motor nucleus. B, shows positive control, DNAase-treated spinal cord 
displaying brown apoptotic bodies. Arrow indicates the central canal. 
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4.3.6 Cervical spinal cord monoamine concentration 
Monoamine concentrations were determined in the C3-C5 spinal cord of wild-type 
and mdx mice (Fig. 4.7). Levels of NA and 5-HT and its metabolite 5-HIAA were 
quantified using HPLC. The concentration of NA (P < 0.0001; unpaired Student’s t 
test; Fig. 4.7A) and 5-HT (P = 0.0006; unpaired Student’s t test; Fig. 4.7B) were 
significantly increased in the C3-C5 spinal cord in mdx compared with wild-type. 
There was no significant difference in 5-HIAA concentration (P = 0.1769; Mann 
Whitney non-parametric test; Fig. 4.7C) between wild-type and mdx spinal cords.  
 
 
Figure 4.7 Cervical spinal cord monoamine concentration 
A, B, and C, group data for the concentrations of noradrenaline (A; NA), 5-
hydroxytryptamine (B; 5-HT) and 5-hydroxyindoleacetic acid (C; 5-HIAA) in the spinal cord 
(C3-C5 region) of wild-type (WT) and mdx mice. Values are expressed as scatter point box 
and whisker plots (median, 25-75 percentile and scatter plot). Data were statistically 
compared by unpaired Student’s t tests or Mann Whitney non-parametric test. ****P < 
0.0001 (Fig. 4.7A), ***P = 0.0006 (Fig. 4.7B), compared with corresponding WT value. 
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4.3.7 Cervical spinal cord gene expression  
Messenger RNA (mRNA) levels were assessed in the C3-C5 spinal cord of wild-type 
and mdx mice (Fig. 4.8). Dystrophin mRNA was expressed in the cervical spinal cord 
of wild-type mice; dystrophin mRNA was significantly lower in mdx mice compared 
with wild-type (P = 0.004; unpaired Student’s t test). GFAP mRNA was significantly 
lower in the spinal cord of mdx mice compared to wild-type (P = 0.0173). There 
were no significant differences in the expression of NFNB, TNF-D, CD11b, IL-6, HIF-
1D, HIF-2D and iNOS between wild-type and mdx cervical spinal cords. 
 
 
 
 
Figure 4.8 Cervical spinal cord gene expression analysis 
Group data (mean ± SD) for messenger RNA (mRNA) expression in spinal cord (C3-C5 
region) of wild-type (WT) and mdx mice. Data were statistically compared by unpaired 
Student’s t tests. *P = 0.0173, **P = 0.004 compared with corresponding WT value. 
Definition of abbreviations: NFNB, nuclear factor kappa-light-chain-enhancer of activated B 
cells; TNF-D, tumour necrosis factor alpha; GFAP, glial fibrillary acidic protein; CD11b, 
cluster of differentiation molecule 11B; IL-6, interleukin-6; HIF, hypoxia-inducible factor; 
iNOS, inducible nitric oxide synthase.  
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4.4 Discussion 
The main findings of this study are: (i) there is no evidence of respiratory instability 
in young mdx mice; (ii) ventilatory capacity in response to maximum 
chemostimulation is equivalent between mdx and wild-type mice; (iii) despite 
substantial diaphragm muscle weakness, inspiratory oesophageal pressure 
generation is equivalent during basal and chemoactivated breathing and is greater 
during augmented breaths in mdx mice compared with wild-type; (iv) monoamine 
concentrations are elevated in the cervical spinal cord of mdx mice; (v) the density 
of activated astrocytes and microglia is equivalent in mdx and wild-type cervical 
spinal cords; (vi) dystrophin mRNA is expressed in the cervical spinal cord of wild-
type mice, and expression is significantly lower in mdx; (vii) there is no increase in 
pro-inflammatory gene expression in mdx cervical spinal cords. Despite profound 
diaphragm dysfunction, ventilatory capacity is well preserved in mdx mice, probably 
through increased drive in accessory motor pathways of breathing. 
 
Dystrophin is expressed in the CNS (Lidov, 1996), but the effect of dystrophin 
deficiency on respiratory rhythm and stability is not well described. Increased 
respiratory instability has the potential to contribute to disordered breathing during 
sleep, which is a feature of DMD (LoMauro et al., 2017). Dysregulated control of 
respiratory timing could exacerbate ventilatory insufficiency in DMD due to 
recognised mechanical deficits. Our study demonstrated that respiratory timing 
variability in young mdx mice is equivalent to age-matched wild-type mice. 
Moreover, we observed no increase in the propensity for post-sigh or spontaneous 
apnoea during normoxia in mdx mice. Similarly, the frequency of augmented 
breaths (sighs) examined during normoxia was not different in mdx mice compared 
with wild-type. Our study cannot rule out a potential emergence of unstable 
respiratory timing in later stages of the progressive disease, but suggests that 
dystrophin deficiency does not manifest an overt respiratory control phenotype at a 
disease stage characterised by respiratory muscle pathology. 
 
Our study confirmed substantial diaphragm muscle weakness in young mdx mice, 
consistent with our recent reports (Burns et al., 2017a; Burns et al., 2017c). 
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Diaphragm deficits in mdx mice were evidenced by significantly reduced twitch and 
tetanic isometric force compared with wild-type. The force-frequency relationship 
revealed considerable force loss in the frequency range of 60-160 Hz, 
corresponding to a broad range of ventilatory behaviours (Sieck et al., 2013; 
Mantilla et al., 2014). We have previously documented considerable muscle fibre 
damage and remodelling in dystrophic diaphragm at this age, with increased 
variability of muscle fibre size and centralised myonuclei (Burns et al., 2017c).  
 
We assessed ventilation in response to hypercapnic, and hypercapnic hypoxic 
(asphyxic) challenges, which revealed a remarkable capacity for mdx mice to 
enhance ventilation, despite substantial intrinsic diaphragm muscle weakness. Peak 
ventilation during graded hypercapnia was equivalent in mdx and wild-type mice, 
revealing that CO2 chemosensitivity is intact in mdx mice, which retain considerable 
ventilatory reserve and, notwithstanding diaphragm dysfunction, maintain a 
capacity to elevate minute ventilation (through rate and volume changes) to wild-
type levels. This impressive preserved capacity to elevate pulmonary ventilation 
was revealed during exposure to hypercapnic hypoxia with peak ventilation 
increasing more than 3-fold in mdx mice, equivalent to wild-type values. We 
acknowledge that compensatory mechanisms supporting ventilatory capacity early 
in disease progression may not prevail at later stages. Indeed, in older animals, 
blunted ventilatory responses to hypercapnic challenge have been observed in 7- 
and 16-month-old mdx mice (Gosselin et al., 2003; Gayraud et al., 2007). In DMD, 
there is a progressive decline in pulmonary function and respiratory muscle 
strength culminating in reduced ventilation (Smith et al., 1989; De Bruin et al., 
1997; Hukins & Hillman, 2000; Khirani et al., 2014). There is a paucity of data within 
the literature examining ventilatory responsiveness to hypercapnia in DMD 
patients. 
 
In anaesthetised mice, we demonstrated that peak inspiratory oesophageal 
pressure generation was equivalent during basal breathing (FiO2 = 0.6) in mdx and 
wild-type mice. Acute chemoactivation (FiO2 = 0.15 and FiCO2 = 0.05) increased 
ventilatory drive and the magnitude of the enhanced peak inspiratory oesophageal 
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pressure was equivalent in mdx and wild-type mice. This revealed that there is no 
apparent mechanical deficit limiting sub-atmospheric pressure generating capacity 
in young adult mdx mice. Considering the substantial diaphragm weakness and the 
force-frequency relationship of mdx diaphragm compared with wild-type, a right-
ward shift associated with increased chemoactivation produces only a small 
increment in force-generating capacity in the severely weakened mdx diaphragm. 
The increase in force above that required for basal breathing might suffice in 
generating the subatmospheric pressures required for chemoactivated breathing. 
Alternatively, potentiated neural recruitment of the diaphragm via the phrenic 
nerve (corresponding to a further right-shift in the force-frequency relationship) 
might facilitate inspiratory pressure generating capacity in mdx mice. Indeed, in 
support of this latter notion, we have recently reported apparent compensatory 
neuroplasticity in the motor drive to the diaphragm under some circumstances in 
mdx compared with wild-type mice (Burns et al., 2017c).  However, in the present 
study, the diaphragm EMG response to hypercapnic hypoxia was not potentiated in 
mdx mice compared with wild-type responses.  This suggests that either the 
weakened diaphragm in mdx is sufficient to support ventilatory demand during 
chemoactivation (without neural compensation by way of added recruitment), 
which is unlikely, or ventilation is compensated in mdx by way of enhanced 
recruitment of accessory muscles of breathing. 
 
We extended this line of enquiry by way of assessment of spontaneous augmented 
breaths (sighs), which result in elevated motor unit recruitment of the diaphragm 
beyond that observed during chemoactivation (Mantilla et al., 2011; Seven et al., 
2014). In the light of our findings in respect of inspiratory pressure-generating 
capacity in anaesthetised mice, we also evaluated tidal volume during spontaneous 
augmented breaths in conscious mice during plethysmography studies. Surprisingly, 
during augmented breaths peak inspiratory oesophageal pressure generation was 
significantly greater in mdx mice compared with wild-type, once again 
demonstrating no mechanical constraint in 8-week-old mdx mice despite 
substantial diaphragm weakness (approaching 50% force loss compared with wild-
type in the range 60-100Hz). Moreover, enhanced diaphragm EMG activity during 
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spontaneous augmented breaths was equivalent (not potentiated) in mdx 
compared with wild-type mice. Together, these observations strongly suggest that 
preservation of inspiratory pressure-generating capacity in mdx is independent of 
the motor drive to the diaphragm. Force-generating capacity of the diaphragm is 
severely curtailed in mdx such that even maximum activation of the muscle may not 
be sufficient to generate substantial subatmospheric pressures, unless one 
considers that the loss of force corresponds to loss of the considerable ventilatory 
reserve of the diaphragm affecting airway protective behaviours but allowing for 
‘normal’ ventilation and activity capable of generating augmented breaths. 
Although this possibility remains, at least presumably until progressive further loss 
of diaphragm force with disease progression, we favour the likelihood that 
ventilatory capacity is maintained owing to enhanced accessory muscle activation 
in support of pulmonary ventilation.   
 
We acknowledge that our assessment of ventilatory capacity is limited to peak 
ventilation during chemoactivation of breathing (albeit pronounced hypercapnic 
hypoxia), and spontaneous single augmented breaths. It may be that the preserved 
capacity in mdx, whatever the mechanism, is limited such that dysfunction would 
be revealed by maximal inspiratory efforts particularly over sustained periods. For 
example, it would be interesting to determine peak inspiratory pressure-generating 
capacity in mdx mice during progressive tracheal occlusion, which results in further 
motor recruitment beyond that of augmented breaths (Mantilla et al., 2011; 
Greising et al., 2013; Seven et al., 2014). We further acknowledge that trans-
diaphragmatic pressure is a clinically-relevant index of diaphragm strength in situ 
(Syabbalo, 1998). Trans-diaphragmatic pressure can be recorded in mice, but 
requires significant abdominal banding, which impacts on the potential contribution 
of abdominal musculature to ventilatory mechanics in spontaneously breathing 
mice. Nevertheless, we recognise that peak trans-diaphragmatic pressure 
recordings during maximum ventilatory behaviours, and bilateral phrenic nerve 
stimulation, would provide a useful index of diaphragm performance in vivo 
(Greising et al., 2013). 
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Full length dystrophin (Dp427) is expressed in the central nervous system of healthy 
individuals. Similar to muscle, dystrophin has a structural role in neurons where it 
associates with membrane spanning proteins forming the dystrophin associated 
protein complex and connects the intracellular cytoskeleton to the extracellular 
matrix. The consequences of dystrophin lack in the brainstem and spinal cord are 
unclear. Studies indicate altered acetylcholine and GABA neurotransmission and 
receptor expression in the CNS of mdx mice, although much of this work has been 
limited to the hippocampus since cognitive deficits are apparent in DMD (Sekiguchi 
et al., 2009; Kueh et al., 2011; Ghedini et al., 2012; Parames et al., 2014; Cohen et 
al., 2015; Xu et al., 2015; Vaillend & Chaussenot, 2017). In the light of our previous 
observations of potentiated diaphragm EMG responsiveness in mdx mice in 
circumstances of high ventilatory demand (Burns et al., 2017c), we examined the 
concentrations of monoamines in cervical spinal cord, with a focus on serotonin, 
which is implicated in experimental paradigms of phrenic motor facilitation 
(MacFarlane et al., 2014; Fields et al., 2015; Perim et al., 2018). The concentrations 
of serotonin and noradrenaline were significantly elevated in mdx cervical spinal 
cords providing a substrate for potentiated neuro-modulatory tone, although 
diaphragm EMG activity was not elevated in mdx compared with wild-type mice 
under any condition in the present study.  
 
Systemic inflammation is a hallmark feature of dystrophin deficiency (Cruz-Guzmán 
et al., 2015), and prior research has pointed to blood brain barrier leakiness 
(Goodnough et al., 2014). We explored the possibility of a neuroinflammatory 
signature in the cervical spinal cord of mdx, which would have potential 
implications for motor control of the diaphragm and capacity for motor facilitation, 
since it is established that neuroinflammatory mediators strongly suppress phrenic 
motor facilitation (Huxtable et al., 2013; Hocker et al., 2017; Hocker & Huxtable, 
2018). In the current study, we examined the density of activated immune cells 
(GFAP-positive astrocytes and Iba-1-positive microglia) in putative phrenic motor 
nuclei (C3-C5, (Qiu et al., 2010)) demonstrating no evidence of neuroinflammation 
within the ventral horn and putative phrenic motor nuclei of the cervical spinal cord 
of mdx mice. Moreover, gene expression of pro-inflammatory molecules (NFNB, 
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TNFD, interleukin-6) and inducible nitric oxide synthase was not elevated in mdx 
cervical spinal cord homogenates. To examine cellular apoptosis, TUNEL assay was 
performed on wild-type and mdx spinal cord sections revealing no evidence of 
apoptotic bodies within putative phrenic motor nuclei of mdx mice. These findings 
reveal that there is no apparent neuroinflammatory signature that might otherwise 
curtail the capacity for respiratory plasticity and phrenic motor facilitation. The 
absence of apoptosis in mdx suggests no loss of trophic input to dystrophic 
diaphragm. 
 
Interestingly, our previous finding of enhanced neural drive to the diaphragm 
muscle during chemostimulation (15% O2 and 5% CO2), revealed in diaphragm EMG 
recordings in anaesthetised mdx mice, which we considered a compensatory 
mechanism supporting ventilation, was not replicated in the current study. One 
major difference between studies is that the vagus nerves were sectioned in our 
former study in the mid-cervical region (Burns et al., 2017c), but remained intact in 
the present study. Vagotomy and subsequent chemoactivation of breathing 
produces greater activation of diaphragm EMG compared with vagi intact, 
particularly in mice which adopt a pronounced frequency response to 
chemoactivation. Thus, it may be that potentiation of neural drive to the diaphragm 
in mdx mice is only revealed during near maximum or maximum ventilatory drive, 
or requires an absence of vagal inhibition of breathing (and perhaps superimposed 
chemoactivation), which would have relevance to obstructive airway events. The 
latter are characteristic features of sleep-disordered breathing common in DMD.   
 
In summary, young adult mdx mice retain a remarkable capacity to preserve 
inspiratory pressure-generating and ventilatory capacity despite substantial 
diaphragm pathology and weakness. We conclude that enhanced recruitment of 
accessory muscles facilitates breathing. An increased understanding of the 
neuromechanical control of breathing in DMD and animal models is important in 
the context of disease progression, and may offer novel therapeutic strategies in 
respect of pulmonary support and rehabilitation in DMD boys. 
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Cover image panel shows a collection of immunofluorescent and histological images 
of mouse respiratory muscle. Top left shows sternohyoid muscle fluorescently 
labelled for type IIa (red), type IIx (untagged, appearing black) and type IIb (green) 
fibres. Top right shows sternohyoid muscle stained with Masson’s trichrome to 
examine collagen content. Bottom left shows sternohyoid muscle stained with 
Haematoxylin and Eosin to examine muscle fibre nucleation and cellular infiltrates. 
Bottom right shows diaphragm muscle immunofluroescently labelled for laminin 
(green) and myonuclei (blue).    
  
 179 
 
Key points 
What is the central question of this study? 
We previously reported impaired upper airway dilator muscle function in the mdx 
mouse model of Duchenne muscular dystrophy (DMD). Our aim was to assess the 
effect of blocking interleukin-6 receptor signalling and stimulating corticotrophin-
releasing factor receptor 2 signalling on mdx sternohyoid muscle structure and 
function.  
What is the main finding and its importance? 
The interventional treatment had a positive inotropic effect on sternohyoid muscle 
force, restoring mechanical work and power to wild type values, reduced myofibre 
central nucleation and preserved the myosin heavy chain type IIb fibre complement 
of mdx sternohyoid muscle. These data might have implications for the 
development of pharmacotherapies for DMD with relevance to respiratory muscle 
performance. 
 
Abbreviations: SDB, sleep disordered breathing; CRF, corticotrophin releasing 
factor; CRFR, CRF receptor; TNF, tumor necrosis factor; IL, interleukin; IL-6R, 
interleukin-6 receptor; Ucn2, urocortin2; MyHC, myosin heavy chain; WT, wild-type; 
xIL-6R, anti-IL-6R; CSA, cross-sectional area; Lo, optimum length; CT, contraction 
time; ½ RT, half relaxation time; Smax, total shortening; Vmax, shortening velocity. 
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Abstract 
The mdx mouse model of Duchenne muscular dystrophy (DMD) shows evidence of 
impaired pharyngeal dilator muscle function. We hypothesised that inflammatory 
and stress-related factors are implicated in airway dilator muscle dysfunction. Six-
week-old mdx (n = 26) and wild-type (WT; n = 26) mice received either saline (0.9% 
w/v) or a co-administration of neutralising interleukin-6 receptor antibodies (0.2 
mg/kg) and corticotrophin releasing factor receptor 2 agonist (urocortin 2; 30μg/kg) 
over 2 weeks. Sternohyoid muscle isometric and isotonic contractile function was 
examined ex vivo. Muscle fibre centronucleation, and muscle cellular infiltration, 
collagen content, fibre type distribution and fibre cross-sectional area were 
determined by histology and immunofluorescence. Muscle chemokine content was 
examined by use of a multiplex assay. Sternohyoid peak specific force at 100Hz was 
significantly reduced in mdx compared with WT. Drug treatment completely 
restored force in mdx sternohyoid to WT levels. The percentage of centrally-
nucleated muscle fibres was significantly increased in mdx and this was partially 
ameliorated following drug treatment. The areal density of infiltrates and collagen 
content were significantly increased in mdx sternohyoid; both indices were 
unaffected by drug treatment. The abundance of myosin heavy chain type IIb fibres 
was significantly decreased in mdx sternohyoid; drug treatment preserved myosin 
heavy chain type IIb complement in mdx muscle. The chemokines macrophage 
inflammatory protein 2, interferon-J-induced protein 10 and macrophage 
inflammatory protein 3α were significantly increased in mdx sternohyoid compared 
with WT. Drug treatment significantly increased chemokine expression in mdx but 
not WT sternohyoid. Recovery of contractile function was impressive in our study, 
with implications for DMD. The precise molecular mechanisms by which the drug 
treatment exerts an inotropic effect on mdx sternohyoid muscle remains to be 
elucidated.  
 
Keywords: Duchenne muscular dystrophy, mdx, interleukin-6, stress, corticotrophin 
releasing factor, sternohyoid muscle. 
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5.1 Introduction 
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease that occurs 
in 1:3,500 male births (Emery, 1991). Patients have defects in the dystrophin gene, 
which results in a lack of the structural protein dystrophin (427 kDa). Dystrophin is a 
rod-shaped protein expressed in skeletal, cardiac and smooth muscle, where it links 
cytoskeleton actin to the sarcolemma and has a physiological role in preventing 
damage during muscle contraction (Nowak & Davies, 2004). The absence of 
dystrophin in DMD induces severe damage to muscle fibres, with resultant 
inflammation (Deconinck & Dan, 2007). As the disease progresses there is a loss of 
functional muscle fibres due to necrosis and the deposition of fibrotic and adipose 
tissue prevails, resulting in muscle weakness.  
 
The respiratory system is severely impaired in DMD due to respiratory and 
abdominal muscle weakness, as well as scoliosis (De Bruin et al., 1997; Beck et al., 
2006). DMD is a progressive disease and thus respiratory function deteriorates with 
age, with patients often presenting with reduced vital capacity and breathing 
disturbances such as hypoventilation and sleep-disordered breathing (SDB) (Smith 
et al., 1989; Hill et al., 1992; Barbé et al., 1994). While the diaphragm has been the 
focus of many studies in this field, there is a paucity of information pertaining to the 
upper airway muscles controlling airway calibre and collapsibility, thereby 
facilitating breathing (White & Younes, 2012). The prevalence of obstructive sleep 
apnoea (OSA) in DMD (Suresh et al., 2005), suggests that upper airway muscle 
dysfunction, and poor control of airway patency during sleep, potentially 
contributes to breathing disturbances in DMD. 
 
The mdx mouse is the most widely studied animal model of DMD. We have 
previously reported respiratory dysfunction, which presents at an early age in the 
mdx mouse (8 weeks), consisting of hypoventilation and upper airway (sternohyoid) 
muscle weakness (Burns et al., 2015; Burns & O'Halloran, 2016). In human patients 
and mdx mice, functional impairments are driven by pathological changes in 
skeletal muscles due to dystrophin deficiency, including fibre degeneration and 
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necrosis, with inflammation thought to play an integral part in DMD muscle 
pathology (Deconinck & Dan, 2007).  
 
In patients and mdx mice, sarcolemmal damage is accompanied by the infiltration 
of immune cells, primarily macrophages and T cells, a key source of inflammatory 
cytokines (Moran & Mastaglia, 2014). These molecules mount an inflammatory 
response through activation of additional cytokines and recruitment of further 
immune cells to the damaged muscle (Villalta et al., 2015). Immune cells are not the 
only source of cytokines, with damaged muscles fibres also serving as a 
contributory factor (Whitham & Febbraio, 2016). In DMD, the heightened 
expression of pro-inflammatory cytokines such as tumour necrosis factor alpha 
(TNF-α) and interleukins (IL)-1 and -6, are early disease indicators and are 
associated with exacerbation of the inflammatory response in dystrophic muscle 
(Evans et al., 2009b, a). IL-6 is released from a variety of tissues including immune 
cells and adipocytes and is commonly referred to as a myokine as it can be secreted 
from muscle in response to physical activity (Jonsdottir et al., 2000; Pedersen & 
Febbraio, 2008). This inflammatory cytokine is of particular interest in DMD 
pathology since it is elevated in muscle and plasma samples from DMD patients 
(Messina et al., 2011; Rufo et al., 2011; Pelosi et al., 2015a) and mdx mice (Pelosi et 
al., 2015a). IL-6 is pleiotropic, however it mediates its pro-inflammatory effects via 
its trans-signalling pathway by use of the soluble IL-6 receptor (IL-6R) (Pedersen & 
Febbraio, 2008). Its importance in mdx skeletal muscle pathology was recently 
highlighted (Pelosi et al., 2015a), showing that blockade of IL-6 signalling in mdx 
mice has beneficial functional outcomes in dystrophic skeletal muscle.  
 
Muscle wasting is a common feature of DMD due to muscle proteolysis, thus 
pharmacological interventions aimed at rescuing muscle are attractive. 
Corticotrophin releasing factor receptor 2 (CRFR2) agonists have been shown to 
modulate muscle mass through the activation of anabolic signalling pathways and a 
capacity to alter the rate of proteolysis during atrophying conditions (Hall et al., 
2007). In addition, CRFR2 can reduce nerve damage, corticosteroid-induced atrophy 
and loss of muscle mass due to immobilisation (Hinkle et al., 2003). The CRFR2 
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agonist, urocortin 2 (Ucn2), has been shown to improve diaphragm function and 
reduce fibrosis and immune cell infiltration in mdx mice (Reutenauer-Patte et al., 
2012). Recent work demonstrated that neutralisation of IL-6 receptor (xIL-6R) or 
stimulation of CRFR2 both had positive inotropic effects on the major pump muscle 
of breathing – the diaphragm (Manning et al., 2017). Furthermore, Manning et al. 
(2017) reported that co-treatment of xIL-6R and Ucn2 had an additive inotropic 
effect on diaphragm muscle force. We hypothesised that co-administration of xIL-
6R antibodies and Ucn2 alleviates upper airway muscle weakness in dystrophin 
deficient mdx mice. We sought to examine structure and function of sternohyoid 
muscle (pharyngeal dilator) from age-matched wild type (WT) and mdx mice 
following saline or combined xIL-6R and Ucn2 drug treatment.  
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5.2 Methods 
5.2.1 Ethical approval 
All procedures were performed under licence in accordance with National and 
European guidelines following local research ethics committee approval. 
 
5.2.2 Animals 
Male and female wild type (WT; C57BL/10ScSnJ) and mdx (C57BL/10ScSn-Dmdmdx/J) 
mice were purchased from the Jackson Laboratory (Jackson Laboratory, Bar Harbor, 
ME) and were bred in our institution’s animal housing facility. Animals were housed 
conventionally in a temperature- and humidity-controlled facility, operating on a 12 
h light: 12 h dark cycle with food and water available ad libitum. 6 week old male 
WT and mdx mice received a treatment consisting of a co-administration of xIL-6R 
(IL-6R neutralising antibody; MR1-61 (Okazaki et al., 2002); 0.2 mg/kg) and Ucn2 
(CRFR2 agonist; 30 μg/kg; U9507, Sigma Aldrich, Wicklow, Ireland) or saline (vehicle 
control; 0.9% w/v). MR1-61 stock was kept at -80oC and Ucn2 stock at -20oC. A 
working solution containing both MR1-61 (26.7µg/ml) and Ucn2 (4µg/ml) was made 
in sterile saline, aliquoted and stored at -20oC until day of injection. Doses and 
treatment protocol were chosen based on previous studies (Manning et al., 2016, 
2017). Treatment consisted of six sub-cutaneous injections to the scruff of the neck 
on alternate days over the course of two weeks beginning at 6 weeks of age. A 20g 
mouse received an injection bolus of 150μl. WT and mdx animals were assigned at 
random to saline or drug treatment, establishing 4 groups: WT saline (21.4 ± 1.6g; n 
= 13), WT treatment (22.0 ± 1.2g; n = 13), mdx saline (24.4 ± 1.6g; n = 13) and mdx 
treatment (24.5 ± 1.7g; n = 13). Animals were anaesthetised with 5% isoflurane by 
inhalation in oxygen and euthanised by cervical dislocation. 
 
5.2.3 Muscle physiology 
5.2.3.1 Ex vivo muscle preparation 
The sternohyoid muscles were immediately excised and placed in a tissue bath at 
room temperature containing continuously gassed hyperoxic (95% O2/ 5% CO2) 
Krebs solution (NaCl 120 mM, KCl 5mM, Ca2+ gluconate 2.5 mM, MgSO4 1.2 mM, 
NaH2PO4 1.2 mM, NaHCO3 25mM, glucose11.5mM) and D-tubocurarine (25μM). 
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The paired sternohyoid muscles were carefully separated along a natural division in 
the midline. One half was used immediately for functional analysis and the other 
half was snap frozen in liquid nitrogen for subsequent molecular analysis (section 
2.5). A single longitudinal muscle strip (2mm in diameter) for each animal was 
studied in a water-jacketed muscle bath, containing Krebs solution, maintained at 
35oC gassed with 95% O2/ 5% CO2. Each muscle strip was placed between a pair of 
platinum plate electrodes, with the caudal end fixed to an immobile hook and the 
rostral end attached to a dual-mode lever transducer system by non-elastic string. 
Muscle preparations were allowed a 5-min equilibration period. 
 
5.2.3.2 Isometric protocol 
Following equilibration, the optimum length (Lo) was determined by adjusting the 
position of the force transducer by use of a micro-positioner between intermittent 
twitch contractions. The Lo was taken as the muscle length associated with maximal 
isometric twitch force in response to single isometric twitch stimulation 
(supramaximal stimulation, 1ms duration). Once Lo was determined, the muscle 
stayed at this length for the duration of the protocol. A single isometric twitch was 
measured. Peak isometric twitch force, contraction time (CT; time to peak force) 
and half relaxation time (½ RT; time for peak force to decay by 50%) were 
determined. Next, an isometric tetanic contraction was elicited by stimulating 
muscle strips with supramaximal voltage at 100 Hz for 300 ms duration. Peak 
isometric tetanic force was determined at 100Hz (O'Halloran, 2006; Burns & 
O'Halloran, 2016). 
 
5.2.3.3 Isotonic protocol 
Following the isometric protocol, concentric contractions were elicited in 
incremental steps with varying load (0%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 
60%; % of force at 100Hz) with 30 s rest between each contraction. Muscle length 
returned to Lo following each contraction. Total shortening was determined as the 
maximum distance shortened during contraction. Shortening velocity was 
determined as the distance shortened during the initial 30 ms of shortening (Lewis 
et al., 2015; Lewis et al., 2016). Mechanical work (force x total shortening) and 
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power (force x shortening velocity) were determined at each step of the 
incremental load step test (Lewis et al., 2015; Williams et al., 2015; Burns & 
O'Halloran, 2016; O'Leary & O'Halloran, 2016). 
 
5.2.4 Muscle immunohistochemistry and histology 
5.2.4.1 Tissue preparation 
The sternohyoid muscles were excised and divided down the midline; one half was 
embedded in optimum cutting temperature (OCT) embedding medium and frozen 
in isopentane cooled in liquid nitrogen and stored at -80oC for subsequent 
structural analysis (n = 4-5 per group). The other half of the muscle was placed in 
4% paraformaldehyde overnight at 4oC before being transferred to 70% ethanol 
prior to tissue processing and paraffin embedding for histological analysis (n = 4-5 
per group). 
 
5.2.4.2 Myosin heavy chain fluorescence immunohistochemistry 
Serial transverse muscle sections (10 µm) were cryo-sectioned (Model CM30505; 
Leica Microsystems, Nussloch, Germany) at –22oC and mounted on polylysine-
coated glass slides (VWR International, Dublin, Ireland). Sections were captured 
from the middle belly and distal regions of the muscle. Slides were immersed in PBS 
(0.01 M) containing 1% bovine serum albumin (BSA) for 15 minutes. After 3x5 
minute PBS washes, slides were immersed in PBS containing 5% goat serum for 30 
minutes. Following a further 3x5 minute PBS rinses, slides were incubated with an 
unconjugated AffiniPure Fab Fragment Goat Anti-Mouse IgG (H+L) diluted in PBS 
(1:13, Jackson ImmunoResearch Labs) for 1 hour at room temperature, to enable 
the use of mouse monoclonal primary antibody staining on mouse tissue. After 3x2 
minute washes in PBS, primary antibodies were applied. Primary monoclonal 
myosin antibodies were obtained from the Developmental Studies Hybridoma Bank 
(DSHB), University of Iowa, Iowa City, IA, USA and a rabbit anti-laminin antibody 
was obtained from Sigma-Aldrich (L9393). A triple-labelling approach was applied to 
tag MyHC types I (BAD5, 1:100), IIa (sc71 1:100) and IIb (BFF3 1:100) on a single 
section. On a serial section, a double-labelling approach consisted of a rabbit anti-
laminin antibody (1:500) and a pan-MyHC antibody for the indirect determination 
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of pure MyHC IIx fibres, BF35 (1:50), labelling all MyHC isoforms but IIx, enabling 
visualisation of IIx fibres by absence of staining; all antibodies were diluted in PBS 
and 1% BSA solution. Triple and double labelling solutions were applied on 
alternate sections on each slide. Individual sections were encircled with a 
hydrophobic pen (ImmEdgeTM Vector Labs) to prevent contamination from 
neighbouring sections on the same slide. Slides were incubated with the primary 
antibodies overnight at 4oC in a humidity chamber.  
 
After the incubation period, slides were washed with PBS for 3x5 minutes before 
the appropriate secondary antibodies were applied. All secondary antibodies were 
diluted in PBS and 1% BSA. For the triple-labelled slides, a cocktail of secondary 
antibodies was prepared containing AlexaFluor350-conjugated goat anti-mouse 
IgG2b (1:500, Invitrogen, Biosciences Ltd, Dun Laoghaire, Ireland), Dylight594-
conjugated goat anti-mouse IgG1 (1:500, Jackson ImmunoResearch Europe Ltd, 
Suffolk, UK) and AlexaFluor488-conjugated goat anti-mouse IgM (1:250, Invitrogen), 
targeting MyHC I, IIa and IIb, respectively. Secondary antibodies for double-labelled 
sections were Dylight594-conjugated goat anti-mouse IgG1 (1:500, Jackson) and 
FITC-conjugated anti-rabbit secondary antibody (1:250, Sigma-Aldrich). Secondary 
antibodies were applied and slides were incubated for 1 hour in the dark at room 
temperature. Slides were rinsed with PBS for 3x5 minutes, cover slipped with 
polyvinyl alcohol mounting medium with DABCO® anti-fade (Sigma) before 
observation with a fluorescent microscope (Olympus BX51). Negative controls were 
also performed in which primary antibodies were omitted and sections were 
instead incubated in diluent. Images were merged using ImageJ software (W. S. 
Rasband, ImageJ; US National Institutes of Health, Bethesda, MD, USA). 
 
5.2.4.3 Histological analysis 
Muscle samples were dehydrated (70% ethanol, 80% ethanol, 95% ethanol, 60 
minutes each) and then placed in 100% ethanol (60 minutes x2). Samples were then 
cleared in xylene (60 minutes x2), before being transferred to two changes of 
paraffin (one hour each) (Leica TP1020, Histokinet). Tissue samples were then 
embedded in paraffin (Sakura Tissue-Tek TEC, Histolab Histowax embedding 
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medium), and serial cross-sections (5 μm thick) were sectioned using a microtome 
(Leica RM2135). Serial sections were collected throughout the muscle (mid-belly 
and distal regions) onto glass slides and oven-dried (overnight at 37°C).  
 
To examine putative inflammatory cell infiltration, and central nucleation of muscle 
fibres, tissue sections were stained with haematoxylin and eosin (H&E). Tissue 
sections were deparaffinised in xylene (2 x 5 minutes each), rehydrated through a 
graded series of alcohols (100% ethanol, 95% ethanol, 70% ethanol, one minute 
each). Sections were stained with haematoxylin (Delafield’s Haematoxylin) (5 min) 
and subsequently rinsed in distilled H2O (5 min), stained in eosin (alcoholic Eosin-Y, 
Sigma Aldrich; 1 min), rinsed in distilled H2O, and dehydrated (70% ethanol, 95% 
ethanol, 1 min each, 100% ethanol, 2 x 1 minute) and xylene (5 min). For collagen 
staining, a Masson’s trichrome protocol was followed (Sigma Aldrich). Slides were 
mounted using DPX mounting medium (Sigma Aldrich, USA), air-dried and visualised 
on a bright field microscope (Olympus BX51) x 20 magnification.  
 
5.2.5 Molecular studies 
5.2.5.1 Tissue preparation 
Sternohyoid samples stored at -80oC were removed and allowed to defrost at 4oC 
for 5 minutes. All procedures were performed at 4oC to prevent protein 
degradation. Samples were homogenized in a lysis buffer (RIPA) made up from 10X 
RIPA, deionized water, 200mM sodium fluoride (NAF), 100mM 
phenylmethylsulfonylfluoride (PMSF), protease cocktail inhibitor 1 and phosphatase 
cocktail inhibitor 2. Following the homogenization process, the reactant mixtures 
were centrifuged (14,000 x rpm) at 4oC for 20 min and the supernatants were 
harvested. Total amount of protein for each tissue sample was determined using 
Pierce ® Bicinchoninic Acid Assay (BCA assay, Thermo Scientific, Fisher, Dublin, 
Ireland). Supernatants were stored at -80oC for future use. 
 
5.2.5.2 Chemokines 
A chemokine assay (U-PLEX Chemokine Combo; K15099K-1, Meso Scale Discovery, 
Rockville, MD) was used to examine chemokines in sternohyoid muscle from all 
 189 
 
four groups: WT saline (n = 7-8), WT treatment (n = 7-8), mdx saline (n = 8) and mdx 
treatment (n = 7). The assay was performed according to the manufacturer’s 
instructions using an extended incubation time to improve detection (the plate was 
incubated overnight at 4oC). Following incubation, the plate was read on QuickPlex 
SQ 120 imager (Meso Scale Discovery, Rockville, MD). Signals within the detectable 
range were achieved with reliability for the following 3 chemokines: macrophage 
inflammatory protein 2 (MIP-2), interferon-γ-induced protein 10 (IP-10) and 
macrophage inflammatory protein-3α (MIP-3α). 
 
5.2.6 Data and image analysis 
Specific force was calculated in N/cm2 of estimated muscle cross-sectional area 
(CSA). The CSA of each strip was determined by dividing the muscle mass (weight in 
grams) by the product of muscle Lo (cm) and muscle density (assumed to be 1.06 
g/cm3). The CT and ½ RT were measured as indices of isometric twitch kinetics. For 
isotonic load relationships, data were plotted as the measured variable versus % 
load. Total muscle shortening was normalised to Lo and expressed in L/Lo. Similarly, 
shortening velocity was normalised to Lo and expressed in Lo/s. Maximum total 
shortening (Smax) and maximum shortening velocity (Vmax) were measured when 
both were maximal at 0% load. Mechanical work was measured in J/cm2. 
Mechanical power was expressed in W/cm2. Maximum mechanical work (Wmax) 
and power (Pmax) were also measured and typically occurred between 30% and 
40% load. 
 
For MyHC fibre type analysis, muscle sections were viewed at x10 magnification 
and images captured using an Olympus BX51 microscope and an Olympus DP71 
camera. Cell Sens™ (Olympus) was used to digitally capture the images. Analysis 
was carried out using image J software, where fibre type CSA and fibre type 
distribution for each MyHC fibre type were determined. CSA measurements were 
made by fibre “circling” based on MyHC labelling. A square test frame (640,000 
μm2) with inclusion and exclusion boundaries was employed to calculate these 
parameters in a given randomly chosen field. For each animal, multiple sections 
throughout the length of the muscle were viewed and 3-4 images analysed per fibre 
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type. H&E stained sections were visualised x20 magnification. Six sections were 
examined across the muscle from the rostral, middle and caudal regions. Two 
randomly selected areas were captured per muscle section from non-overlapping 
areas for analysis. Muscle pathology was scored using ImageJ software. The number 
of myofibres displaying central nucleation was expressed as a percentage of the 
total number of myofibres per image. Putative inflammatory cell infiltration (the 
presence of cells in the extracellular matrix), was also scored and expressed as a 
percentage of the total area of muscle. For Masson’s trichrome staining, the 
microscope lighting exposure was maintained throughout.  Three sections, with two 
images captured per section, from the mid-portion of the muscle, were analysed 
per animal. Images were analysed using a colour balance threshold (ImageJ 
software), and the area of collagen was expressed as a percentage of the total area 
of muscle. For chemokine analysis, chemokine signals within the detectable range 
were expressed as relative fluorescence units per μg protein (RFU/μg protein), with 
equal protein loading in all wells. 
 
5.2.7 Statistical analysis  
Values are expressed as mean ± SD Muscle functional data were statistically 
compared using two-way ANOVA (genotype x treatment) with Bonferroni post hoc 
test. For muscle histology, group means were generated from multiple images 
averaged per animal and then compared by two-way ANOVA (genotype x 
treatment) with Bonferroni post hoc test. P < 0.05 was deemed to be statistically 
significant.   
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5.3 Results 
5.3.1 Body mass 
There was a significant difference in body mass (P < 0.0001; two-way ANOVA) 
between age-matched WT and mdx mice; the latter were slightly heavier. Drug 
treatment had no effect on body mass. 
 
5.3.2 Isometric force and twitch contractile kinetics 
Table 5.1 shows data for sternohyoid muscle twitch force and contractile kinetics 
(CT and ½ RT) from animals following drug or saline treatment. Mdx sternohyoid 
twitch force was significantly lower  (P = 0.01 (genotype); two-way ANOVA) 
compared with WT. Post hoc analysis revealed that drug treatment significantly 
increased twitch force in mdx sternohyoid (P < 0.01; two-way ANOVA with 
Bonferroni), but not in WT (P > 0.05). There was no significant difference between 
WT and mdx in values for CT and ½ RT; both were unaffected by drug treatment. 
Although statistical differences were not observed for CT and ½ RT across groups, 
sizeable effects were noticed which could have physiological relevance. CT was 
increased by ~45% and ½ RT by ~28% for mdx sternohyoid compared with WT. 
Treatment reduced CT by ~18% and ½ RT by ~19% in mdx mice. Peak force at 100Hz 
was significantly lower in mdx sternohyoid (P = 0.0003) compared with WT (Fig. 
5.1). Post hoc analysis showed that drug treatment significantly increased force for 
WT (P < 0.01) and mdx (P < 0.01) sternohyoid. 
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Figure 5.1 Peak isometric tetanic force 
Group data (mean ± SD) for tetanic force in wild-type WT (n = 7-8) and mdx (n = 7-8) 
sternohyoid muscle following 6 sub-cutaneous injections with saline (0.9% w/v) or 
treatment (xIL-6R (0.2 mg/kg) and Ucn2 (30 μg/kg); co-administered) over two weeks. Peak 
tetanic force was measured following stimulation at 100Hz ex vivo. Data were statistically 
compared by two-way ANOVA followed by Bonferroni post hoc test. ** P < 0.01. Genotype: 
*** P = 0.0003; treatment P = 0.0001; interaction P = 0.9.  
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5.3.3 Isotonic contractile parameters and kinetics 
Table 5.1 shows data for sternohyoid muscle isotonic contractile parameters: 
Wmax, Pmax, Smax and Vmax. Wmax was significantly reduced in mdx sternohyoid 
(P = 0.004; two-way ANOVA) compared with WT. Drug treatment significantly 
increased Wmax for WT (P < 0.05; two-way ANOVA with Bonferroni), but not mdx 
muscle (P > 0.05). Pmax was significantly reduced in mdx sternohyoid (P = 0.0003) 
compared with WT, and drug treatment significantly increased Pmax in mdx (P = 
0.01). Vmax was significantly reduced in mdx sternohyoid (P = 0.008) compared 
with WT, and this was unaffected by drug treatment. There was no significant 
difference in Smax between WT and mdx. Drug treatment had no effect on Smax in 
both groups. 
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Table 5.1 Sternohyoid muscle contractile properties 
Values (mean ± SD) for twitch contraction time (CT), twitch half-relaxation time (½ RT), peak twitch force, maximum mechanical work (Wmax), maximum 
mechanical power (Pmax), peak shortening (Smax) and peak shortening velocity (Vmax) of sternohyoid muscle from wild-type (WT), n = 7-8) and mdx (n = 7-
8) mice injected sub-cutaneously with saline (0.9% w/v) or drug treatment (xIL-6R (0.2mg/kg) and Ucn2 (30μg/kg); co-administered) for two weeks. Data 
were statistically compared by two-way ANOVA followed by Bonferroni post hoc test. £ mdx saline significantly different from corresponding WT saline 
value; P < 0.05. $ WT treatment significantly different from corresponding WT saline value, P < 0.05. # mdx treatment significantly different from 
corresponding mdx saline value, P < 0.05. 
  
 WT mdx Two-way ANOVA 
 Saline 
(n = 8) 
Treatment 
(n = 7) 
Saline 
(n = 7) 
Treatment 
(n = 8) 
Genotype Treatment Interaction 
CT (ms) 11.7 ± 2.0 12.6 ± 3.4 17.0 ± 8.8 13.9 ± 4.3 P = 0.1 P = 0.6 P = 0.3 
½ RT (ms) 18.2 ± 6.4 18.0 ± 5.8 23.4 ± 0.8 18.8 ± 5.7 P = 0.1 P = 0.2 P = 0.3 
Twitch Force (N/cm2) 1.2 ± 0.4 1.8 ± 0.6 0.5 ± 0.3 £ 1.5 ± 0.8 # P = 0.01 P = 0.0004 P = 0.5 
Wmax (J/cm2) 0.4 ± 0.1 0.6 ± 0.4 $ 0.2 ± 0.08 0.3 ± 0.09 P = 0.004 P = 0.01 P = 0.2 
Pmax (W/cm2) 4.7 ± 1.7 7.4 ± 3.9 2.1 ± 1.5 £ 3.6 ± 0.6 P = 0.0003 P = 0.01 P = 0.5 
Smax (L/Lo) 0.3 ± 0.07 0.3 ± 0.06 0.3 ± 0.07 0.3 ± 0.08 P = 0.3 P = 0.7 P = 0.3 
Vmax (Lo/s) 4.6 ± 1.8 4.1 ± 1.5 2.4 ± 1.1 £ 3.3 ± 1.2 P = 0.008 P = 0.8 P = 0.2 
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5.3.4 Isotonic load relationships 
Fig. 5.2 (A-D) shows data for sternohyoid muscle isotonic load relationships. 
Loading had a significant effect on work (P < 0.0001; two-way ANOVA; Fig. 5.2A), 
power (P < 0.0001; Fig. 5.2B), shortening (P < 0.0001; Fig. 5.2C) and shortening 
velocity (P < 0.0001; Fig. 5.2D) for both WT and mdx sternohyoid. Mdx muscle had 
significantly reduced work (P < 0.0001), power (P < 0.0001) and shortening velocity 
(P < 0.0001) compared with WT. Drug treatment significantly increased work 
production for WT (P < 0.0001; two-way ANOVA with Bonferroni) and mdx muscle 
(P < 0.0001). Power production was also significantly increased for WT (P < 0.0001) 
and mdx (P < 0.0001) sternohyoid following drug treatment. Shortening velocity 
was significantly increased for mdx muscle (P = 0.02) following drug treatment.
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Figure 5.2 Sternohyoid muscle isotonic contractile properties 
Group data (mean ± SD) for work-load (A), power-load (B), shortening-load (C) and shortening velocity-load (D) relationships in wild-type (WT, n = 7-8) and 
mdx (n = 7-8) sternohyoid muscle following 6 sub-cutaneous injections of saline (0.9% w/v) or treatment (xIL-6R (0.2 mg/kg) and Ucn2 (30 μg/kg); co-
administered) over two weeks. Data were statistically compared by two-way ANOVA. Work: load P < 0.0001; genotype P < 0.0001; WT treatment P < 
0.0001; mdx treatment P < 0.0001. Power: load P < 0.0001; genotype P < 0.0001; WT treatment P < 0.0001; mdx treatment P < 0.0001. Shortening: load P < 
0.0001; genotype P = 0.2; WT treatment P = 0.5; mdx treatment P = 0.2. Velocity: load P < 0.0001; genotype P < 0.0001; WT treatment P = 0.2; mdx 
treatment P = 0.002.  
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5.3.5 Myosin heavy chain fibre type distribution 
Type I fibres were absent from sternohyoid muscle in all groups. A positive control 
image for type I fibre staining in WT mouse diaphragm muscle is shown in Fig. 5.3A. 
The fibre type distribution of type IIa fibres did not vary significantly between the 
four groups (Fig. 5.3B). For mdx saline, the distribution of type IIx fibres was 
significantly increased compared with WT saline (Fig. 5.3C; P < 0.0001; two-way 
ANOVA), whereas the distribution of type IIb fibres was significantly reduced in mdx 
saline compared with WT saline (Fig. 5.3D; P < 0.01). Sternohyoid fibre type changes 
were prevented/reversed by drug treatment in mdx with significant changes in type 
IIx (Fig. 5.3C; P < 0.01; two-way ANOVA with Bonferrroni) and type IIb fibres (Fig. 
5.3D; P < 0.05) compared with mdx saline.  
 
5.3.6 Fibre cross-sectional area  
Figure 5.3E shows data for the CSA for all fibre types. There was a significant 
increase in the CSA of type IIa (P < 0.05; two-way ANOVA) and type IIx fibres (P < 
0.05) in mdx sternohyoid compared with WT. Drug treatment had no significant 
effect on type IIa (P = 0.08) or type IIx (P = 0.628) CSA for both WT and mdx. The 
CSA of type IIb fibres were not significantly different between WT and mdx. With 
treatment, type IIb CSA was significantly increased in WT only (P < 0.05; two-way 
ANOVA with Bonferroni).  
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Figure 5.3 Sternohyoid muscle fibre distribution and cross-sectional area 
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Representative immunofluorescence images of Sternohyoid (SH) muscle fibre type 
distribution (A), showing type IIa fibres (red), type IIx (untagged, appearing black) and type 
IIb (green) for WT saline (top left), mdx saline (top middle), WT drug-treated (bottom left) 
and mdx drug-treated (bottom middle). Note: the mouse sternohyoid muscle is devoid of 
type I – slow fibres, a positive control from type I fibre staining is shown in a section of WT 
mouse diaphragm (top right).  Scale bars = 200 µm. Group data (mean ± SD) showing fibre 
distribution of type IIa fibres (B), type IIx (C) and type IIb (D) in WT (n = 4) and mdx saline 
treated mice (n = 5), and WT drug-treated (n = 4) and mdx drug-treated mice (n = 4). Mice 
received 6 sub-cutaneous injections of saline (0.9% w/v) or treatment (xIL-6R (0.2 mg/kg) 
and Ucn2 (30 μg/kg); co-administered) over two weeks. Data were statistically compared 
by two-way ANOVA followed by Bonferroni post hoc test. In mdx mice, type IIx areal 
density was significantly increased (C), whereas type IIb fibre distrubution was decreased 
(D). With drug treatment, type IIx fibre distribution was significantly decreased in mdx mice 
compared with mdx saline (C), while type IIb fibre distribution (D) was increased compared 
with mdx saline. * P < 0.05; ** P < 0.01. B) Genotype P = 0.3; treatment P = 0.3; interaction 
P = 0.4. C) Genotype P = 0.0001; treatment P = 0.007; interaction P = 0.03. D) Genotype P = 
0.006; treatment P = 0.04; interaction P = 0.1. E, Group data (mean ± SD) showing mean 
CSAs of sternohyoid muscle fibre type IIa, type IIx and type IIb (E). The CSA of type IIa and 
type IIx fibres was significantly increased in mdx mice. Drug treatment increased the CSA of 
type IIb fibres in WT mice only. Type IIa: Genotype * P = 0.03; treatment P = 0.08; 
interaction P = 0.5. Type IIx: Genotype * P = 0.02; treatment P = 0.6; interaction P =0.8. 
Type IIb: Genotype P = 0.3; treatment: * P = 0.049; interaction P = 0.1. 
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5.3.7 Central nucleation and putative inflammatory cell infiltration  
The percentage of sternohyoid muscle fibres with centrally located nuclei was 
significantly increased in mdx (Fig 5.4A-B; P < 0.0001; two-way ANOVA) compared 
with WT sternohyoid. Central nucleation was reduced slightly in mdx mice following 
drug treatment compared with mdx saline (Fig 5.4A-B; P < 0.05; two-way ANOVA 
with Bonferroni). The areal density of inflammatory cell infiltration was significantly 
increased in mdx sternohyoid muscle (Fig 5.4A+C; P < 0.001; two-way ANOVA) 
compared with WT. Drug treatment had no significant effect on the relative area of 
putative immune cell infiltration (Fig 5.4 A+C). 
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Figure 5.4 Central nucleation and inflammatory cell infiltration of sternohyoid 
muscle 
Representative histological images (A) of sternohyoid muscle transverse sections stained 
with H&E in WT saline (top left), mdx saline (bottom left), WT drug-treated (top right) and 
mdx drug-treated (bottom right) scale bars 100 µm. Peripherally located nuclei are 
apparent in WT saline and WT drug-treated images. In comparison, mdx mice (saline and 
drug-treated) displayed an increased incidence of centrally located nuclei. Inflammatory 
cell infiltration is not apparent in WT saline and WT drug-treated groups. Mdx muscle 
(saline and treatment) displayed inflammatory cell infiltration, highlighted with black 
arrows. Group data (mean ± SD) showing percentage of central nucleation (B) and 
percentage of infiltration of inflammatory cells (C) in sternohyoid muscle from saline-
treated WT (n = 4-5) and saline-treated mdx mice (n = 5), and WT (n = 4-5) and mdx (n = 4-
5) mice treated with xIL-6R (0.2 mg/kg) and Ucn2 (30 µg/kg) given as 6 sub-cutaneous 
injections over 2 weeks. Data were statistically compared by two-way ANOVA followed by 
Bonferroni post hoc test. The percentage of centrally nucleated fibres was significantly 
increased in mdx mice. Drug treatment slightly ameliorated central nucleation in mdx mice 
only. The percentage of inflammatory cell infiltrates was significantly increased in mdx 
mice. Drug treatment did not affect this response; P = 0.2284 compared with mdx. * P < 
0.05. Central nucleation: Genotype P < 0.0001; treatment P = 0.1; interaction P = 0.02. 
Infiltration: Genotype: *** P = 0.0002, treatment P = 0.2; interaction P = 0.2. 
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5.3.8 Collagen content 
Masson’s trichrome staining was applied to investigate muscle collagen content 
between groups. The percentage area of collagen was significantly increased in mdx 
sternohyoid compared with WT (Fig. 5.5A+B; P = 0.0103; two-way ANOVA). Drug 
treatment had no significant effect on collagen content for both WT (P > 0.05) and 
mdx (P > 0.05) sternohyoid. 
 
5.3.9 Chemokines  
Figure 5.6 shows data for chemokine content in sternohyoid muscle from WT and 
mdx mice following drug or saline treatment. MIP-2, IP-10 and MIP-3α were 
significantly increased in the mdx sternohyoid (P < 0.0002, MIP-2 and IP-10; P = 
0.004, MIP-3α; two-way ANOVA) compared with WT controls. Post hoc analysis 
revealed that drug treatment significantly increased MIP-2, IP-10 and MIP-3α in 
mdx sternohyoid (P < 0.0001, MIP-2 and IP-10; P < 0.01 MIP-3α; two-way ANOVA 
with Bonferroni), but not in WT mice (P > 0.05, Fig. 5.6A-C). 
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Figure 5.5 Collagen deposition in sternohyoid muscle 
Representative histological images (A) of sternohyoid muscle transverse sections stained 
with mason’s trichrome in WT saline (top left), mdx saline (bottom left), WT drug-treated 
(top right) and mdx drug-treated (bottom right) scale bars 100 µm. Group data (mean ± SD) 
showing percentage of collagen content (B) in sternohyoid muscle from saline-treated WT 
(n = 5) and saline-treated mdx mice (n = 4), and WT (n = 4) and mdx (n = 5) mice treated 
with xIL-6R (0.2 mg/kg) and Ucn2 (30 µg/kg) given as 6 sub-cutaneous injections over 2 
weeks. Data were statistically compared by two-way ANOVA followed by Bonferroni post 
hoc test. The percentage of collagen content was significantly increased in mdx mice. Drug 
treatment had no significant effect on collagen content for both WT and mdx. Genotype: P 
= 0.0103, treatment: P = 0.0673; interaction P = 0.7779. 
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Figure 5.6 Chemokine expression in sternohyoid muscle 
Values (mean ± SD) for macrophage inflammatory protein 2 (MIP-2; A), interferon-γ induced protein (IP-10; B) and macrophage inflammatory protein-3 
(MIP-3α; C) chemokine expression in sternohyoid muscle from WT (n = 7-8) and mdx (n = 7-8) mice injected sub-cutaneously with saline (0.9% w/v) or drug 
treatment (xIL-6R (0.2mg/kg) and Ucn2 (30μg/kg); co-administered) for two weeks. Data were statistically compared by two-way ANOVA followed by 
Bonferroni post hoc test. ** P < 0.01; **** P < 0.0001. MIP-2: genotype: P < 0.0001; treatment P < 0.0001; interaction: P < 0.0001. IP-10: genotype: P = 
0.0002; treatment: P = 0.0007; interaction: P = 0.0022. MIP-3α: genotype: P = 0.0004; treatment: P = 0.0033; interaction: P = 0.0510. 
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5.4 Discussion 
The key findings of the present study are: (1) Sternohyoid muscle weakness in mdx 
mice is evidenced by reduced specific force and power output; (2) Sternohyoid 
weakness is associated with changes in myosin heavy chain isoform expression, 
with an increase in the abundance of type IIx and a concomitant decrease in type 
IIb fibres; (3) The incidence of centrally-nucleated muscle fibres, percentage and 
areal density of inflammatory cell infiltrates, and deposition of collagen was 
significantly increased in mdx sternohyoid; (4) Chemokines were significantly 
increased in mdx sternohyoid; (5) Co-treatment with the xIL-6R antibody and Ucn2 
restored mechanical force and power production in mdx sternohyoid muscle; (6) 
Drug treatment significantly prevented or reversed fibre transitions in mdx 
sternohyoid, reduced the proportion of centrally nucleated fibres, but did not affect 
the total area of putative inflammatory cell infiltration, or collagen content within 
mdx muscle; (7) Drug treatment significantly increased chemokines in mdx 
sternohyoid muscle. 
 
Chronic respiratory insufficiency is a cardinal feature of DMD. The diaphragm is 
severely affected, with muscle fibre degeneration and fibrosis central 
characteristics of the disease (De Bruin et al., 1997). DMD patients often suffer 
from SDB, with episodes of hypoventilation during sleep, associated with aberrant 
blood gas disturbances, necessitating ventilator use at later stages to maintain 
respiratory function, (Hukins & Hillman, 2000).  
 
The mdx mouse, a dystrophin deficient model (Bulfield et al., 1984), has been 
studied extensively to understand the pathophysiology of DMD and has also served 
as a pre-clinical model for the study of pharmacological treatment strategies 
(Manning & O'Malley, 2015). As DMD progresses, cardiopulmonary failure is the 
leading cause of death (Hukins & Hillman, 2000). The dystrophin deficient mdx 
mouse has a milder phenotype than DMD patients in the context of cardiac and 
limb muscle. In contrast, the respiratory muscles, including the sternohyoid muscle, 
show severe mechanical weakness at a young age in the mdx mouse (Burns & 
O'Halloran, 2016). Dystrophic diaphragm muscle undergoes repetitive cycles of 
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degeneration and regeneration, with additional activation of inflammatory 
cascades that further exacerbate muscle weakness. Whilst diaphragm muscle 
function has been well characterised in DMD (De Bruin et al., 1997), and the mdx 
mouse (Coirault et al., 1999; Coirault et al., 2003; Bates et al., 2013), little is known 
about the complementary muscles of breathing, especially the airway dilator 
muscles of the pharynx that are critical in the control of airway calibre, which is 
surprising given the prevalence of SDB in DMD boys (Bersanini et al., 2012). 
 
In the present study, we demonstrate that mdx sternohyoid muscle shows impaired 
performance at 8 weeks of age, consistent with our recent report (Burns & 
O'Halloran, 2016). This functional impairment is characterised by reduced specific 
force (twitch and tetanic contractions), reduced maximum mechanical work and 
power production, and reduced Vmax. Work and power production as a function of 
load bearing was significantly reduced for mdx saline compared with WT saline. We 
observed a ~44% decrease in sternohyoid muscle peak tetanic force for mdx saline 
versus WT saline, which is consistent with previous findings (Attal et al., 2000; 
Burns & O'Halloran, 2016). These studies reveal severe mechanical dysfunction in 
sternohyoid muscle from young and aged mdx mice suggesting that upper airway 
obstruction in DMD may be a result of increased collapsibility of the pharyngeal 
airway arising from dysfunction of upper airway dilator muscles.  
 
Sternohyoid muscle weakness in mdx was associated with a shift in the myosin 
heavy chain isoform distribution. Contractile performance in muscle correlates with 
fibre type distribution (Schiaffino & Reggiani, 2011). The sternohyoid muscle is 
phasically active during respiration (Van de Graaff et al., 1984; O'Halloran et al., 
2002) and is composed solely of fast fibres (type II). Type II fibres display 
progressively increasing force production from type IIa to IIx fibres, with type IIb 
fibres producing the greatest forces but least resistance to fatigue (Polla et al., 
2004; Schiaffino & Reggiani, 2011). We observed a significant decrease in the 
relative proportion of type IIb fibres with a concomitant increase in the type IIx 
fibre count in mdx muscle. Since the type IIb fibres are the maximum force 
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producing units with the fastest kinetics, this finding is consistent with the 
functional data demonstrating decreased force-generating capacity and reduced 
shortening velocity in mdx compared with WT. Our findings are consistent with the 
observations of others (Attal et al., 2000), who likewise reported reduced force-
generating capacity and an increased proportion of type IIx and reduced type IIb in 
sternohyoid muscle from aged (6 month) mdx mice. We reason that this shift in the 
fibre type composition of the sternohyoid relates to muscle fibre degeneration and 
regeneration such that the muscle is in a relatively immature state. Muscle fibre 
remodelling will also alter motor neuronal input to the muscle. Since muscle fibre 
types are determined by the motor unit they are innervated by (Mantilla & Sieck, 
2003), it is plausible to speculate that dystrophic muscle may have an altered motor 
unit innervation pattern which warrants investigation. There is a paucity of 
information pertaining to the accessory muscles of breathing in mdx mice. Unlike 
the well-characterised mdx diaphragm, the temporal profile of mdx sternohyoid 
muscle structure-function relationship throughout life is unknown, but published 
works suggest that the sternohyoid most likely undergoes a similar pathology to 
mdx diaphragm muscle (Attal et al. 2000; Burns et al. 2016).  
 
The CSA of a muscle fibre is a determinant of force production. CSA varies between 
fibres increasing from type I fibres to type IIa and IIx, and type IIb (figure 5.3E). In 
DMD, the cycles of degeneration and regeneration within muscles leads to 
alterations in fibre size. As such, dystrophic muscle has myofibres of varying size 
compared to the uniformity of diameter found in a normal muscle (Pastoret & 
Sebille, 1995). Investigation of the CSA of individual muscle fibre types revealed 
that mdx sternohyoid shows evidence of hypertrophied type IIa and type IIx fibres. 
Increasing CSA can be viewed as an adaptive mechanism in the context of force 
production, often observed with resistance training increasing muscle strength. 
However, alterations in fibre size secondary to degeneration and regeneration are 
characteristic of mdx muscle with regeneration producing hypertrophied fibres, 
which are often functionally weaker (Lynch et al., 2001).  
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Dystrophic skeletal muscle undergoes progressive cycles of fibre degeneration and 
regeneration following damage, a process that continues until the regenerative 
capacity is exhausted. Skeletal muscle fibre central nucleation is a histological 
indicator of muscle fibre repair and regeneration. We observed a significant 
increase in the percentage of centrally nucleated myofibres in mdx sternohyoid 
compared with WT, with ~25% of mdx sternohyoid fibres presenting with central 
nuclei. This reveals that sternohyoid muscle from mdx mice is undergoing 
significant muscle damage and repair as early as 8 weeks of age, consistent with 
evidence of severe muscle weakness.  
 
Inflammation is recognised to be a contributing factor to DMD pathology, which is 
characterised by a persistent inflammatory response in skeletal muscle due to 
chronic damage and stress to functional muscle fibres due to the absence of 
dystrophin (Deconinck & Dan, 2007). Inflammatory cell infiltration of damaged and 
degenerating dystrophic muscle fibres is a hallmark feature of skeletal muscle 
pathology in DMD. Inflammatory cell infiltration has been shown to exacerbate 
myofibre damage in mdx mice (Evans et al., 2009a), with loss of muscle fibres, 
subsequent fibrosis, and adipose tissue deposition culminating in impaired muscle 
function (Deconinck & Dan, 2007).  We observed a significant increase in putative 
inflammatory cell infiltration in young mdx sternohyoid muscle, typically thought to 
be associated with muscle damage and subsequent regeneration. Enhanced 
inflammatory cell infiltrate drives a fibrotic environment (Pelosi et al., 2015b). 
Indeed, we observed a significant increase in the collagen content of the mdx 
sternohyoid. Fibrosis is well characterised in the diaphragm of mdx mice (Stedman 
et al., 1991), but to our knowledge this is the first report of enhanced collagen 
deposition in a complementary muscle of breathing, the sternohyoid. Enhanced 
collagen deposition within the muscle impairs muscle functional performance, 
which given the role of the sternohyoid as an airway dilator has implications for 
adequate control of airway calibre in DMD.    
 
DMD patients and the mdx mouse have elevated levels of circulating pro-
inflammatory cytokines, namely IL-1, IL-6 and TNFα (Gosselin & Williams, 2006), 
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promoting an inflammatory response associated with dystrophic changes (Kumar & 
Boriek, 2003). Anti-inflammatory treatment with glucocorticoids is the main 
treatment strategy in delaying loss of ambulation in DMD but treatment is 
unfortunately associated with deleterious side effects (Pichavant et al., 2011). 
Therefore, there is a need for new therapeutic strategies that can rescue or at least 
halt muscle impairments in DMD.  
 
IL-6 is a pleiotropic cytokine, exhibiting both pro and anti-inflammatory properties, 
hence mediating diverse biological functions (Pedersen & Febbraio, 2008). Several 
studies have targeted pro-inflammatory cytokine signalling in mdx and examined 
their respective roles in the dystrophic process. TNF-α inhibition has been shown to 
have beneficial effects in mdx mice (Messina et al., 2006; Messina et al., 2009). IL-6 
has been shown to promote muscle atrophy in rats (Haddad et al., 2005) and mice 
(Tsujinaka et al., 1996), which is amenable to blockade. Additionally, mdx mice 
crossed with mice overexpressing IL-6, present with a significant reduction in limb 
muscle force and a decline in performance during treadmill exercise, indicative of 
impaired muscle function (Pelosi et al., 2015b). Treatment with an xIL-6R antibody, 
blocking IL-6 signalling, has been shown to decrease pro-inflammatory cytokine 
expression in the diaphragm, improving treadmill performance in mdx mice (Pelosi 
et al., 2015b).  
 
In the present study, co-administration of an IL-6 neutralising antibody (xIL-6R) and 
a CRFR2 agonist (Ucn2) in mdx mice resulted in significantly increased force-
generating capacity compared with mdx mice treated with saline (~86% increase). 
Specific force in mdx sternohyoid following treatment was increased to values 
equivalent to WT saline. Drug treatment increased mdx sternohyoid work, power 
and shortening velocity over the load continuum (0-60% max tension). Increased 
work production following treatment in mdx is due to a positive inotropic effect on 
force-generating capacity since we observed no significant difference in peak 
shortening between mdx treatment and mdx saline. In contrast, increased mdx 
sternohyoid power production is due to both an increase in force-generating 
capacity and shortening velocity. Drug treatment in WT also had a positive inotropic 
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effect on force generation (~49% increase) compared with WT saline. For WT, drug 
treatment increased sternohyoid work and power as a function of load bearing, 
both of which are due to an inotropic effect on muscle force. Significant increases in 
WT sternohyoid specific force suggest direct inotropic effects of drug co-treatment 
on sternohyoid muscle fibres. However, it should be noted that we determined 
tissue, and not fibre, CSA for our calculation of specific force. Therefore, whilst our 
measurement accounts for force normalised to tissue CSA, it does not account for 
alterations in myofibre CSA, which contribute to force-generation in muscle. This is 
an important distinction since drug co-treatment caused fibre hypertrophy in WT 
(but not mdx) muscle. Ucn2 elevates cAMP, protein kinase A and the cAMP-binding 
protein Epac (Reutenauer-Patte et al., 2012), and improves calcium homeostasis in 
calcium over-loaded mdx striated muscle with beneficial protective effects reducing 
muscle necrosis (Reutenauer-Patte et al., 2012). CRFR2 agonists increase muscle 
fibre mass, with evidence of increased muscle fibre CSA and absolute muscle force 
(Hinkle et al. 2004), in addition to actions that prevent atrophying of muscle in 
various experimental models (Hinkle et al., 2003, 2004). As such, we posit that fibre 
hypertrophy likely contributed to enhanced force generation in WT sternohyoid. It 
remains unclear however, if drug co-treatment exerted direct inotropic effects on 
myofibres contributing to muscle force. Of interest, direct positive inotropic effects 
of Ucn2 have been noted in the treatment of heart failure (Bale et al, 2004) and 
Ucn2 has been shown to exert a positive inotropic effect in the isolated rat heart 
through cAMP-dependent mechanisms (Calderon-Sanchez et al., 2009), a major 
regulator of skeletal muscle contractility (Berdeaux et al., 2012).  
 
Drug treatment in mdx mice significantly reduced type IIx and increased type IIb 
fibre distribution compared with untreated mdx saline. As such, drug treatment 
restored/ prevented fibre type transitions that are evident in the mdx saline group 
compared with WT saline. The preservation of type IIb fibres is likely contributing to 
the restoration of muscle force in mdx sternohyoid. Conversely, there was no 
difference in the distribution of any fibre type in the WT drug treatment group 
compared with WT saline. Ucn2 has been shown to induce anabolism in skeletal 
muscle (Reutenauer-Patte et al., 2012). Anabolism in fibres supports increased 
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force production, which could be beneficial to the dystrophic muscles of mdx mice. 
Interestingly, we observed hypertrophy of type IIb fibres in WT sternohyoid, but not 
mdx sternohyoid following drug treatment, revealing a different structural basis for 
improved force comparing WT (hypertrophy) to mdx (fibre preservation).   
 
Drug treatment in mdx slightly ameliorated sternohyoid muscle fibre central 
nucleation compared with mdx saline; conversely, percentage central nucleation 
was unaffected by treatment in WT sternohyoid. This suggests that drug treatment 
suppressed muscle fibre damage, resulting in fewer necrotic fibres, which should be 
beneficial for muscle performance. This observation highlights that muscle fibre 
preservation (and maturation to type IIb) is likely an important contributor to force 
generation in mdx-treated muscles in our study. However, of interest, drug 
treatment had no effect on collagen content or putative immune cell infiltration in 
mdx sternohyoid. As such, drug treatment was ineffective in reducing muscle 
fibrosis, perhaps resulting from muscle inflammation. As we did not characterise 
the nature of the infiltrate area (which we concede will also include non-immune 
cell types), we are unable to determine if drug treatment altered the cellular milieu 
in the interstitial spaces between myofibres. Chemokines were significantly 
increased in mdx sternohyoid muscle which is consistent with previous reports of 
elevated chemokines in muscle from mdx mice (Porter et al., 2003; Demoule et al., 
2005). Interestingly, drug treatment in mdx significantly increased the content of 
chemo-attractant agents, suggesting that there may follow a heightened immune 
response in mdx muscle following drug treatment. Such a response could act to 
recruit immune cells to repair damaged muscle fibres, and thus lead to functional 
improvements in sternohyoid muscle, perhaps contributing to the impressive force 
recovery observed in our study.  
 
From the present work we cannot ascertain which of the two drug treatments is 
responsible for the inotropic and structural effects observed in WT and mdx mice. 
Recent work investigated the individual roles of xIL-6R and Ucn2 in improving mdx 
diaphragm force (Manning et al., 2017). Of relevance to the current study, Manning 
et al. (2017) revealed an additive effect of xIL-6R and Ucn2 co-treatment on 
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diaphragm muscle force providing the rationale for our combined drug approach. 
Additional studies describing the cellular mechanisms whereby xIL-6R and Ucn2 
improve sternohyoid muscle function are warranted. 
 
Our relatively short (2 week) intervention has yielded impressive findings, 
preserving sternohyoid muscle force-generating capacity in mdx mice. Although 
there are no temporal studies of the mdx sternohyoid during development to 
adulthood, the drug treatment began at a time when significant muscle remodelling 
is likely to be under way (based on work in mdx diaphragm (Coirault et al., 2003). 
Intervention at a younger age and for a longer treatment duration would be an 
interesting study to explore the efficacy of the drug treatment before onset of 
muscle necrosis. It would also be of interest to determine if performance is 
preserved in older animals following treatment and if there are any adverse side 
effects due to prolonged drug treatment. Although drug treatment fully restored 
sternohyoid muscle force, there was no difference in the relative area of infiltration 
in the mdx sternohyoid drug-treatment group compared with mdx saline. Our data 
suggest that the beneficial effect of drug treatment on sternohyoid muscle fibre 
form and function is achieved without any apparent influence on local muscle 
inflammation and fibrosis, linked to on-going muscle fibre damage and repair. This 
suggests that the beneficial effect of the drug therapy relates to a retardation in 
muscle fibre damage allowing maturation of functional fibres, but without overt 
changes in muscle infiltrate. However, it is important to note that the nature of the 
inflammatory infiltrate may be favourably altered by drug treatment. Macrophages 
can exist in one of two states, M1 or M2. While M2 macrophages contribute to 
muscle repair, M1 macrophages can increase muscle fibre lysis (Villalta et al., 2015). 
Therefore, depending on the state of the infiltrating macrophage, inflammation can 
result in adaptive or maladaptive processes promoting regeneration or driving 
muscle wasting. We did not characterise the nature of the infiltrate in mdx muscle 
and therefore we cannot comment on the effect of drug treatment on the immune 
cell signature in mdx muscle. This requires further investigation, especially in the 
light of our observation that chemokines were increased in mdx and further 
increased by drug treatment, which may have established a beneficial immune 
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response that favoured muscle performance. We also acknowledge that IL-6 
blockade may have arrested beneficial actions of the myokine in muscle such as 
promoting myoblast proliferation and myotube formation.  
 
In summary, mdx sternohyoid shows evidence of severe mechanical dysfunction 
and fibre type immaturity at an early age. Co-treatment with an anti-IL-6 receptor 
antibody and CRF-2 receptor agonist (Ucn2) had a positive inotropic effect, 
restoring mechanical force and power in dystrophic sternohyoid muscle. Drug 
treatment preserved fibre complement in mdx sternohyoid and slightly ameliorated 
the proportion of fibres with evidence of central nucleation indicative of damage. 
Preservation of MyHC type IIb fibres as well as a partial reduction in 
centronucleation suggesting a preservation of functional fibres may underpin, at 
least in part, recovery of force production in the mdx drug-treated mice. Following 
a relatively short drug intervention period, recovery of contractile function was 
impressive in our study highlighting the potential utility of this combination therapy 
in DMD. 
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Key points 
• Impaired ventilatory capacity and diaphragm muscle weakness are 
prominent features of Duchenne muscular dystrophy (DMD), with strong 
evidence of attendant systemic and muscle inflammation. 
• We performed a two-week intervention in young wild-type and mdx mice, 
consisting of either injection of saline or co-administration of a neutralizing 
interleukin-6 receptor antibody (xIL-6R) and urocortin-2 (Ucn2), a 
corticotrophin releasing factor receptor 2 agonist. We examined breathing 
and diaphragm muscle form and function. 
• Breathing and diaphragm muscle functional deficits are improved following 
xIL-6R and Ucn2 co-treatment in mdx mice. The functional improvements 
were associated with a preservation of mdx diaphragm muscle myosin 
heavy chain IIx fibre complement. 
• The concentration of the pro-inflammatory cytokine interleukin-1β was 
reduced and the concentration of the anti-inflammatory cytokine 
interleukin-10 was increased in mdx diaphragm following drug co-
treatment. 
• Our novel findings may have implications for the development of 
pharmacotherapies for the dystrophinopathies with relevance for breathing 
and respiratory muscle performance. 
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Abbreviations: ANOVA, analysis of variance; BBn, breath-to-breath; BBn+1, breath-
to-breath interval; CRFR, corticotrophin releasing factor receptor; CSA, cross-
sectional area; CT, contraction time; DMD, Duchenne muscular dystrophy; FiO2, 
fractional inspired oxygen concentration; fR, respiratory frequency; IL, interleukin; 
IL-6R, IL-6 receptor; Lo, optimum length; MyHC, myosin heavy chain; OCT, optimum 
cutting temperature; Pmax, maximum mechanical power; SD1, short-term 
variability; SD2, long-term variability; Smax, maximum total shortening; Te, 
expiratory duration; Ti, inspiratory duration; TNF-α, tumor necrosis factor alpha; 
Ucn2, Urocortin-2; Vmax, maximum shortening velocity; VE, minute ventilation; 
VE/VCO2, ventilatory equivalent for carbon dioxide; VE/VO2, ventilatory equivalent 
for oxygen; VCO2, carbon dioxide production; VO2, oxygen consumption; VT, tidal 
volume; Wmax, maximum mechanical work; WT, wild-type; xIL-6R, anti-IL-6R; ½ RT, 
half relaxation time. 
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Abstract 
The mdx mouse model of Duchenne muscular dystrophy shows evidence of 
hypoventilation and pronounced diaphragm dysfunction. Six-week-old male mdx (n 
= 32) and wild-type (WT; n = 32) mice received either saline (0.9% w/v) or a co-
administration of neutralizing interleukin-6 receptor antibodies (xIL-6R; 0.2 mg/kg) 
and corticotrophin-releasing factor receptor 2 agonist (urocortin-2; 30 µg/kg), 
subcutaneously over 2 weeks. Breathing and diaphragm muscle contractile function 
(ex vivo) were examined. Diaphragm structure was assessed using histology and 
immunofluorescence. Muscle cytokine concentration was determined using a 
multiplex assay. Minute ventilation and diaphragm muscle peak specific force at 
100 Hz were significantly depressed in mdx compared with WT. Drug treatment 
completely restored ventilation in mdx mice during normoxia and significantly 
increased mdx diaphragm force- and power-generating capacity. The number of 
centrally nucleated muscle fibres and the areal density of infiltrates and collagen 
content were significantly increased in mdx diaphragm; all indices were unaffected 
by drug co-treatment. The abundance of myosin heavy chain (MyHC) type IIx fibres 
was significantly decreased in mdx diaphragm; drug treatment preserved MyHC 
type IIx complement in mdx muscle. Drug co-treatment increased the cross-
sectional area of MyHC type I and IIx fibres in mdx diaphragm. The cytokines IL-1β, 
IL-6, KC/GRO and tumor necrosis factor-α were significantly increased in mdx 
diaphragm compared with WT. Drug co-treatment significantly decreased IL-1β and 
increased IL-10 in mdx diaphragm. Drug co-treatment had no significant effect on 
WT diaphragm muscle structure or cytokine concentrations. Recovery of breathing 
and diaphragm force was impressive in our studies, with implication for human 
dystrophinopathies. 
 
Keywords: Duchenne muscular dystrophy; mdx; interleukin-6; Urocortin-2; 
corticotrophin releasing factor; diaphragm muscle; breathing. 
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6.1 Introduction 
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease wherein 
patients lack the structural protein dystrophin. In the absence of dystrophin, 
extensive skeletal muscle weakness, damage and fibre remodelling occurs (Blake et 
al., 2002). Weakness extends to the striated muscles of breathing, with patients 
displaying diaphragm muscle dysfunction (De Bruin et al., 1997; Khirani et al., 2014) 
with consequential respiratory disturbance (Smith et al., 1989; Khan & Heckmatt, 
1994) and disrupted blood gas homeostasis (Smith et al., 1988).  
 
Similar to DMD, the mdx mouse model of DMD shows evidence of diaphragmatic 
dysfunction and impaired ventilation (Stedman et al., 1991; Coirault et al., 1999; 
Mosqueira et al., 2013; Burns et al., 2015; Burns et al., 2017c). Skeletal muscle 
weakness due to dystrophin deficiency is further driven by pathological changes 
due to extensive muscle damage, including muscle fibre degeneration and necrosis, 
fibrosis, inflammation and adipose tissue deposition. Inflammation is a secondary 
feature of DMD due to muscle damage caused by the absence of dystrophin 
(Deconinck & Dan, 2007). Inflammatory cells infiltrate damaged muscles mounting 
an inflammatory response through activation of cytokines and recruitment of 
additional immune cells to the damaged muscle (De Paepe & De Bleecker, 2013).  
 
The expression of inflammatory cytokines is elevated in muscle biopsies and plasma 
samples from DMD patients and the mdx mouse model of DMD, some of which 
include tumor necrosis factor (TNFα), interleukin-1 (IL-1) and interleukin-6 (IL-6) 
(Chahbouni et al., 2010; Messina et al., 2011; Pelosi et al., 2015a). IL-6 is considered 
a myokine that can be released from damaged muscle in response to muscle injury 
and is pleiotropic in nature. IL-6 exerts its pro-inflammatory actions via its trans-
signalling pathway, mediated by the soluble IL-6 receptor (IL-6R). Recent studies 
examining blockade of IL-6 signalling in mdx mice have shown functional 
improvements in skeletal and smooth muscle (Pelosi et al., 2015a; Manning et al., 
2016, 2017). 
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Muscle fibre loss occurs in DMD, with necrotic muscle fibres replaced by connective 
and adipose tissue. Signalling through the corticotrophin releasing factor receptor 
(CRFR) has been shown to modulate muscle mass. Activation of CRFR2 (expressed 
in skeletal muscle) in mice has been shown to increase muscle mass and prevent 
muscle mass and function loss in atrophying muscle (Hinkle et al., 2003a; Hinkle et 
al., 2003b; Hinkle et al., 2004). Similarly, the CRFR2 agonist urocortin-2 (Ucn2) has 
been demonstrated to increase muscle mass and force in mdx mice (Reutenauer-
Patte et al., 2012; Manning et al., 2017). Moreover, Ucn2 has been shown to exert 
beneficial effects on cardiac function in healthy subjects and heart failure patients 
(Stirrat et al., 2016). 
 
Recent studies have demonstrated that neutralization of the IL-6R (xIL-6R) and 
stimulation of CRFR2 (Ucn2) via a combined drug strategy in young mdx mice leads 
to beneficial improvements in diaphragm muscle functional capacity (Manning et 
al., 2017), with a combinational strategy more effective than either drug 
administered independently. Similarly, a co-treatment of xIL-6R and Ucn2 
completely recovered pharyngeal dilator muscle force loss in mdx mice (Burns et 
al., 2017b). 
 
We hypothesized that co-administration of xIL-6R antibodies and Ucn2 would 
improve ventilatory capacity in mdx by improvements in diaphragm muscle force-
generating capacity. We further hypothesized that drug co-treatment would reduce 
inflammation and improve the quality of diaphragm muscle, preserving muscle 
fibre type distribution. We sought to examine ventilation and the form and function 
of diaphragm muscle from age-matched wild-type (WT) and mdx mice following 
saline or combined xIL-6R and Ucn2 drug treatment. 
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6.2 Methods 
6.2.1 Ethical approval 
Procedures on live animals were performed under licence in accordance with Irish 
and European directive 2010/63/EU following approval by University College Cork 
animal research ethics committee. 
 
6.2.2 Animals 
Male and female WT (C57BL/10ScSnJ) and mdx (C57BL/10ScSn-Dmdmdx/J) mice 
were purchased from the Jackson Laboratory (Jackson Laboratory, Bar Harbor, ME, 
USA) and were bred in our institution’s animal housing facility. Animals were 
housed conventionally in a temperature- and humidity-controlled facility, operating 
on a 12 h light:12 h dark cycle with food and water available ad libitum. Six-week-
old male WT and mdx mice received an interventional drug treatment consisting of 
a co-administration of xIL-6R (IL-6R neutralizing antibody; MR16-1 (Okazaki et al., 
2002); 0.2 mg/kg; Chugai Pharmaceuticals, Chuo, Tokyo, Japan) and Ucn2 (CRFR2 
agonist; 30 μg/kg; U9507; Sigma Aldrich, Wicklow, Ireland) or saline (vehicle 
control; 0.9% w/v). MR1-61 stock was stored at -80oC and Ucn2 stock was stored at 
-20oC. A working solution containing both MR16-1 (26.7µg/ml) and Ucn2 (4µg/ml) 
was made in sterile saline, distributed in aliquots and stored at -20oC until day of 
injection. The doses and treatment protocol were chosen based on previous studies 
by our research group (Manning et al., 2016; Manning et al., 2017). Drug treatment 
consisted of a total of six consecutive subcutaneous injections to the scruff of the 
neck, each on alternate days over the course of two weeks beginning at 6 weeks of 
age. Animals were injected with a 7.5 μl bolus per gram body mass. Male WT and 
mdx mice were assigned at random to saline or drug treatment, establishing the 
following four groups: WT + saline, WT + treatment, mdx + saline and mdx + 
treatment. Animals were anaesthetised with 5% isoflurane by inhalation in air and 
euthanized by cervical dislocation. A study of sternohyoid muscle form and function 
from these mice was published previously (Burns et al., 2017b).  
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6.2.3 Respiratory measurements 
Whole body plethysmography was used to examine ventilation in unrestrained and 
unanaesthetised mice during quiet rest. Mice from all four groups were studied: 
WT + saline (n = 14), WT + treatment (n = 10), mdx + saline (n = 10) and mdx + 
treatment (n = 12). Mice were introduced into plethysmograph chambers (Model 
PLY4211; volume=0.6L, Buxco Research Systems, Wilmington, NC, USA) and allowed 
a 60-90 minute acclimation period until sufficiently settled, with room air passing 
through each chamber (1 L/min).  
 
Experimental protocol: Following acclimation, a 20-30 minute baseline recording 
was performed in normoxia. This was followed by a 20 minute hypoxic challenge 
(FiO2 = 0.1; balance N2). Following a 60 minute recovery in normoxia, a 20-30 
minute normoxic baseline was recorded. Following this period, ventilatory 
responses to hypercapnic challenge (5% CO2; balance O2) were assessed in mice 
from all four groups. Unfortunately, technical issues encountered in two groups 
(WT + treatment and mdx + treatment) relating to inaccurate pre-calibrated gases 
necessitated exclusion of the complete data set, limiting comparisons to WT + 
saline versus mdx + saline during hypercapnic ventilation. Respiratory parameters 
including respiratory frequency (fR), tidal volume (VT), minute ventilation (VE), 
inspiratory duration (Ti) and expiratory duration (Te) were recorded on a breath-by 
breath basis for analysis offline.  
 
Data analysis: For the assessment of ventilatory parameters in normoxia, both 
normoxia bouts were pooled to generate one set of baseline (normoxia) data. For 
the hypoxic gas challenge, data are compared to the preceding baseline period and 
data are presented on a minute-by-minute basis thereafter. VT and VE were 
normalised for body mass (g). To assess respiratory stability during normoxia, the 
breath-to-breath (BBn) and subsequent interval (BBn+1) of 200 consecutive breaths 
were analysed. Short-term variability (SD1) and long-term variability (SD2) were 
calculated for all four groups (Peng et al., 2011; Souza et al., 2015). 
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6.2.4 Metabolism measurements 
O2 consumption (VO2) and CO2 production (VCO2) were measured in mice 
undergoing the whole-body plethysmography protocol during normoxic baseline 
periods and during exposure to hypoxia. Airflow through the chamber was 
maintained at 1 L/min. Fractional concentrations of O2 and CO2 were measured in 
air entering and exiting the plethysmograph (O2 and CO2 analyser; ADInstruments, 
Colorado Springs, CO, USA) as previously described (Burns et al., 2017c).  
 
Data analysis: Calculation of VO2 and VCO2 was performed as previously described 
(Haouzi et al., 2009; Burns et al., 2017c). For the 20 min hypoxic challenge, data are 
shown after 5 min of exposure and are presented on a minute-by-minute basis 
thereafter. Data during hypoxia exposure were compared with the preceding 
baseline (FiO2 = 0.21). VO2 and VCO2 were normalised for body mass (g).  
 
6.2.5 Tissue collection 
The distance from nose-to-anus and nose-to-tail was examined postmortem as an 
index of somatic growth. The diaphragm muscle was excised with rib and central 
tendon intact and placed in a tissue bath at room temperature containing 
continuously gassed hyperoxic (95% O2/ 5% CO2) Krebs solution (in mM: NaCl, 120; 
KCl, 5; Ca2+ gluconate, 2.5; MgSO4, 1.2; NaH2PO4, 1.2; NaHCO3, 25; and glucose, 
11.5) and d-tubocurarine (25μM) prior to functional analysis. The following organs 
and muscles were weighed (wet weight): spleen, lung, whole heart, right heart 
ventricle, left heart ventricle, tibialis anterior, extensor digitorum longus and 
soleus. 
 
6.2.6 Muscle physiology 
6.2.6.1 Ex vivo muscle preparation 
One costal portion of the diaphragm was used immediately for functional analysis 
and the other portion was snap frozen in liquid nitrogen and stored at -80oC for 
subsequent molecular analysis. Longitudinally arranged bundles were prepared for 
assessment of contractile function. A single longitudinal strip (2 mm in diameter) 
for each animal was suspended vertically between two platinum plate electrodes. 
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Rib was attached to a fixed hook at one end and the central tendon was attached to 
a dual-mode lever transducer system (Aurora Scientific Inc.; Aurora, ON, Canada) by 
non-elastic string. Muscle preparations were studied in a water-jacketed muscle 
bath, containing Krebs solution, maintained at 35oC gassed with 95% O2/ 5% CO2. 
Preparations were allowed a 5 min equilibration period. 
 
6.2.6.2 Isometric protocol 
Following equilibration, the optimum length (Lo) was determined by adjusting the 
position of the force transducer by use of a micro-positioner between intermittent 
twitch contractions. The Lo was taken as the muscle length associated with maximal 
isometric twitch force in response to single isometric twitch stimulation 
(supramaximal stimulation, 1ms duration). Once Lo was determined, the muscle 
stayed at this length for the duration of the protocol. A single isometric twitch was 
measured. Peak isometric twitch force, contraction time (CT; time to peak force) 
and half relaxation time (½ RT; time for peak force to decay by 50%) were 
determined. Next, an isometric tetanic contraction was elicited by stimulating 
muscle strips with supramaximal voltage at 100 Hz for 300 ms duration. Peak 
isometric tetanic force was determined at 100Hz (O'Halloran, 2006; Burns & 
O'Halloran, 2016).  
 
Data analysis: Specific force was calculated in N/cm2 of muscle cross-sectional area 
(CSA). The CSA of each muscle strip was determined by dividing the muscle mass 
(weight in grams) by the product of muscle Lo (cm) and muscle density (assumed to 
be 1.06 g/cm3). The CT and ½ RT were measured as indices of isometric twitch 
kinetics. 
 
6.2.6.3 Isotonic protocol 
Following the isometric protocol, concentric contractions were elicited in 
incremental steps with varying load (0%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 
60%, 80, 100; % of force at 100Hz), with 30 s rest between each contraction. Muscle 
length returned to Lo following each contraction. Total shortening was determined 
as the maximum distance shortened during contraction. Shortening velocity was 
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determined as the distance shortened during the initial 30 ms of shortening (Lewis 
et al., 2015; Lewis et al., 2016). Mechanical work (force x total shortening) and 
power (force x shortening velocity) were determined at each step of the 
incremental load step test (Lewis et al., 2015; Williams et al., 2015; Burns & 
O'Halloran, 2016; O'Leary & O'Halloran, 2016).  
 
Data analysis: Data were plotted as the measured variable versus % load. Total 
muscle shortening was normalised to Lo and expressed in L/Lo. Similarly, shortening 
velocity was normalised to Lo and expressed in Lo/s. Maximum total shortening 
(Smax) and maximum shortening velocity (Vmax) were measured when both were 
maximal at 0% load. Mechanical work was measured in J/cm2. Mechanical power 
was expressed in W/cm2. Maximum mechanical work (Wmax) and power (Pmax) 
were also measured and typically occurred between 30% and 40% load. 
 
6.2.7 Muscle immunohistochemistry and histology 
6.2.7.1 Tissue preparation 
A section of the diaphragm muscle was excised and mounted on a cube of liver, 
allowing for a transverse orientation of muscle fibres. The tissue was covered in 
optimum cutting temperature (OCT; VWR International, Dublin, Ireland) embedding 
medium and frozen in isopentane cooled in liquid nitrogen and stored at -80oC for 
subsequent structural analysis (n = 4-5 per group). A separate section of the muscle 
was placed in 4% paraformaldehyde overnight at 4oC before being transferred to 
70% ethanol prior to tissue processing (Leica TP1020, Histokinet; Leica Biosystems, 
Dublin, Ireland) and paraffin embedding (Sakura Tissue-Tek TEC, Histolab Histowax 
embedding medium), for histological analysis (n = 4-5 per group). 
 
6.2.7.2 Myosin heavy chain fluorescence immunohistochemistry 
Serial transverse sections (10µm) were cryosectioned (Model CM30505; Leica 
Microsystems, Nussloch, Germany) at –22ºC and mounted on polylysine-coated 
glass slides (VWR International). Two slides per animal from 2 distinct regions 
containing a minimum of 4 sections per slide were processed for myosin heavy 
chain (MyHC) immunofluorescence. A hydrophobic pen (ImmEdgeTM; Vector 
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Laboratories Ltd., Peterborough, UK) was used to circumscribe each section on the 
slide, creating a well allowing for the containment of antibodies and to stop cross-
reactivity of antibodies between muscle sections. Slides were immersed in 
phosphate-buffered saline (0.01M PBS; Sigma-Aldrich, Wicklow, Ireland) containing 
1% bovine serum albumin (BSA; Sigma-Aldrich) for 15 mins, followed by three 5 min 
PBS rinses. This was followed by a 30 min wash in PBS containing 5% goat serum 
(Sigma-Aldrich). Before application of the primary mouse monoclonal antibodies 
(developed by S. Schiaffino and obtained from the Developmental Studies 
Hybridoma Bank (DSHB) at the University of Iowa, IA, USA), slides were subject to a 
further blocking step to enable the use of mouse monoclonal primary antibody 
staining on mouse tissue. Slides were incubated for 1 hour at room temperature 
with an unconjugated AffiniPure Fab Fragment Goat Anti-Mouse IgG (1:13; Jackson 
ImmunoResearch Labs, West Grove, PA, USA) diluted in PBS, followed by three 2 
min washes in PBS. A triple-labelled approach was used to tag the 3 principal 
myosin isoforms using a cocktail of antibodies that targeted MyHC types I (BAD5, 
1:100), IIa (sc71 1:100) and IIb (BFF3 1:100) on a single section. On a serial section a 
double-labelled approach was employed using a cocktail which consisted of a rabbit 
anti-laminin antibody (1:500, Sigma-Aldrich) and a pan-MyHC antibody for the 
indirect determination of pure MyHC IIx fibres, BF35 (1:50), labelling all MyHC 
isoforms but IIx, enabling visualization of IIx fibres by the absence of staining. The 
antibodies were diluted in PBS and 1% BSA and were incubated overnight at 4°C in 
a humidity chamber. Following this, slides were rinsed for three 5 min washes in 
PBS before application of the relevant secondary antibodies, diluted in PBS and 1% 
BSA. A cocktail of secondary antibodies was prepared containing AlexaFluor350-
conjugated goat anti-mouse IgG2b (1:500, Invitrogen, Biosciences Ltd, Dun 
Laoghaire, Ireland), Dylight594-conjugated goat anti-mouse IgG1 (1:500; Jackson 
ImmunoResearch) and AlexaFluor488-conjugated goat anti-mouse IgM (1:250; 
Invitrogen), targeting MyHC I, IIa and IIb, respectively. For the double-labelled 
sections a Dylight594-conjugated goat anti-mouse IgG1 (1:500; Jackson) and FITC-
conjugated anti-rabbit secondary antibody (1:250; Sigma-Aldrich) were applied for 
1 hour in the dark at room temperature. Slides were rinsed with PBS for three 5 min 
washes, cover slipped with polyvinyl alcohol (PVA) mounting medium with DABCO® 
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anti-fade (Sigma-Aldrich) before observation with a fluorescent microscope 
(Olympus BX51). Negative control experiments were run in parallel where the 
primary antibodies were omitted and the secondary antibodies were applied to 
ensure that tagging was specific.  
 
Data analysis: For MyHC fibre type analysis, muscle sections were viewed at x10 
magnification and images captured using an Olympus BX51 microscope and an 
Olympus DP71 camera. Cell Sens™ (Olympus) was used to digitally capture the 
images. Analysis was carried out using image J software, where fibre type CSA and 
fibre type distribution (areal density) for each MyHC fibre type were determined 
(Burns et al., 2017b). For each animal, multiple sections throughout the muscle 
were viewed and 3-4 images analysed per fibre type.  
 
6.2.7.3 Histological analysis 
Paraffin embedded diaphragm muscle samples were sectioned using a microtome 
(Leica RM2135). Serial cross-sections (5 μm thick) were collected throughout the 
muscle (mid-belly and distal regions) onto polylysine coated glass slides (VWR) and 
oven-dried (overnight at 37°C) for histological analysis. To examine putative 
inflammatory cell infiltration, and central nucleation of muscle fibres, tissue 
sections were stained with Haematoxylin and Eosin (H&E). For collagen staining, a 
Masson’s trichrome protocol was followed (Sigma-Aldrich). Slides were mounted 
using DPX mounting medium (Sigma-Aldrich, USA), air-dried and visualized on a 
bright field microscope (Olympus BX51) at x20 magnification.  
 
Data analysis: H&E stained sections were visualized at x20 magnification. Six 
sections were examined across the muscle from the rostral, middle and caudal 
regions. Two randomly selected areas were captured per muscle section from non-
overlapping areas for analysis. Muscle pathology was scored using ImageJ software. 
The number of myofibres displaying central nucleation was expressed as a 
percentage of the total number of myofibres per image. Putative inflammatory cell 
infiltration (the presence of cells in the extracellular matrix) was also scored and 
expressed as a percentage of the total area of muscle. For Masson’s trichrome 
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staining, the microscope lighting exposure was maintained throughout.  Three 
sections, with two images captured per section, from the mid-portion of the 
muscle, were analysed per animal. Images were analysed using a colour balance 
threshold (ImageJ software), and the area of collagen was expressed as a 
percentage of the total area of muscle. 
 
6.2.7.4 Fluorescently labelled collagen binding protein 
Additional collagen staining of the diaphragm muscle was carried out using a 
fluorescent collagen marker (CNA35-OG488), developed by (Krahn et al., 2006) and 
kindly gifted by the Department of Zoology, Trinity College Dublin. The CNA-35 
probe is specific for type I and III collagen, found abundantly in skeletal muscle 
tissue. Following deparaffinisation, slides were prepared for a citrate buffer (pH 6) 
antigen retrieval step and subsequently stored in PBS (0.01M) prior to fluorescent 
staining. Slides were incubated over night at 4◦C with CNA35-OG488 (1:100 dilution 
in PBS). Following staining, sliders were washed with PBS, incubated with Hoescht 
stain (Sigma-Aldrich) to visualize cell nuclei and finally cover slipped with PVA-
DABCO mounting medium before observation with a confocal microscope (Leica 
SP8).  
 
Data analysis: For CNA35-OG488 analysis, non-overlapping serial images (x20 
magnification) were taken across a whole diaphragm muscle section. Images were 
analysed using a colour balance threshold (ImageJ software), and the area of 
collagen was expressed as a percentage of the total area of muscle. 
 
6.2.8 Molecular studies  
6.2.8.1 Tissue preparation 
Diaphragm samples stored at -80oC were removed and allowed to defrost at 4oC for 
5 minutes. All procedures were performed at 4oC to prevent protein degradation. 
Samples were homogenized in a lysis buffer (RIPA) made up from 10X RIPA, 
deionized water, 200mM sodium fluoride (NAF), 100mM 
phenylmethylsulfonylfluoride (PMSF), protease cocktail inhibitor 1 and phosphatase 
cocktail inhibitor 2. Following the homogenization process, the reactant mixtures 
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were centrifuged (15,339 x g) at 4oC for 20 min and the supernatants were 
harvested. The total amount of protein for each tissue sample was determined 
using the Pierce Bicinchoninic Acid Assay (BCA assay; Thermo Fisher Scientific, 
Dublin, Ireland). Supernatants were stored at -80oC for subsequent use.  
 
6.2.8.2 Cytokines 
A multiplex cytokine assay (K15048G-1; Meso Scale Discovery, Rockville, MD) was 
used to examine cytokine concentrations in diaphragm muscle from all four groups 
(n = 8 per group). The assay was performed according to the manufacturer’s 
instructions using an extended incubation time to improve detection (the plate was 
incubated overnight at 4oC). Following incubation, the plate was read on a 
Quickplex SQ 120imager (Meso Scale Discovery).  
 
6.2.9 Statistical analysis  
Data are expressed as scatter point box and whisker plots (median, 25-75 centile, 
and scatter plot) or as mean ± SD Data were statistically compared using Prism 6.0 
(Graphpad Software, San Diego, CA, USA). For muscle immunohistochemistry and 
histology, group means were generated from multiple images averaged per animal. 
All data were statistically compared by two-way ANOVA (genotype x treatment) 
with Bonferroni post hoc test. P < 0.05 was deemed to be statistically significant.  
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6.3 Results 
6.3.1 Body mass and organ measurements 
Table 6.1 compares body mass, body length, organ and muscle mass in WT and mdx 
mice treated with saline or xIL-6R and Ucn2 (treatment). Spleen mass was 
significantly increased in mdx + saline (P < 0.0001; two-way ANOVA with 
Bonferroni) compared with WT + saline. Muscle mass was significantly increased for 
mdx + saline tibialis anterior (P < 0.0001) and soleus (P < 0.01) compared with WT + 
saline. Extensor digitorum longus from mdx mice was significantly heavier than WT 
(P = 0.001 (genotype); two-way ANOVA). There was a significant difference in body 
mass (P < 0.0001 (genotype); two-way ANOVA) between age-matched WT and mdx 
mice; mdx mice were heavier. Drug co-treatment had no effect on body mass (P = 
0.411 (treatment); two-way ANOVA). Spleen and muscle mass were also unaffected 
by drug treatment.  
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 WT mdx  
 Saline 
(n = 10) 
Treatment 
(n = 7) 
Saline 
(n = 10) 
Treatment 
(n = 6) 
Two-way ANOVA 
Body mass (g) 21.0 ± 1.3 21.6 ± 0.8 24.4 ± 1.7* 24.7 ± 1.6 Genotype: P < 0.0001; Treatment: P = 0.411; Interaction: P = 0.7638 
N-A (cm) 9.1 ± 0.2 9.2 ± 0.3 9.4 ± 0.2 9.1 ± 0.3 Genotype: P = 0.2576; Treatment: P = 0.2576; Interaction: P = 0.0121 
N-T (cm) 16.5 ± 0.3 16.8 ± 0.4 16.6 ± 0.3 16.8 ± 0.4 Genotype: P = 0.4746; Treatment: P = 0.038; Interaction: P = 0.549 
Spleen (mg) 55.8 ± 8.9 60.6 ± 6.2 119.4 ± 13.5* 118.8 ± 23.3 Genotype: P < 0.0001; Treatment: P = 0.6693; Interaction: P = 0.5816 
Wet lung (mg) 124.5 ± 10.2 113.7 ± 7.5 121.8 ± 9.0 124.0 ± 9.4 Genotype: P = 0.2576; Treatment: P = 0.1966; Interaction: P = 0.0556 
Heart (mg) 103.1 ± 8.1 96.7 ± 7.6 106.0 ± 10.1 110.1 ± 11.0 Genotype: P = 0.0167; Treatment: P = 0.7295; Interaction: P = 0.1112 
RV (mg) 25.8 ± 5.3 30.9 ± 3.5 31.5 ± 5.3 31.7 ± 6.8 Genotype: P = 0.1073; Treatment: P = 0.1821; Interaction: P = 0.2172 
LV (mg) 77.4 ± 7.6 68.5 ± 7.1 74.5 ± 7.1 78.5 ± 8.4 Genotype: P = 0.2028; Treatment: P = 0.3757; Interaction: P = 0.027 
RV:LV 0.34 ± 0.09 0.46 ± 0.09 0.42 ± 0.07 0.41 ± 0.09 Genotype: P = 0.5691; Treatment: P = 0.105; Interaction: P = 0.0354 
TA (mg) 34.7 ± 2.5 35.7 ± 1.5 58.4 ± 3.4* 70.0 ± 4.8 Genotype: P < 0.0001; Treatment: P = 0.1363; Interaction: P = 0.5224 
EDL (mg) 7.6 ± 2.2 6.2 ± 1.5 9.1 ± 1.8 9.2 ± 0.6 Genotype: P = 0.001; Treatment: P = 0.2852; Interaction: P = 0.266 
Sol (mg) 5.9 ± 1.3 6.0 ± 1.2 8.5 ± 1.7* 8.7 ± 1.9 Genotype: P < 0.0001; Treatment: P = 0.7927; Interaction: P = 0.9906 
 
Table 6.1 Body mass, somatic growth, organ and muscle mass 
Definition of abbreviations: N-A, distance from nose to anus; N-T, distance from nose to tip of tail; RV, right heart ventricle; LV, left heart ventricle; TA, 
tibialis anterior; EDL, extensor digitorum longus; sol, soleus; WT, wild-type. WT (n = 7-10) and mdx (n = 6-10) mice were injected subcutaneously with saline 
(0.9% w/v) or treatment [neutralizing interleukin-6 receptor antibodies (0.2 mg/kg) and urocortin 2 (30 μg/kg); co-administered] over 2 weeks. Data are 
shown as mean ± SD and were statistically compared using two-way ANOVA with Bonferroni post hoc test. *mdx saline significantly different from 
corresponding WT saline values, P < 0.05. 
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6.3.2 Baseline ventilation and metabolism 
Respiratory flow traces for WT and mdx mice following saline or drug co-treatment 
are shown in Fig. 6.1A. Minute ventilation during normoxia was significantly lower 
in mdx + saline compared with WT + saline (Fig. 6.1B; P < 0.01; two-way ANOVA 
with Bonferroni). The reduction in normoxic ventilation was due to a significantly 
lower tidal volume in mdx + saline compared with WT + saline (Table 6.2; P < 0.05). 
Respiratory frequency was significantly higher in mdx mice (Table 6.2; P = 0.0047 
(genotype); two-way ANOVA). Drug co-treatment in mdx mice significantly 
increased minute ventilation (Fig. 6.1B; P < 0.001; two-way ANOVA with 
Bonferroni), due to a significant increase in tidal volume (Table 6.2. P < 0.05; two-
way ANOVA with Bonferroni) and respiratory frequency (Table 6.2; P = 0.0018 
(treatment); two-way ANOVA). There was no evidence of altered respiratory 
stability in mdx mice compared with WT, based on measures of breathing variability 
(SD1 and SD2; Table 6.2). Moreover, drug co-treatment had no effect on SD1 or SD2 
for both WT and mdx mice. 
 
When normalised for body mass, there was no difference in VO2 (Table 6.2; P = 
0.4439 (genotype); two-way ANOVA) and VCO2 (Figure 6.1C.; P = 0.8405). When 
expressed in absolute terms, there was a slight increase in VO2 in mdx mice 
compared with WT (Table 6.2; P = 0.0432); no difference was observed for VCO2 
(Table 6.2. P = 0.117). Drug co-treatment significantly decreased VO2 (Table 6.2.) 
and VCO2 (Fig. 6.1C) in WT (P < 0.05 and P < 0.01; two-way ANOVA with Bonferroni; 
VO2 and VCO2, respectively) and mdx mice (P < 0.05 and P < 0.05). The ventilatory 
equivalent for O2 (VE/VO2) was significantly increased in WT (Table 6.2.; P < 0.05) 
and mdx mice (P < 0.05) following drug co-treatment. Similarly, the ventilatory 
equivalent for CO2 (VE/VCO2) was significantly increased by drug co-treatment for 
both WT (Fig. 6.1D; P < 0.001) and mdx mice (Fig. 6.1D; P < 0.001). Drug co-
treatment had a significant effect on the ratio of VCO2 to VO2 (Table 6.2; P = 0.0344 
(treatment); two-way ANOVA).  
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Figure 6.1 Ventilation in conscious 
mice 
A, representative respiratory flow 
traces during normoxia (21% O2) and 
hypoxia (10% O2) in wild-type (WT) 
and mdx mice following six 
subcutaneous injections with saline 
(S; 0.9% w/v) or treatment [T; 
neutralizing interleukin-6 receptor 
antibodies (0.2 mg/kg) and urocortin 
2 (30 μg/kg); co-administered] over 2 
weeks. Inspiration downwards. B-D, 
minute ventilation (B), carbon dioxide 
production (C; VCO2) and ventilatory 
equivalent for carbon dioxide (D; 
VE/VCO2) for WT and mdx mice 
following saline or drug treatment. 
Values (B-D) are expressed as scatter 
point box and whisker plots (median, 
25-75 centile and scatter plot). Data 
were statistically compared by two-
way ANOVA with Bonferroni post hoc 
test. **P < 0.01; ***P < 0.001. 
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 WT mdx  
 Saline 
(n = 14) 
Treatment 
(n = 10) 
Saline 
(n = 10) 
Treatment 
(n = 12) 
Two-way ANOVA 
fR (bpm) 165.0 ± 11.2 177.7 ± 11.9ǂ 176.4 ± 15.7 189.0 ± 12.7 Genotype: P = 0.0047; Treatment: P = 0.0018; Interaction: P = 0.977 
VT (ml/g) 0.0074 ± 0.001 0.0076 ± 0.001 0.0053 ± 0.001* 0.0071 ± 0.001# Genotype: P < 0.0001; Treatment: P = 0.0016; Interaction: P = 0.017 
VO2 (ml/min) 1.38 ± 0.5 0.77 ± 0.2ǂ 1.66 ± 0.4 1.04 ± 0.5# Genotype: P = 0.0432; Treatment: P < 0.0001; Interaction: P = 0.979 
VO2 (ml/g/min) 0.065 ± 0.02 0.037 ± 0.01ǂ 0.068 ± 0.02 0.043 ± 0.02# Genotype: P = 0.4439; Treatment: P < 0.0001; Interaction: P = 0.7139 
VCO2 (ml/min) 1.16 ± 0.3 0.77 ± 0.2ǂ 1.12 ± 0.2 0.90 ± 0.2# Genotype: P = 0.117; Treatment: P < 0.0001; Interaction: P = 0.8778 
VE/VO2 21.9 ± 11.7 38.3 ± 10.6ǂ 14.6 ± 5.1 35.5 ± 14.3# Genotype: P = 0.1344; Treatment: P < 0.0001; Interaction: P = 0.5089 
VCO2/VO2 0.85 ± 0.2 1.03 ± 0.3 0.80 ± 0.2 0.97 ± 0.3 Genotype: P = 0.4647; Treatment: P = 0.0344; Interaction: P = 0.9504 
Ti: SD1 18.9 ± 18.2 22.0 ± 8.6 16.3 ± 8.7 14.0 ± 5.0 Genotype: P = 0.128; Treatment: P = 0.9128; Interaction: P = 0.432 
Ti: SD2 27.2 ± 14.0 28.1 ± 9.9 26.2 ± 21.1 21.0 ± 5.8 Genotype: P = 0.3048; Treatment: P = 0.579; Interaction: P = 0.4387 
Te: SD1 59.8 ± 34.7 59.1 ± 26.0 63. 7 ± 36.7 45.5 ± 17.6 Genotype: P = 0.5739; Treatment: P = 0.2777; Interaction: P = 0.3155 
Te: SD2 93.1 ± 41.0 79.5 ± 19.6 75.6 ± 49.9 60.9 ± 19.5 Genotype: P = 0.0888; Treatment: P = 0.1827; Interaction: P = 0.9323 
 
Table 6.2 Baseline ventilation and metabolic measurements 
Definition of abbreviations: fR, breathing frequency; VT, tidal volume; VO2, oxygen consumption; VCO2, carbon dioxide production; VE/VO2, ventilatory 
equivalent for oxygen; VCO2/VO2, respiratory exchange ratio; Ti, inspiratory duration; Te, expiratory duration; SD1, short-term variability; SD2, long-term 
variability; WT, wild-type. WT (n = 10-14) and mdx (n = 10-12) mice were injected subcutaneously with saline (0.9% w/v) or treatment [neutralizing 
interleukin-6 receptor antibodies (0.2 mg/kg) and urocortin 2 (30 μg/kg); co-administered] over 2 weeks. Data are shown as mean ± SD and were 
statistically compared using two-way ANOVA with Bonferroni post hoc test. ǂWT treatment significantly different from corresponding WT saline values, P < 
0.05; *mdx saline significantly different from corresponding WT saline values, P < 0.05; #mdx treatment significantly different from corresponding mdx 
saline values, P < 0.05.  
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6.3.3 Ventilatory responsiveness to hypoxia 
Figure 6.2A shows the time course of changes in minute ventilation in response to a 
20 min hypoxic challenge (FiO2 = 0.1; balance N2). Ventilation increased rapidly in all 
four groups at the onset of hypoxia (P < 0.0001; two-way ANOVA) and then 
declined thereafter. Ventilation was significantly lower in mdx + saline compared 
with WT + saline when examined either over the time course of the hypoxic 
ventilatory response (Fig 6.2A; P = 0.0004) or as maximum ventilation during 
challenge (Fig. 6.2B; P < 0.0001). The peak ventilatory response to hypoxia (ΔVE) 
was lower in mdx + saline compared with WT + saline (Fig. 6.2C; P < 0.001; two-way 
ANOVA with Bonferroni). Drug co-treatment significantly increased minute 
ventilation for mdx + treatment compared with mdx + saline (Fig. 6.2A; P = 0.02; 
two-way ANOVA) during the 20 min exposure to hypoxia; peak ventilation was also 
higher (Fig. 6.2B; P = 0.0006). However, the peak ventilatory response to hypoxia 
(ΔVE) was unchanged in mdx + treatment compared with mdx + saline (Fig. 6.2C; P > 
0.05). By comparison, in WT mice, drug co-treatment had no significant effect on 
ventilation during exposure to hypoxia (Fig. 6.2A; P = 0.9) or peak ventilation in 
response to hypoxia (Fig. 6.2B; P = 0.716). VE/VCO2 increased in response to hypoxia 
(Fig. 6.2D; P < 0.0001). Drug co-treatment significantly increased VE/VCO2 during 
hypoxia in WT (P = 0.024) but not mdx mice (P = 0.268). Ventilation was significantly 
lower in mdx + saline compared with WT + saline during hypercapnic challenge (VE 
during hypercapnia was 4.0 ± 1.4 versus 2.4 ± 0.8 ml/min/g, two-way ANOVA with 
Bonferroni post hoc test, P < 0.001 for WT + saline (n = 8) versus mdx + saline (n = 
8)). The peak ventilatory response to hypercapnia (ΔVE) was lower in mdx + saline 
compared with WT + saline (delta VE was 2.9 ± 1.5 versus 1.4 ± 0.7 ml/min/g, 
unpaired Student’s t test, P = 0.21  for WT + saline (n = 8) versus mdx + saline (n = 
8)). We were unable to compare the effect of drug co-treatment on hypercapnic 
ventilation in WT and mdx mice. 
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Figure 6.2 Ventilatory responsiveness to hypoxia 
A, Group data (mean ± SD) for minute ventilation during baseline and 20 min of exposure to hypoxia 
(A; 10% inspired oxygen; balance N2) for wild-type (WT) and mdx mice following six subcutaneous 
injections with saline (0.9% w/v) or treatment [neutralizing interleukin-6 receptor antibodies (0.2 
mg/kg) and urocortin 2 (30 μg/kg); co-administered] over 2 weeks. Data were statistically compared 
by repeated measures two-way ANOVA. B, Group data (mean ± SD) for minute ventilation during 
baseline and peak ventilation 
during hypoxia for WT and mdx 
mice following saline or drug 
treatment. Data were statistically 
compared by repeated measures 
two-way ANOVA. C, Group data 
for peak ventilatory 
responsiveness (ΔVE) to hypoxia 
for WT and mdx mice following 
saline or drug treatment. Values 
are expressed as scatter point box 
and whisker plots (median, 25-75 
centile and scatter plot). Data 
were statistically compared by 
two-way ANOVA with Bonferroni 
post hoc test. *P < 0.05; ***P < 
0.001. D, group data (mean ± SD) 
for ventilatory equivalent for 
carbon dioxide (VE/VCO2) during 
baseline and after 5-20 min of 
exposure to hypoxia for WT and 
mdx mice following saline or drug 
treatment. Data were statistically 
compared by repeated measures 
two-way ANOVA.  
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6.3.4 Isometric force and twitch contractile kinetics 
Table 6.3 shows data for diaphragm muscle contractile kinetics (CT and ½ RT) from 
WT and mdx mice following saline or drug co-treatment. Diaphragm CT was 
significantly higher for mdx + saline (P < 0.05; two-way ANOVA with Bonferroni) 
compared with WT + saline. Drug co-treatment had no significant effect on CT. 
There was no significant difference between WT and mdx for ½ RT. Representative 
original traces for diaphragm muscle twitch and tetanic contractions, and maximum 
unloaded shortening are shown in Fig. 6.3A-C. Diaphragm twitch force was 
significantly lower in mdx + saline (Fig. 6.3D; P < 0.05) compared with WT + saline. 
Drug co-treatment had no significant effect on diaphragm twitch force (Fig. 6.3D; P 
= 0.1766 (treatment); two-way ANOVA). Diaphragm peak tetanic force at 100 Hz 
was significantly lower in mdx + saline (Fig. 6.3E; P < 0.001; two-way ANOVA with 
Bonferroni) compared with WT + saline. Post hoc analysis showed that drug 
treatment significantly increased tetanic force in mdx, but not WT diaphragm (Fig. 
6.3E; P < 0.05). 
 
6.3.5 Isotonic contractile parameters and kinetics 
Table 6.3 shows data for diaphragm muscle isotonic contractile parameters: Wmax, 
Pmax, Smax and Vmax. Diaphragm Wmax was significantly reduced in mdx + saline 
compared with WT + saline (P < 0.05; two-way ANOVA with Bonferroni). There was 
no significant effect of drug co-treatment on Wmax (P = 0.0857 (treatment); two-
way ANOVA). Pmax was significantly reduced in mdx + saline compared with WT + 
saline (P < 0.05; two-way ANOVA with Bonferroni). Drug treatment significantly 
increased Pmax (P = 0.0276 (treatment); two-way ANOVA); Pmax was increased by 
~130% in mdx diaphragm following drug treatment. There was no significant 
difference in Smax or Vmax between WT and mdx diaphragms. Although statistical 
significance was not achieved for the effect of drug co-treatment on Wmax and 
Vmax in mdx diaphragm, sizeable effects were noted, which may have physiological 
relevance. Drug co-treatment increased mdx diaphragm Wmax by ~100% and Vmax 
by ~58% compared with mdx + saline. 
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 WT mdx  
 Saline 
(n = 10) 
Treatment 
(n = 7) 
Saline 
(n = 8) 
Treatment 
(n = 8) 
Two-way ANOVA 
CT (ms) 18.4 ± 2.8 19.4 ± 2.1 21.8 ± 2.5* 21.6 ± 2.5 Genotype P = 0.0038; Treatment P = 0.6824; Interaction P = 0.5097 
½ RT (ms) 23.5 ± 2.2 22.3 ± 2.6 23.9 ± 1.2 21.2 ± 6.4 Genotype P = 0.8129; Treatment P = 0.1353; Interaction P = 0.5761 
Wmax (J/cm2) 1.5 ± 0.7 1.7 ± 1.0 0.5 ± 0.3* 1.0 ± 0.1 Genotype P = 0.0008; Treatment P = 0.0857; Interaction P = 0.6102 
Pmax (W/cm2) 9.6 ± 3.9 11.9 ± 7.2 3.7 ± 2.9* 8.5 ± 2.5 Genotype P = 0.0047; Treatment P = 0.0276; Interaction P = 0.4137 
Smax (L/Lo) 0.37 ± 0.11 0.42 ± 0.07 0.33 ± 0.11 0.39 ± 0.02 Genotype P = 0.2412; Treatment P = 0.0998; Interaction P = 0.7863 
Vmax (Lo/s) 4.5 ± 1.3 4.3 ± 1.7 3.1 ± 1.9 4.9 ± 0.9 Genotype P = 0.4947; Treatment P = 0.1557; Interaction P = 0.0564 
 
Table 6.3 Diaphragm muscle contractile properties 
Group data (mean ± SD) for twitch contraction time (CT), twitch half-relaxation time (1/2 RT), maximum mechanical work (Wmax), maximum mechanical 
power (Pmax), peak shortening (Smax) and peak shortening velocity (Vmax) of diaphragm muscle from wild-type (WT; n = 7-10) and mdx (n = 8) mice 
injected subcutaneously with saline (0.9% w/v) or treatment [neutralizing interleukin-6 receptor antibodies (0.2 mg/kg) and urocortin 2 (30 μg/kg); co-
administered] over 2 weeks. Data were statistically compared by two-way ANOVA followed by Bonferroni post hoc test. *mdx saline significantly different 
from corresponding WT saline value, P < 0.05.  
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6.3.6 Isotonic load relationships 
Figure 6.3 (F-I) shows data for diaphragm muscle isotonic load relationships. 
Loading had a significant effect on work (Fig. 6.3F; P < 0.0001; two-way ANOVA), 
power (Fig. 6.3G; P < 0.0001), shortening (Fig. 6.3H; P < 0.0001) and shortening 
velocity (Fig. 6.3I; P < 0.0001). Diaphragm from mdx + saline had significantly 
reduced work (P < 0.0001), power (P < 0.0001), shortening (P < 0.0001) and 
shortening velocity (P = 0.0003) compared with WT + saline. Drug treatment 
increased mdx diaphragm work (P < 0.0001) and WT diaphragm work (P = 0.059). 
Following drug co-treatment, power production was significantly increased in WT (P 
= 0.009) and mdx diaphragm (P < 0.0001). Shortening (P = 0.0001) and shortening 
velocity (P < 0.0001) were also significantly increased for mdx diaphragm after drug 
co-treatment.  
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Figure 6.3 Diaphragm muscle function 
A-C, original traces of muscle twitch (A) and tetanic (B) contractions and maximum unloaded 
shortening (C) for diaphragm muscle from wild-type (WT) and mdx mice following six subcutaneous 
injections with saline (S; 0.9% w/v) or treatment [T; neutralizing interleukin-6 receptor antibodies 
(0.2 mg/kg) and urocortin 2 (30 μg/kg); co-administered] over 2 weeks. D and E, group data for 
twitch (D) and tetanic (E) force in WT (n = 7-10) and mdx (n = 8) diaphragm muscle following saline 
or treatment. Peak tetanic force was measured following stimulation at 100Hz ex vivo. Values are 
expressed as scatter point box and whisker plots (median, 25-75 centile and scatter plot). Data were 
statistically compared by two-way ANOVA followed by Bonferroni post hoc test. *P < 0.05; ***P < 
0.001. F-I, group data (mean ± SD) for work-load (F), power-load (G), shortening-load (H) and 
velocity-load (I) relationships in WT (n = 7-10) and mdx (n = 8) diaphragm muscle following saline or 
drug treatment. Data were statistically compared by two-way ANOVA. Work: load, P < 0.0001; 
genotype, P <0.0001; WT treatment, P = 0.059; and mdx treatment, P < 0.0001. Power: load, P < 
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0.0001; genotype, P < 0.0001; WT treatment, P = 0.009; and mdx treatment, P < 0.0001. Shortening: 
load, P < 0.0001; genotype, P < 0.0001; WT treatment, P = 0.968; and mdx treatment, P = 0.0001. 
Velocity: load, P < 0.0001; genotype, P = 0.0003; WT treatment, P = 0.642; and mdx treatment, P < 
0.0001. 
 
 
 
6.3.7 Myosin heavy chain fibre-type distribution 
Figure 6.4 shows data for MyHC fibre distribution of diaphragm muscles. The fibre 
type distribution of MyHC type I fibres did not vary significantly between the four 
groups (Fig. 6.4B). For mdx + saline, the abundance of MyHC type IIa fibres was 
significantly increased compared with WT + saline (Fig. 6.4C; P < 0.001; two-way 
ANOVA with Bonferroni), whereas the abundance of MyHC type IIx fibres was 
significantly reduced in mdx + saline compared with WT + saline (Fig. 6.4D; P < 
0.001). The abundance of MyHC type IIb fibres was significantly reduced in mdx 
compared with WT diaphragm (Fig. 6.4E; P = 0.0079 (genotype); two-way ANOVA). 
Diaphragm fibre type changes were prevented or reversed by drug co-treatment in 
mdx with a significant decrease in type IIa fibres (P < 0.001; two-way ANOVA with 
Bonferrroni) and a significant increase in type IIx fibres (P < 0.001) observed 
compared with mdx + saline.  
 
6.3.8 Fibre cross-sectional area  
Figure 6.4F shows data for CSA for all fibre types in all 4 groups. There was no 
significant difference in the CSA of MyHC type I, type IIa, type IIx or type IIb fibres in 
mdx diaphragm compared with WT. Drug co-treatment significantly increased 
MyHC type I fibre CSA (P < 0.05; two-way ANOVA with Bonferroni) and MyHC type 
IIx fibre CSA (P < 0.05) in mdx mice only. Drug co-treatment had no effect on the 
CSA of MyHC type IIa or type IIb fibres in WT and mdx diaphragms.   
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Figure 6.4 Diaphragm muscle fibre distribution and cross-sectional area 
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A, Representative immunofluorescence images of diaphragm muscle fibre-type distribution 
(A), showing type I (blue), type IIa (red), type IIx (untagged, appearing black) and type IIb 
fibres (green) for WT + saline (WT-S; top left), mdx + saline (mdx-S; top right), WT + 
treatment (WT-T; bottom left) and mdx + treatment (mdx-T; bottom right). Scale bars = 200 
µm. B-E, group data showing fibre distribution of type I (B), type IIa (C), type IIx (D) and 
type IIb fibres (E) in WT and mdx saline treated mice, and WT drug-treated and mdx drug-
treated mice (n = 5) per group. Mice received six sub-cutaneous injections of saline (0.9% 
w/v) or treatment [neutralizing interleukin-6 receptor antibodies (0.2 mg/kg) and urocortin 
2 (30 μg/kg); co-administered] over two weeks. Values are expressed as scatter point box 
and whisker plots (median, 25-75 centile and scatter plot). Data were statistically compared 
by two-way ANOVA followed by Bonferroni post hoc test. ***P < 0.001. F, Group data 
(mean ± SD) showing mean CSAs of diaphragm muscle fibre type I, type IIa, type IIx and 
type IIb. Data were statistically analysed by two-way ANOVA with Bonferroni post hoc test. 
*P < 0.01. Type I: Genotype, P = 0.908; treatment, P = 0.036; interaction, P = 0.009. Type 
IIa: Genotype, P = 0.839; treatment, P = 0.291; interaction, P = 0.27. Type IIx: Genotype, P = 
0.276; treatment, P = 0.005; interaction, P =0.106. Type IIb: Genotype, P = 0.12; treatment, 
P = 0.905; interaction, P = 0.281. 
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6.3.9 Central nucleation and putative inflammatory cell infiltration  
Figure 6.5 shows data for diaphragm muscle histology. The proportion of 
diaphragm muscle fibres with centrally located nuclei was significantly increased in 
mdx + saline (Fig 6.5D; P < 0.001; two-way ANOVA with Bonferroni) compared with 
WT + saline. Drug co-treatment had no significant effect on central nucleation (P = 
0.414 (treatment); two-way ANOVA). The areal density of inflammatory cell 
infiltration was significantly increased in mdx + saline diaphragm compared with 
WT + saline (Fig. 6.5E; P < 0.001; two-way ANOVA with Bonferroni). Drug co-
treatment had no significant effect on the relative area of putative immune cell 
infiltration (P = 0.3114 (treatment); two-way ANOVA). 
 
6.3.10 Collagen content 
The areal density of collagen labelled using Masson’s trichrome (type I collagen) 
staining was significantly increased in mdx + saline compared with WT + saline (Fig. 
6.5F; P < 0.0001; two-way ANOVA with Bonferroni). Drug co-treatment had no 
significant effect on type I collagen content (P = 0.278 (treatment); two-way 
ANOVA). Type I and type III collagen co-expression, labelled with the fluorescent 
CNA35-OG488 probe, was significantly increased in mdx diaphragm compared with 
WT (Fig. 6.5G; P = 0.0449 (genotype); two-way ANOVA). Drug co-treatment did not 
affect the expression of diaphragm type I and III collagen (P = 0.99 (treatment); 
two-way ANOVA). 
 
6.3.11 Inflammatory mediators 
Figure 6.6 shows data for selective cytokine concentrations in diaphragm muscle 
from WT and mdx mice after saline administration or drug co-treatment. There was 
a significantly increased concentration of IL-2 (Fig. 6.6B; P = 0.021 (genotype); two-
way ANOVA) and IL-5 (Fig. 6.6D; P = 0.002) in mdx diaphragm compared with WT. 
Diaphragms from mdx + saline showed significantly increased expression of IL-1β 
(Fig. 6.6A; P < 0.001; two-way ANOVA with Bonferroni), IL-6 (Fig. 6.6E; P < 0.001), 
KC/GRO (Fig. 6.6H; P < 0.001) and TNF-α (Fig. 6.6J; P < 0.001) compared with WT + 
saline. Post hoc analysis revealed that drug co-treatment significantly decreased the 
pro-inflammatory cytokine IL-1β (P < 0.01; two-way ANOVA with Bonferroni) and 
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significantly increased the anti-inflammatory cytokine IL-10 (Fig. 6.6F; P < 0.05) in 
mdx diaphragm compared with mdx + saline. The expression of IL-4 (Fig. 6.6C), IL-
12p70 (Fig. 6.6G) and IFN-γ (Fig. 6.6I) were unchanged in mdx diaphragm compared 
with WT, and the concentrations of each of these were unaffected by drug co-
treatment.  
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Figure 6.5 Diaphragm muscle histology 
A-C, Representative histological images of diaphragm muscle transverse sections stained 
with Haematoxylin and Eosin (A), Masson’s trichrome (B; type I collagen) and CNA35-
OG488 (C; type I and III collagen) in WT + saline (WT-S; first column), mdx + saline (mdx-S; 
second column), WT + treatment (WT-T; third column) and mdx + treatment (mdx-T; fourth 
column) groups. Scale bars represent 100 µm. Peripherally located nuclei are apparent in 
WT saline and WT drug-treated images. In comparison, mdx mice (saline and drug-treated) 
displayed an increased incidence of centrally located nuclei. Inflammatory cell infiltration is 
not apparent in WT saline and WT drug-treated groups. The mdx muscle (saline and 
treatment) displayed inflammatory cell infiltration, highlighted with black arrows. D and E, 
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group data showing the percentage of central nucleation (D) and percentage of infiltration 
of inflammatory cells (E) in diaphragm muscle from saline-treated WT (n = 5) and saline-
treated mdx mice (n = 4), and WT (n = 5) and mdx (n = 5) mice treated with neutralizing 
interleukin-6 receptor antibodies (0.2 mg/kg) and urocortin 2 (30 µg/kg), co-administered 
as six sub-cutaneous injections over 2 weeks. F and G, group data showing percentage of 
type I collagen content (C) and type I and III collagen content (D) in diaphragm muscle from 
saline-treated WT and saline-treated mdx mice, and WT and mdx mice (n = 4-5 per group) 
treated with neutralizing interleukin-6 receptor antibodies (0.2 mg/kg) and urocortin 2 (30 
µg/kg) co-administered as six sub-cutaneous injections over 2 weeks. Values are expressed 
as scatter point box and whisker plots (median, 25-75 centile and scatter plot). Data were 
statistically compared by two-way ANOVA followed by Bonferroni post hoc test. ***P < 
0.001.  
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Figure 6.6 Cytokine concentrations in diaphragm muscle 
A-J, Group data (mean ± SD) for selective cytokine concentrations in diaphragm muscle. 
Cytokines include interleukin-1β (A; IL-1β), interleukin-2 (B; IL-2), interleukin-4 (C; IL-4), 
interleukin-5 (D; IL-5), interleukin-6 (E; IL-6), interleukin-10 (F; IL-10); interleukin-12 (F; IL-
12p70), (G; KC/GRO), interferon-γ (F; IFN- γ) and tumour necrosis factor-α (TNF-α) in 
diaphragm muscle from wild-type (WT) and mdx mice (n = 8 per group) injected 
subcutaneously with saline (S; 0.9% w/v) or drug treatment [T; neutralizing interleukin-6 
receptor antibodies (0.2 mg/kg) and urocortin 2 (30 μg/kg); co-administered] over 2 weeks. 
Red represents an increase in concentration. Data were statistically compared by two-way 
ANOVA followed by Bonferroni post hoc test. * P < 0.05; **P < 0.01; ***P < 0.001.  
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6.4 Discussion 
The key findings of the present study are: (i) drug co-treatment with xIL-6R and 
Ucn2 restored muscle fibre complement equivalent to WT; (ii) drug co-treatment 
improved diaphragm force-generating capacity at 100Hz and restored normoxic 
ventilation in mdx mice; (iii) drug co-treatment had no significant effect on central 
nucleation, inflammatory cell infiltration and collagen deposition in mdx 
diaphragm; and (iv) drug co-treatment decreased IL-1β concentration and increased 
IL-10 concentration in mdx diaphragm. 
 
Striated muscle weakness is a devastating result of dystrophin deficiency in DMD. 
Respiratory muscle function is compromised and boys with DMD have reduced 
ventilatory capacity, which declines with age (De Bruin et al., 1997; Khirani et al., 
2014). Diaphragm muscle weakness and likely impaired performance of the upper 
airway musculature translates to sleep disordered breathing including obstructive 
sleep apnoea and hypoventilation in many boys with DMD (Smith et al., 1989; 
Barbé et al., 1994). Cardiorespiratory failure is the leading cause of death in DMD, 
thus treatment strategies aimed at improving and prolonging adequate cardio-
respiratory function are necessary.  
 
Diaphragm muscle weakness is well described in mdx mice from a young age 
(Coirault et al., 2003). In the current study, diaphragm muscle from mdx + saline 
mice showed significantly reduced twitch force and increased contraction time 
compared with WT + saline. Similarly, peak tetanic force at 100Hz and maximum 
work- and power-generating capacity were significantly reduced for mdx + saline 
diaphragm compared with WT + saline. These data confirm previous findings 
illustrating mechanical dysfunction in the mdx diaphragm due to the absence of 
dystrophin (Stedman et al., 1991). We have previously reported depressed 
diaphragm force-generating capacity in mdx diaphragm at stimulation frequencies 
relevant to eupnoeic (basal) breathing, which has the capacity to limit tidal volume 
generation (Burns et al., 2017c). Although the principal inspiratory muscle is 
compromised in DMD and mdx mice, few studies have comprehensively examined 
respiratory function and ventilatory capacity in mdx mice, both important measures 
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to consider when examining the effects of novel therapeutic strategies in animal 
models of myopathic disease. 
 
In the current study, we assessed breathing in conscious unrestrained mice using 
whole-body plethysmography. Minute ventilation during normoxia was significantly 
reduced in mdx + saline compared with WT + saline mice, consistent with our 
recent reports (Burns et al., 2015; Burns et al., 2017c). The observed reductions in 
ventilation were the result of significant reductions in tidal volume in mdx mice, 
likely due to mechanical dysfunction and reduced force-generating capacity of the 
diaphragm muscle compared with WT. Although minute ventilation was lower in 
mdx mice, there was no difference in whole-body metabolism (as measured by 
VCO2) between age-matched saline-treated WT and mdx mice, consistent with 
recent data (Burns et al., 2017c). Consequentially, VE/VCO2 was lower in mdx 
compared with WT (24 versus 18; WT versus mdx), although this was not 
statistically significant by post hoc analysis. Despite evidence of impaired normoxic 
ventilation in the mdx model, there is no apparent evidence of inherent respiratory 
instability based on the analysis of variability of inspiratory and expiratory durations 
in young mdx mice.  
 
Ventilatory capacity was significantly blunted in mdx mice evidenced by decreased 
minute ventilation during hypoxic gas exposure. Drug co-treatment significantly 
increased hypoxic ventilation, consistent with recovery of the mechanical deficits in 
mdx mice. Of note, the acute ventilatory response to hypoxia, measured as the 
absolute change in ventilation from baseline was blunted in mdx mice, a finding 
consistent with mdx carotid body hypoactivity (Burns et al., 2017c). Drug co-
treatment did not reverse this effect suggesting that the sensory deficit is unrelated 
to IL-6-dependent and/or CRFR2-dependent signalling in the hypoxic chemoafferent 
pathway of mdx mice. VE/VCO2 was elevated during hypoxic exposure revealing a 
hypoxic hyperventilation in WT and mdx mice. Drug co-treatment significantly 
increased VE/VCO2 during hypoxia in WT, but not in mdx mice. 
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Murine diaphragm muscle expresses MyHC type I, IIa, IIx and IIb fibres (Sieck et al., 
2012). Diaphragm muscle weakness in mdx + saline diaphragm was associated with 
an alteration in the distribution of MyHC isoform composition, with mdx + saline 
diaphragm expressing fewer MyHC IIx fibres and more MyHC IIa fibres compared 
with WT + saline. MyHC type II fibres display an incremental increase in force 
production from IIa to IIx to IIb, respectively. Thus, a shift in MyHC composition 
from IIx to IIa in mdx diaphragm muscle fibres likely has functional implications, 
consistent with mdx diaphragm exhibiting lower force- and power-generating 
capacity ex vivo. Similar alterations in MyHC distribution have been reported in 
pharyngeal dilator muscles from mdx mice (Burns et al., 2017b) and are likely due 
to ongoing muscle fibre damage and repair processes preventing muscle fibre 
MyHC isoform maturation during muscle development. 
 
Mechanical dysfunction of striated muscle is coupled with extensive inflammation 
of the respiratory and non-respiratory musculature in DMD (Messina et al., 2011) 
and mdx mice (Barros Maranhão et al., 2015). Inflammation occurs due to muscle 
fibre damage as a result of dystrophin deficiency. Inflammatory cells are recruited 
to the damaged muscle to repair injured fibres. There is heightened expression of 
inflammatory cytokines in plasma and muscle biopsies from DMD boys (De 
Pasquale et al., 2012; Cruz-Guzmán et al., 2015) and mdx mice (Rufo et al., 2011). 
Chronic immune activation and attendant inflammation, observed in DMD, can 
have detrimental effects on normal physiological function. During the years of 
ambulation, plasma cytokine levels appear to be near maximal in DMD boys and 
begin to decline thereafter when patients become non-ambulatory (Cruz-Guzmán 
et al., 2015), perhaps due to the disuse of the lower limb musculature. IL-6 is one of 
many cytokines reported to be elevated in DMD (Rufo et al., 2011; Cruz-Guzmán et 
al., 2015; Pelosi et al., 2015a) and is of particular relevance due to its role as a 
myokine and muscle signalling molecule. Plasma IL-6 is known to increase in 
response to intense exercise and in pathological diseases such as Crohn’s disease 
and rheumatoid arthritis (Maggio et al., 2006). IL-6 binds to the IL-6R which signals 
via the Janus kinase/signal transducer activator of transcription (JAK/STAT) 
pathway. IL-6 can have divergent actions on skeletal muscle signalling such as 
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promoting both muscle growth and wasting. These opposing effects are consistent 
with the pro- and anti-inflammatory actions of IL-6. In some cases, IL-6 has been 
linked with hypertrophic muscle growth and paradoxically linked to muscle atrophy 
and wasting (Muñoz-Cánoves et al., 2013). These conflicting actions may relate to 
different concentration levels of IL-6 and acute versus persistent activation of IL-6 
signalling pathways.  
 
The pro-inflammatory cytokines IL-1β, IL-6, KC/GRO and TNF-α were significantly 
increased in mdx + saline diaphragm muscle compared with WT + saline, indicating 
a pro-inflammatory signature, consistent with previous reports in mdx muscle 
(Porter et al., 2002). This elevated expression of inflammatory cytokines was 
associated with a significant increase in the percent infiltration of putative 
inflammatory cells in mdx + saline diaphragm compared with WT + saline. The 
number of muscle fibres expressing central nuclei in mdx + saline diaphragm was 
also elevated compared with WT + saline, indicating muscle fibre repair and 
regeneration. Blockade of IL-6 signalling in mdx mice has been shown to improve 
the capacity for treadmill exercise (Pelosi et al., 2015a), to normalise function of 
gastrointestinal smooth muscle (Manning et al., 2016), and exert modest effects on 
improving diaphragm force (Manning et al., 2017). Conversely, overexpression of IL-
6 in mdx mice promotes muscle necrosis and satellite cell exhaustion (Pelosi et al., 
2015b). Blockade of IL-6 signalling in dystrophin-/utrophin-deficient mice 
ameliorated skeletal muscle damage and promoted muscle regeneration in the 
limb, but no beneficial effects were observed for cardiac and respiratory muscle 
(Wada et al., 2017). 
 
Muscle wasting and proteolysis are pathophysiological features of myopathies such 
as DMD. Corticosteroids have been the treatment of choice for many years in DMD, 
notwithstanding their unwanted side effects (Ricotti et al., 2013). Therapies aimed 
at activating anabolic signalling in functional muscle fibres may act to improve 
muscle force in DMD and mdx mice. The urocortins which bind to the CRFRs are 
known to modulate muscle mass and anabolic signalling pathways in skeletal 
muscle (Hinkle et al., 2003a). Upon activation of CRFR2, there is an increase in 
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adenylyl cyclase and cAMP formation (Reutenauer-Patte et al., 2012). Skeletal 
muscle is known to express CRFR2, and activation of CRFR2 decreased nerve 
damage and corticosteroid- and disuse-induced skeletal muscle mass and function 
loss in mice, and increased muscle mass in non-atrophying muscle (Hinkle et al., 
2003b). The CRFR2 agonist, Ucn2, has been shown to improve diaphragm muscle 
force (Hinkle et al., 2007; Manning et al., 2017), increase muscle mass (Hall et al., 
2007) and decrease muscle damage (Reutenauer-Patte et al., 2012) in mdx mice.  
 
In the current study, we investigated the effects of IL-6R blockade (xIL-6R) and 
CRFR2 agonism (Ucn2) on ventilation and metabolism and diaphragm muscle 
structure, function and cytokine concentration. Blocking the action of IL-6 was 
performed using a neutralizing IL-6R monoclonal antibody (Okazaki et al., 2002). 
Recent findings from our group have shown this treatment strategy to improve 
diaphragm force-generating capacity (Manning et al., 2017) and to restore 
pharyngeal dilator muscle force in mdx mice (Burns et al., 2017b). In the latter 
study, the observed improvements in mdx pharyngeal dilator muscle function was 
associated with significantly reduced central nucleation of sternohyoid muscle from 
mdx mice following drug co-treatment (Burns et al., 2017a). 
 
Co-treatment of xIL-6R and Ucn2 significantly increased diaphragm specific force in 
mdx + treatment compared with saline-treated mdx (9 versus 16 N/cm2; mdx + 
saline versus mdx + treatment). For isotonic load relationships, drug co-treatment 
significantly increased diaphragm work, power, shortening and shortening velocity 
for mdx diaphragm. These findings confirm previous data describing improved 
muscle force following administration of xIL-6R and Ucn2 in mdx diaphragm 
(Manning et al., 2017) and upper airway muscle (Burns et al., 2017b). Of interest, 
enhanced force-generating capacity in WT diaphragm was not observed following 
co-treatment with xIL-6R and Ucn2.  
 
Diaphragm muscle MyHC composition was significantly altered following xIL-6R and 
Ucn2 co-treatment in mdx mice. Drug co-treatment significantly reduced MyHC 
type IIa and increased MyHC type IIx fibre distribution in mdx diaphragm compared 
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with saline treated mdx mice. Improved mdx diaphragm force-generating capacity 
following drug co-treatment may be due to preservation of MyHC type IIx fibres. 
Drug co-treatment in WT mice had no effect on diaphragm fibre type distribution 
compared with saline-treated WT, consistent with no change in force-generating 
capacity in WT diaphragm. Progression of mdx diaphragm muscle fibres from MyHC 
IIa to IIx may be due, at least in part, to a suppression of muscle fibre damage and 
thus maturation of muscle fibres. The findings are consistent with previous 
observations in sternohyoid muscle from mdx mice following the same therapeutic 
intervention (Burns et al., 2017b). In addition to preservation of MyHC fibre type 
distribution, drug co-treatment promoted hypertrophy (increased CSA) of MyHC 
type I and IIx fibres in mdx diaphragm which likely translates to functional 
improvements, since muscle force-generating capacity is proportional to fibre 
cross-sectional area. The observed hypertrophy of MyHC type I and IIx fibres may 
be a result of altered anabolic signaling mediated by Ucn2 in mdx mice. Drug co-
treatment had no effect on muscle fibre central nucleation indicating there were no 
apparent improvements in muscle fibre damage and repair processes. Moreover, 
collagen content was also unaffected by drug co-treatment. These data suggest 
that functional improvements observed in the mdx diaphragm are not as a result of 
improvements in muscle damage and fibrosis.  
 
Enhanced diaphragm functional capacity and altered MyHC isoform composition 
following drug co-treatment in mdx mice, was associated with significantly 
increased tidal volume and minute ventilation during normoxia compared with 
saline-treated mdx. Both tidal volume and minute ventilation, which were 
decreased in mdx + saline compared to WT + saline, were restored to WT + saline 
values in mdx mice following co-treatment. Indices of metabolism, VO2 and VCO2 
were significantly reduced by drug co-treatment in WT and mdx compared with 
saline controls. The ventilatory equivalents for O2 and CO2 were both significantly 
increased by drug treatment in WT and mdx compared with saline-treated controls. 
Drug co-treatment had no effect on the variability of breathing in WT and mdx mice 
showing no overt effects of xIL-6R and Ucn2 on respiratory stability. The 
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mechanism of the hypometabolic effect of drug co-treatment is unclear and 
warrants attention in future studies. 
 
Interestingly, drug co-treatment significantly decreased IL-1β concentration in mdx 
diaphragm, with a concomitant increase in the concentration of the anti-
inflammatory cytokine, IL-10. These data suggest modest improvements in the 
pro/anti-inflammatory cytokine balance in mdx diaphragm. There was no significant 
effect of drug co-treatment on the relative area of the putative inflammatory cell 
infiltration. Blockade of IL-6 signalling with xIL-6R did not significantly affect IL-6 
concentration in mdx diaphragm muscle. Drug co-treatment in WT and mdx mice 
had no effect on body mass, indices of somatic growth and muscle and organ mass, 
demonstrating no apparent adverse effects of the drug co-treatment at their 
respective doses for the two-week duration of the current intervention. 
 
In summary, mdx mice have impaired ventilation, diaphragm muscle weakness and 
MyHC fibre-type immaturity at an early age. Co-treatment with xIL-6R antibodies 
and Ucn2 recovered mdx diaphragm force-generating capacity. Drug co-treatment 
preserved the MyHC fibre complement in mdx diaphragm and also promoted 
hypertrophy of MyHC type I and IIx fibres in mdx but not WT diaphragm. 
Preservation and hypertrophy of mdx diaphragm muscle MyHC type IIx fibres may 
be adequate for functional improvements, especially since drug co-treatment did 
not influence measures of necrosis, fibrosis and immune cell infiltration. Normoxic 
ventilation was recovered in mdx drug-treated mice, mediated by restored tidal 
volume. It appears that improvements in diaphragm force-generating capacity and 
MyHC composition has the capacity to improve ventilation in young mdx mice.  
 
Limitations 
Peak diaphragm force-generating capacity was determined in ex vivo preparations 
in this study, and ventilatory capacity in mdx mice was assessed by whole-body 
plethysmography in conscious animals, which provides an estimate of tidal volume 
with known limitations (Mortola & Frappell, 1998; Burns et al., 2017c). We 
employed hypoxic gas challenges to increase ventilation, but this provides only a 
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modest ventilatory challenge, especially in mice, which adopt a hypometabolic 
strategy in response to hypoxia, such that the increase in minute ventilation is 
relatively small. We assessed hypercapnic breathing, which revealed a clear deficit 
in mdx compared with WT, but again the activation of the diaphragm required to 
increase ventilation in response to chemostimulation is modest. As such, we did not 
assess the full range of ventilatory capacity (and deficit) in mdx mice and the 
efficacy of drug co-treatment in restoring physiological function associated with 
high levels of diaphragm and accessory muscle activation. Assessment of 
respiratory muscle function in situ, such as measurements of transdiaphragmatic 
pressure in mice across a range of ventilatory and non-ventilatory behaviours 
(Greising et al., 2013) would be useful in characterizing the magnitude of the 
mechanical deficit in mdx mice at 8 weeks of age, and the efficacy of drug co-
treatment in the preservation of ventilatory capacity.  
 
We acknowledge that our intervention strategy was relatively short-lived and drug 
co-treatment for longer durations are necessary to fully explore the capacity for 
this novel intervention to influence muscle quality and strength, including the 
potential for deleterious outcomes or side effects with long-term drug treatment. 
Moreover, whereas the restoration of diaphragm strength and ventilation was 
impressive in our study, we concede that drug intervention did not affect muscle 
necrosis and fibrosis, and did not reduce the area of immune cell infiltrate in muscle 
tissue, although the explicit cellular nature of the infiltrate was not explored in this 
study. As such, the improvements in muscle function appear to relate to actions on 
healthy fibres, which has implications in the context of translation of this 
interventional strategy to DMD patients.  
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Abstract 
Duchenne muscular dystrophy (DMD) is a genetic disease characterised by a 
deficiency in the structural protein dystrophin. Skeletal muscle weakness is a major 
pathological feature of the disease, which extends to the striated muscles of 
breathing with adverse consequences for respiratory function. Disordered 
breathing is observed in DMD boys, particularly during sleep. We have previously 
described deficits within the respiratory control network of a murine model of 
DMD, the mdx mouse. Extensive muscle weakness and remodelling occurs in the 
diaphragm (respiratory pump) and the sternohyoid muscle (representative 
pharyngeal dilator) in young (8 week old) mdx mice. Herein, we review recent work 
by our group exploring a combined anti-inflammatory and anti-stress interventional 
strategy aimed at alleviating respiratory deficits in the mdx mouse. Treatment 
consisted of a combination of a neutralizing interleukin-6-receptor antibody and 
urocortin-2, a corticotrophin releasing factor receptor 2 agonist. We describe 
encouraging findings from our studies showing impressive restoration of muscle 
function and breathing capacity in mdx mice, of potential translational value for 
human dystrophinopathies. Our work highlights the potential use of combinational 
treatment strategies in the continued search for interventional treatments in DMD.  
 
Keywords: Breathing; Duchenne muscular dystrophy; diaphragm; upper airway; 
interleukin-6; mdx; corticotrophin releasing factor; urocortin. 
 
 
Abbreviations: CCR2, C-C chemokine receptor type 2; CRF, corticotrophin releasing 
factor; CRFR, CRF receptor; IP-10, interferon J-induced protein; MIP-2, macrophage 
inflammatory protein 2; MIP-3D, macrophage inflammatory protein 3D MyHC, 
myosin heavy chain; IL, interleukin; TNF-D, tumour necrosis factor-D; Ucn2, 
urocortin 2; VCO2, carbon dioxide production; VE/VCO2, ventilatory equivalent for 
carbon dioxide;   
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7.1 Respiratory dysfunction in Duchenne muscular dystrophy (DMD) 
Respiratory failure is a leading cause of death in Duchenne muscular dystrophy 
(DMD), a neuromuscular disease that occurs in males (Bye et al., 1990; Yiu & 
Kornberg, 2008). DMD is caused by defects in the dystrophin gene and subsequent 
absence of dystrophin protein. Dystrophin is found in muscle, where it anchors the 
actin cytoskeleton to the sarcolemma and forms part of the dystrophin associated 
protein complex (Ervasti, 2007). Dystrophin deficiency has major consequences for 
the physiological function of muscle. Clinically, patients present with delayed motor 
milestones in the early years of life. As patients grow, they begin to experience 
weakness of the skeletal muscles of the upper and lower limbs, which eventually 
results in reduced ambulation and the requirement for wheelchair assistance (Yiu & 
Kornberg, 2008). Muscle weakness extends to the striated muscles of breathing, 
including the diaphragm muscle, which has major consequences for respiratory 
function (Baydur et al., 1990). Lung volume assessments in DMD boys indicate a 
progressive decline in forced vital capacity with increasing age (Phillips et al., 2001; 
Mayer et al., 2015). Examination of the diaphragm muscle in patients using trans-
diaphragmatic pressure measurements, revealed values lower than predicted in 
DMD for maximal inspiration during sniffing behaviours (Khirani et al., 2014).  
 
Sleep disordered breathing is commonly reported in DMD (Cerveri et al., 1993; 
LoMauro et al., 2017). Sleep studies indicate obstructive sleep apnoea is a 
prominent feature of DMD during the teenage years (Khan & Heckmatt, 1994), 
which suggests inadequate upper airway muscle function during sleep. Muscle 
weakness in DMD extends to the skeletal muscles comprising the upper airway, 
with implications for the control of airway calibre. Diaphragm muscle weakness 
translates to hypoventilation during sleep in patients (Smith et al., 1989). Both 
apnoea and hypoventilation have implications for the maintenance of blood 
oxygenation and the retention of carbon dioxide in patients, both factors which can 
impact on muscle health, compounding the inherent muscle deficits at play in DMD.  
 
Muscle fibre remodelling occurs in dystrophic muscle, wherein fibres display central 
nucleation due to ongoing damage and repair processes; immune cell infiltration is 
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widespread. There is an increased expression of chemokines in DMD myofibres (De 
Paepe et al., 2012), which recruit immune cells to repair damaged myofibres (De 
Paepe & De Bleecker, 2013). Cytokine concentrations are elevated in muscle 
biopsies and plasma samples from DMD patients (Porreca et al., 1999; Saito et al., 
2000; Messina et al., 2011; De Pasquale et al., 2012; Cruz-Guzmán et al., 2015). Of 
interest to our research, interleukin-6 is significantly elevated in serum and muscle 
samples from DMD patients (Messina et al., 2011; Rufo et al., 2011; Cruz-Guzmán 
et al., 2015; Pelosi et al., 2015a). In addition to inflammation, attendant oxidative 
stress presents in DMD, with an elevated redox signature in dystrophic muscle 
(Haycock et al., 1996; Rodriguez & Tarnopolsky, 2003; Nakae et al., 2004; Abdel et 
al., 2007; Petrillo et al., 2017). There is no cure for DMD. The current treatment 
strategy in DMD involves the use of glucocorticoids, notwithstanding their 
undesirable side effects.  
 
7.2 Respiratory muscle remodelling in the dystrophin-deficient mdx mouse 
The mdx mouse is a dystrophin-deficient model of DMD (Bulfield et al., 1984). 
Dystrophin is absent from skeletal, cardiac and smooth muscle in the mdx mouse 
and functional deficits present from a young age (Coirault et al., 2003; Quinlan et 
al., 2004; Manning et al., 2016). Compared to the human condition, the mdx mouse 
presents with modest limb muscle pathology, owing to considerable compensation 
and recovery of force. In comparison, the diaphragm muscle exhibits loss of 
contractile force from a young age, which persists throughout life (Stedman et al., 
1991; Petrof et al., 1993; Coirault et al., 1999; Coirault et al., 2003; Burns et al., 
2017a; Burns et al., 2017c). Moreover, extensive muscle fibre remodelling and 
inflammation is apparent in the diaphragm of mdx mice (Stedman et al., 1991; 
Petrof et al., 1993; Coirault et al., 1999; Coirault et al., 2002; Coirault et al., 2003; 
Burns et al., 2017c).  
 
Diaphragm muscle comprises a mixed myosin heavy chain (MyHC) isoform 
composition in  mice, with the expression of type I, IIa, IIx and IIb fibres (Sieck et al., 
2012). Muscle fibres show an incremental increase in force from MyHC type I to IIa 
to IIx to IIb, sequentially, and a concomitant decrease in fatigue resistance (Polla et 
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al., 2004; Schiaffino & Reggiani, 2011). There is altered expression of MyHC isoform 
composition in the dystrophic diaphragm, characterised by a significant reduction in 
the number of fibres expressing MyHC type IIx and an increase in type IIa (Petrof et 
al., 1993; Coirault et al., 1999; Coirault et al., 2002), highlighting MyHC fibre 
immaturity. We have reported central nucleation in 16-20% of muscle fibres in mdx 
diaphragm, compared with <1% in wild-type (Burns et al., 2017c). Muscle fibre 
central nucleation is a common hallmark of muscle fibre damage. Repeated cycles 
of muscle fibre degeneration and regeneration in dystrophic muscle, ultimately 
culminates in muscle fibre necrosis. Necrotic muscle fibres are replaced by 
connective tissue and adipocytes, resulting in a further decline in muscle force. 
Collagen (type I) accumulation in dystrophic muscle begins at a young age and is 
consistent with muscle fibre damage and resultant necrosis; of note, diaphragm 
contractile dysfunction precedes collagen deposition (Coirault et al., 2003). The 
frequency distribution of muscle fibres is left-shifted for mdx diaphragm, with mdx 
expressing smaller fibres compared with wild-type diaphragm, and an increased 
number of fibres (Burns et al., 2017c). Dystrophic muscle is further characterised by 
an increase in the variability of muscle fibre size. Such remodelling is indicative of 
new regenerating muscle fibres and most likely branched fibres.  
 
An inflammatory signature similar to DMD is revealed in mdx mice, evidenced by 
enhanced muscle and serum cytokines and chemokines (Porter et al., 2002; Nelson 
et al., 2011; Rufo et al., 2011; Pelosi et al., 2015a). Diaphragm from mdx mice 
displays a pro-inflammatory signature, with elevated concentrations of interleukin-
1E (IL-1E), IL-6, TNFD and KC/GRO (Kumar & Boriek, 2003; Pelosi et al., 2015a). 
Moreover, the C-C chemokine receptor type 2 (CCR2) and its ligands are elevated in 
mdx diaphragm (Demoule et al., 2005; Mojumdar et al., 2014).  
 
In conjunction with the diaphragm, other accessory muscles are important for the 
homeostatic regulation of breathing, the maintenance of arterial blood gases and 
pH. The upper airway comprises up to 20 skeletal muscles which strive co-
operatively to maintain airway patency. Despite the occurrence of sleep disordered 
breathing and obstructive apnoeas in DMD, there is a dearth of information 
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pertaining to airway physiology in the dystrophinopathies and pre-clinical models of 
disease. The sternohyoid muscle is a representative pharyngeal dilator involved in 
the maintenance of airway calibre. The sternohyoid muscles attach the hyoid bone 
to the sternum and are principally composed of MyHC type II muscle fibres in 
rodents (Skelly et al., 2011; Skelly et al., 2012; Burns et al., 2017b). Similar to 
diaphragm, sternohyoid muscle from mdx mice express fibres containing 
centralised myonuclei (~25% of fibres) (Burns et al., 2017b). Examination of the 
MyHC isoform composition indicates a significant reduction in type IIb fibres with 
an accompanying increase in type IIa (Attal et al., 2000; Burns et al., 2017b).  
 
Chemoattractant agents including, macrophage inflammatory protein (MIP-2), 
interferon-J induced protein (IP-10) and macrophage inflammatory protein-3 (MIP-
3D), are increased in mdx sternohyoid (Burns et al., 2017b). These molecules have a 
cellular role in the initiation of inflammatory cascades in muscle. We have observed 
a modest increase in collagen expression in mdx sternohyoid compared with wild-
type and an increase in the relative area of putative cell infiltrates. Activation of 
inflammatory cascades in muscle, have implications for normal physiological 
function. In addition to the recruitment of inflammatory mediators to muscle, 
muscle itself is considered an endocrine organ and has been documented to release 
cytokines under physiological stress (Welc & Clanton, 2013).  
 
7.3 Respiratory muscle weakness in the mdx mouse 
Studies of sternohyoid muscle function ex vivo reveal contractile deficits for mdx 
mice at eight weeks (Burns & O'Halloran, 2016; Burns et al., 2017c) and six months 
(Attal et al., 2000) of age. Deficits include reduced twitch and tetanic contractile 
force (Burns & O'Halloran, 2016; Burns et al., 2017b). Twitch contractile kinetics 
were altered for mdx sternohyoid muscle, evidenced by a prolonged contraction 
time and half-relaxation time compared with wild-type, suggesting altered calcium 
release and re-uptake (Burns & O'Halloran, 2016; Burns et al., 2017b). Work and 
power as a function of load bearing were significantly reduced for mdx sternohyoid 
compared with wild-type (Attal et al., 2000; Burns & O'Halloran, 2016; Burns et al., 
2017b). Shortening velocity was reduced over the load continuum, indicating the 
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poor mechanical efficiency of dystrophic muscle (Attal et al., 2000; Burns et al., 
2017b). Such pronounced upper airway muscle dysfunction in mdx, has the 
potential to create a perfect storm for ventilatory control and airway defence 
mechanisms.  
 
The functional consequences of dystrophin deficiency on mdx diaphragm include 
dramatic force loss (Petrof et al., 1993; Coirault et al., 1999; Coirault et al., 2003; 
Burns et al., 2017a; Burns et al., 2017c). Twitch contraction time was elevated 
suggesting slowed calcium release from the sarcoplasmic reticulum for mdx muscle 
preparations; half-relaxation time remained unchanged. Work, power, shortening 
and velocity of shortening were significantly reduced across the load continuum for 
mdx diaphragm compared with wild-type. Diaphragm force-frequency relationships 
show profound muscle weakness in the frequency range of 40-160 Hz for mdx 
diaphragm (Burns et al., 2017c), indicating deficits in the range implicated in 
ventilatory and non-ventilatory (airway protection) behaviours.  
 
7.4 Ventilatory deficits in mdx mice 
Mechanical dysfunction in mdx diaphragm places limits on ventilation (Mosqueira 
et al., 2013; Burns et al., 2015; Burns et al., 2017c). We have recently reported 
reduced minute ventilation in 8-week-old mdx mice, owing to substantial 
reductions in tidal volume during normoxia as measured by whole-body 
plethysmography in conscious unanaesthetised mice (Burns et al., 2017c). It is likely 
that compromised diaphragm muscle performance in mdx mice contributes to 
observed reductions in tidal volume, since diaphragm muscle weakness is present 
in the eupnoeic range of breathing (20-50Hz). Of note, VE/VCO2 (ventilation as a 
function of CO2 production) was significantly reduced in mdx mice confirming 
hypoventilation (Burns et al., 2017c) during basal breathing.  
 
In subsequent studies (chapter 6), we confirmed that mdx mice had significantly 
reduced tidal volume compared with wild-type, contributing to a pronounced 
reduction in minute ventilation for mdx mice, consistent with our prior report 
(Burns et al., 2017c). Ventilatory challenge with hypoxia, indicated decreased 
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minute ventilation across all levels of inspired oxygen (Burns et al., 2017c). 
Ventilation in response to hypercapnic challenge revealed a capacity for mdx mice 
to further increase ventilation despite hypoventilation during normoxia (Burns et 
al., 2017c). Curiously, as revealed in chapter 4, mdx mice retain a remarkable 
capacity to increase ventilation during maximum chemoactivation during 
hypercapnic hypoxia challenge, and during augmented breaths, despite profound 
diaphragm muscle dysfunction. The observations strongly suggest that accessory 
muscle recruitment supports the preservation of ventilatory capacity in mdx mice, 
at least in early adult life. This in turn suggests that the observation of resting 
hypoventilation in mdx mice is at least partly determined by sensory deficit in mdx 
mice (hypoactivity of the carotid body). 
 
7.5 Combinational pharmacotherapy in DMD 
Inflammation 
Evidence is mounting in support of the role of inflammation in promoting muscle 
damage in dystrophic muscle (Deconinck & Dan, 2007; De Paepe et al., 2012; De 
Paepe & De Bleecker, 2013). Blockade of global regulators of inflammation such as 
NFNB and TNFD in mdx mice has alleviated muscle functional deficits and improved 
muscle structural integrity (Pan et al., 2008; Enwere et al., 2013; Ermolova et al., 
2014). In addition to elevated cytokine expression in DMD, mdx mice also have 
elevated levels in plasma and muscle, indicating a pro-inflammatory state. 
Monocyte chemoattractant protein-1 (MCP-1) is increased in the plasma of mdx 
mice (Nelson et al., 2011). Characterisation of cytokines and chemokines in DMD 
has led to interventional studies aimed at reducing chemokine and cytokine 
signalling in mdx mice to test the efficacy of interventions in improving muscle 
physiology. 
 
Blockade of IL-6 signalling in vivo with a neutralizing interleukin-receptor (xIL-6R) 
antibody normalised gastrointestinal morphology and function in mdx mice 
(Manning et al., 2016). Furthermore, xIL-6R reduced NFNB and TNFD in mdx 
diaphragm and improved treadmill exercise (Pelosi et al., 2015a). Conversely, an 
overexpression of IL-6 in mdx had detrimental effects on diaphragm muscle quality 
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and exacerbated the dystrophic muscle phenotype (Pelosi et al., 2015b; Pelosi et 
al., 2017). Inhibition of the cytokine transforming growth factor beta (TGFE) in mdx 
mice by use of a neutralising antibody to all three isoforms of TGFE, led to 
improvements in respiratory function (increased minute ventilation) (Nelson et al., 
2011). Ablation of the anti-inflammatory cytokine IL-10 in mdx mice, led to 
increased muscle damage (Villalta et al., 2011) and promoted cardiovascular 
(reduced % fractional shortening and % ejection fraction) and respiratory (reduced 
tidal volume) dysfunction (Nitahara-Kasahara et al., 2014). These studies suggest a 
role for pro-inflammatory cytokines in mediating muscle and respiratory 
dysfunction in mdx mice. 
 
Stress and anabolic signalling 
The urocortins are a group of proteins belonging to the corticotrophin releasing 
factor (CRF) family. Urocortin-2 (Ucn2) is an endogenous peptide highly selective 
for the CRF 2 receptor. Skeletal muscle is known to express CRF receptors and Ucn2 
has been shown to promote anabolic signalling in muscle, modulating muscle mass 
(Hinkle et al., 2003; Hinkle et al., 2004; Hall et al., 2007). Urocortin treatment in 
mdx mice has been shown to improve diaphragm muscle force, decreasing fibrosis 
and immune cell infiltration (Hinkle et al., 2007; Reutenauer-Patte et al., 2012; 
Manning et al., 2017). 
 
To date, little work has examined a combinational approach to anti-inflammatory 
interventions in mdx mice. We hypothesised that inflammatory and stress related 
factors are implicated in respiratory system deficits in mdx mice. Previous work by 
our research group reported that blockade of IL-6 signalling and Ucn2 treatment in 
mdx mice improved diaphragm muscle force (Manning et al., 2017). In the current 
studies, wild-type and mdx mice received a sub-cutaneous injection of a 
combination of xIL-6R (MR16-1 (Okazaki et al., 2002)) and Ucn2 or saline (0.9% 
w/v). The treatment intervention began at six weeks of age and studies were 
performed following a two week treatment period (Burns et al., 2017b). We 
extended studies by Manning et al. (2007) to breathing and metabolism 
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measurements, diaphragm structure and cytokine concentrations and upper airway 
muscle structure and function.  
 
7.6 Combinational pharmacotherapy in mdx mice: Ventilation 
Ventilation and metabolism was assessed in conscious wild-type and mdx mice 
following xIL-6R and Ucn2 co-treatment, or saline, using whole-body 
plethysmography. Drug co-treatment alleviated tidal volume deficits in mdx mice, 
restoring minute ventilation to wild-type levels. Tidal volume changes were 
restricted to the mdx + vehicle group. Carbon dioxide production (VCO2)  was 
significantly reduced following treatment for both wild-type and mdx mice. The net 
effect of changes in VE and VCO2, was a significant recovery of VE/VCO2 for mdx. A 
similar increase in VE/VCO2 was observed for wild-type mice, due to an increase in 
respiratory frequency and VCO2. These data illustrate a restoration of ventilation 
during normoxia in mdx mice following treatment. Challenging ventilation with 
hypoxia highlighted enhanced ventilation in mdx mice following treatment 
compared with mdx + vehicle, indicating an improved capacity for ventilation. 
Improvements in respiratory function and ventilatory capacity have physiological 
implications for the control of breathing, blood-gas homeostasis and the 
maintenance of pH. 
 
7.7 Combinational pharmacotherapy in mdx mice: Respiratory muscle function 
Therapeutic intervention of combined xIL-6R and Ucn2 for two weeks in mdx mice 
remarkably restored sternohyoid muscle functional deficits (Burns et al., 2017b). 
Isometric force restoration was achieved for twitch and tetanic contractions. 
Mechanical work and power and shortening velocity were considerably potentiated 
for mdx sternohyoid muscle as a function of load bearing. In addition to restoring 
sternohyoid muscle force in mdx, co-treatment had a positive inotropic effect on 
wild-type sternohyoid muscle with significantly enhanced isometric tetanic force 
and mechanical work and power. Such improvements would have benefit for the 
control of upper airway patency and airway behaviours in mdx mice. 
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Neutralisation of IL-6R in mdx mice provided modest improvements in diaphragm 
muscle functional capacity (Manning et al., 2017). Stimulation of CRF-R2 provided a 
further increase in diaphragm force, with a combined treatment of xIL-6R and Ucn2 
revealing the greatest improvement in force and mechanical work (Manning et al., 
2017).  In our subsequent study we revealed that drug co-treatment improved 
maximum force, work and power generation in mdx mice. Moreover, work, power, 
shortening and velocity of shortening were all significantly increased for mdx 
diaphragm following a combined treatment of xIL-6R and Ucn2. Unlike observations 
in sternohyoid muscle, no potentiation in diaphragm muscle force-generating 
capacity was observed following drug co-treatment in wild-type mice. Conversely, 
modest increases in wild-type diaphragm work and power production against 
varied load were noted. Such improvements in diaphragm functional capacity are 
likely contributing to tidal volume restoration and enhanced ventilatory capacity in 
mdx mice following treatment. These findings are of clinical relevance and are of 
translational value in DMD, where respiratory deficits are prominent. 
 
7.8 Combinational pharmacotherapy in mdx mice: Respiratory muscle form 
Sternohyoid muscle fibre central nucleation was slightly ameliorated following 
combinational treatment of xIL-6R and Ucn2. Force restoration in mdx sternohyoid 
muscle was associated with complete restoration of the MyHC isoform 
complement. The proportion of MyHC IIx was significantly reduced and MyHC IIb 
significantly increased in mdx sternohyoid following treatment. MyHC isoform 
composition in wild-type muscle was unaltered following treatment. Combinational 
therapy had no effect on collagen content and areal density of putative cell 
infiltrates in mdx sternohyoid. Surprisingly, treatment increased the relative 
concentrations of the chemokines MIP-2, IP-10 and MIP-3a. For wild-type 
sternohyoid muscle, no histological differences were evidenced following 
treatment. We observed hypertrophy (increased cross-sectional area) of MyHC IIb 
fibres for wild-type muscle following treatment, which may be responsible for the 
force potentiation in this group.  
 
  279 
Preservation of MyHC isoform composition also occurred in mdx diaphragm 
following combinational therapy. There was a significant reduction in the 
distribution of type IIa fibres and a remarkable increase in the distribution of type 
IIx fibres. Hypertrophy of MyHC I and IIx fibres occurred in mdx diaphragm 
following treatment. These adjustments in MyHC composition and cross-sectional 
area likely mediate the improvements in diaphragm force-generating capacity in 
mdx following co-treatment. Wild-type MyHC fibre complement was unchanged 
following treatment. Histologically, there were no improvements in muscle fibre 
central nucleation, relative area of putative cell infiltrates and collagen deposition. 
The pro-inflammatory cytokine IL-1E was reduced and the anti-inflammatory 
cytokine IL-10 was elevated in mdx diaphragm following co-treatment, indicating an 
improvement in the balance of pro- and anti-inflammatory cytokines. 
 
Collectively, these data indicate that restoration of MyHC fibre complement in 
dystrophic sternohyoid and diaphragm muscle is of major benefit to muscle 
functional capacity. Similarly, hypertrophy of functional fibres may also be 
contributing to increased force generation. Therapies which support MyHC fibre 
maturation in dystrophic muscle may have therapeutic value in mdx mice and 
potentially DMD. 
 
7.9 Combinational pharmacotherapy in mdx mice: Knowledge gaps 
We acknowledge that our intervention was of short duration (two weeks) and at a 
young age in a progressive disease. Future studies should examine the safety and 
efficacy of combined xIL-6R and Ucn2 over prolonged treatment periods. Early 
intervention may be key in protecting dystrophic muscle from functional deficits, 
which in turn have implications for respiratory control. Potential side effects or 
adverse outcomes as a result of treatment over prolonged periods should be 
considered. In the current studies, we measured somatic growth, organ and muscle 
mass and did not observe any adverse effects following this two week intervention.  
 
To fully elucidate the benefits of the current therapy in mdx mice, studies should be 
conducted to further examine ventilatory capacity during maximal respiratory 
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activity to determine if breathing is restored across the ventilatory range. 
Recordings of diaphragm EMG and trans-diaphragmatic pressure in vivo would be 
useful in assessing if ventilatory drive and diaphragm mechanics are altered across 
ventilatory and non-ventilatory behaviours following xIL-6R and Ucn2 treatment. 
Similarly, assessment of the force-frequency relationship of sternohyoid and 
diaphragm muscle ex vivo following drug intervention would be useful to determine 
the frequency range in which force generating capacity is improved. Upper airway 
collapsibility should be determined in mdx mice following co-treatment. Further 
examining the benefits of combinational therapy on upper airway physiology will be 
useful in assessing if this therapy promotes improved control of the upper airway in 
mdx mice. 
 
Additional work should be undertaken to examine the precise signalling 
mechanisms of xIL-6R and Ucn2 intervention on mdx sternohyoid and diaphragm 
muscle, underpinning alleviation of respiratory muscle deficits and ventilatory 
dysfunction in mdx mice. Such pathways should be further interrogated in the 
search of therapies for DMD. Studies examining IL-6R signalling blockade and Ucn2 
should be examined in more severe models of dystrophic mice, such at the 
mdx/utrophin double knockout mouse.  
 
7.10 Towards combinational pharmacotherapy for the treatment of respiratory 
dysfunction in DMD 
In summary, studies of dystrophic respiratory muscles from mdx mice indicate 
functional deficits with implications for the maintenance of upper airway calibre 
and ventilation. Our interventional studies in mdx mice provide a rational basis for 
consideration of combinational pharmacotherapy for DMD, with a combined 
treatment intervention in the current studies yielding the most promising results, 
compared to either treatment alone. Our studies support the use of anti-
inflammatory and anti-stress interventions as adjunctive therapies in the treatment 
of respiratory system deficits arising from dystrophin deficiency and associated 
pathology. These studies have relevance for the development of 
pharmacotherapies in DMD, which aim to improve respiratory performance.  
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Chapter 8. Summary and conclusion 
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8.1 Summary of major findings 
Respiratory muscle weakness and decreased ventilatory capacity occurs in 
Duchenne muscular dystrophy (DMD) patients with attendant systemic and muscle 
inflammation. Respiratory failure is a leading cause of death in DMD. This thesis 
addresses knowledge gaps relating to dystrophin deficiency and respiratory control 
in a murine model of DMD, the mdx mouse. Studies were performed to explore 
deficits and intrinsic compensatory mechanisms within the integrated respiratory 
control network of young (8 week old) mdx mice.  
 
We reveal considerable deficits within this network, which have major implications 
for the control of breathing in young mdx mice. Profound diaphragm muscle 
weakness was confirmed in our studies and was associated with considerable 
muscle fibre remodelling, including increased co-efficient of variation of muscle 
fibre size, immune cell infiltration, muscle fibre central nucleation and altered 
distribution of myosin heavy chain isoform composition (increased type IIa and 
decreased IIx). Plethysmography studies in conscious mice indicate tidal volume 
deficits resulting in reduced minute ventilation; carbon dioxide production was 
unchanged. The ventilatory equivalent for carbon dioxide was reduced in mdx, 
indicating hypoventilation during normoxia, which likely related to sensory deficit in 
the peripheral control of breathing and/or mechanical disadvantage due to 
diaphragm muscle weakness (reduced force in 40-160Hz frequency range). 
Dystrophin is expressed in the carotid body (principal oxygen sensor), and carotid 
bodies from mdx mice have a blunted response to hyperoxia, indicating carotid 
body hypoactivity (sensory deficit). Decreased chemoafferent input to the 
cardiorespiratory integrative sites of the central nervous system, could indeed 
contribute to hypoventilation in mdx mice, given the physiological contribution of 
the peripheral oxygen sensors to eupnoeic (basal) ventilation. The carotid body, 
ventilation and metabolic response to hypoxia were equivalent in wild-type and 
mdx mice. Arterial blood gas analysis suggested a compensated respiratory acidosis 
in mdx mice.  
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Conversely, we highlight evidence of compensatory mechanisms, which may serve 
to limit respiratory deficits in mdx mice. Ventilatory capacity in response to 
maximal chemostimulation and peak inspiratory oesophageal pressure during 
baseline and chemoactivation are preserved in mdx mice, in the presence of a 
weakened diaphragm. Interestingly, peak sub-atmospheric pressure during an 
augmented breath (considered near maximal respiratory muscle activation) is 
greater in mdx mice compared with wild-type, while diaphragm EMG activity was 
equivalent in wild-type and mdx mice. In conscious mice, the volume of augmented 
breaths was equivalent between wild-type and mdx. Increased inspiratory pressure 
generation in mdx mice with a profoundly weak diaphragm muscle, suggests 
enhanced accessory respiratory motor drive. A phenomenon of enhanced motor 
output and recruitment of accessory respiratory muscles in mdx mice, could act to 
preserve or limit ventilatory deficits. The cervical spinal cord (C3-5 region), which 
contains the phrenic motor nucleus, was examined in wild-type and mdx mice and 
monoamine concentrations were determined.  NA and 5-HT were increased in the 
cervical spinal cord of mdx mice, suggesting altered neuromodulatory tone. EMG 
recordings assessing neural drive to the diaphragm in anaesthetised vagotomised 
mice, revealed enhanced neural drive to the diaphragm in mdx mice during 
maximal chemoactivation compared with wild-type, suggesting compensatory 
neuroplasticity acting to increase motor output to the diaphragm muscle, in turn 
facilitating ventilation. Of note, however, potentiated diaphragm EMG was not 
observed under all experimental conditions.  
 
Analysis of breathing variability indicated no perturbed respiratory rhythm 
generation in mdx mice. Investigations examining the density of activated 
astrocytes and microglia and pro-inflammatory gene expression in the cervical 
spinal cord of mdx mice highlight no evidence of neuroinflammation in §putative 
phrenic motor nucleus. 
 
Collectively, these data describe deficits at multiple sites of the respiratory control 
network at a young age in mdx mice. In stark contrast, our data also reveal altered 
neuromechanical coupling in mdx mice revealing compensatory mechanisms, which 
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evidently protect ventilatory capacity despite diaphragm muscle dysfunction. 
Studies providing mechanistic insight into the intrinsic compensatory mechanisms 
in mdx mice are important for interventional strategies and adjunct therapies 
aimed at improving respiratory performance in mdx mice and human 
dystrophinopathies.  
 
Inflammation is a major pathological feature of DMD due to dystrophin deficiency 
and resultant muscle damage. Inflammatory mediators such as cytokines and 
chemokines are elevated in plasma and muscle samples from DMD patients and the 
mdx mouse. Histological studies show there is considerable inflammatory cell 
invasion in dystrophic muscle fibres and a progressive accumulation of connective 
tissue and adipocytes following muscle fibre necrosis.  
 
In additional studies, we examined a combinational treatment strategy aimed at 
alleviating respiratory muscle deficits and improving respiratory performance in 
mdx mice. This intervention consisted of neutralizing interleukin-6 receptor 
antibodies and urocortin 2, a corticotrophin releasing factor receptor 2 agonist. This 
combinational therapy had previously been shown by our research group to 
improve diaphragm muscle strength in mdx mice. We repeated this intervention 
and extended studies to breathing and metabolic measurements, diaphragm 
muscle structure and fibre type composition, and cytokine concentrations. In 
concert, we examined the skeletal musculature of the upper airway, which has 
relevance for the physiological control of upper airway patency and airway 
clearance. This involved examination of sternohyoid muscle (representative 
pharyngeal dilator) form and function.  
 
Two weeks of blocking interleukin-6 receptor signalling with neutralizing antibodies 
and stimulating corticotrophin releasing factor receptor 2 with urocortin 2, resulted 
in considerable improvements in respiratory function and diaphragm muscle 
health. Breathing and diaphragm muscle deficits were alleviated following 
treatment, with minute ventilation restored in mdx mice following treatment. 
Diaphragm muscle fibre complement was restored, with a reduction in myosin 
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heavy chain type IIa and an accompanying increase in type IIx. Pro-inflammatory 
cytokines were increased in the diaphragm from mdx mice, and treatment 
decreased the pro-inflammatory cytokine interleukin-1E and increased the anti-
inflammatory cytokine IL-10 in mdx diaphragm. Type I and III collagen was 
increased in mdx diaphragm, along with muscle fibre central nucleation (indicator 
of muscle fibre damage), and immune cell infiltrates; all indices were unaffected by 
treatment.  
 
In addition to the diaphragm, considerable mechanical dysfunction and motor 
deficits have been reported in the sternohyoid muscle of mdx mice. Force- and 
power-generating capacity is severely compromised in mdx sternohyoid. 
Alterations in myosin heavy chain isoform distribution is apparent, with a reduction 
in type IIb fibres and an increase in IIx in mdx muscle. Immune cell infiltrations, 
muscle fibre central nucleation, collagen content and chemokine concentrations 
are increased in mdx sternohyoid muscle compared to wild-type. Combinational 
pharmacotherapy restored sternohyoid muscle force-, work- and power-generating 
capacity to wild-type levels. Myosin heavy chain isoform composition was restored, 
with a reduction in type IIx and a concomitant increase in IIb. Treatment decreased 
central nucleation in mdx sternohyoid, indicating reduced fibre damage. Cell 
infiltrates and collagen content were not affected by treatment.  
 
Collectively, these findings reveal the potential for a combinational approach of 
anti-inflammatory and anti-stress interventions in alleviating respiratory deficits 
and improving respiratory performance in mdx mice. Combinational therapy studies 
have relevance for the development of new pharmacotherapies in the treatment of 
DMD. 
 
  
  293 
8.2 Future studies 
Whilst we have examined many aspects of the control of breathing in mdx mice, 
there are still many questions that remain to be addressed. Longitudinal studies 
tracking ventilatory capacity as a function of age and disease progression in mdx 
mice would allow for a better understanding of ventilation over the entire time 
course of the disease. Contemporaneous recordings of breathing and respiratory 
muscle EMG activity in conscious mice across the sleep wake cycle would provide a 
comprehensive assessment. 
 
Assessment of trans-diaphragmatic pressures are required in mdx mice to fully 
examine diaphragm contractile strength in vivo across ventilatory and airway 
protective behaviours, and during maximal activation with bilateral phrenic nerve 
stimulation. To fully examine the phrenic motor neuron pool, retrograde labelling 
should be performed and motor neuronal counts examined. Phrenic nerve 
recordings in reduced preparations would provide information on motor output to 
the diaphragm muscle. Since alterations in axonal counts have been observed in 
dystrophic nerves, it will be important to assess phrenic nerve morphometry in 
wild-type and mdx mice. It is clear from the current thesis that compensatory 
mechanisms are at play in the respiratory control network of mdx mice. Discerning 
the precise locus and exact mediators of this compensation will be pivotal in future 
work if these findings are to be of translational value.  
 
Studies should further examine neuro-immune interactions and monoamine 
concentrations and receptor expression at sites of the respiratory control network, 
such as pattern generating sites, key integrative centres such as the nucleus tractus 
solitarius (NTS), and at the level of key respiratory motor nuclei in the brainstem 
and spinal cord. Recordings of fictive respiratory neuronal discharge in brainstem 
slice preparations would determine if central pattern generation was affected by 
dystrophin deficiency in developing mdx mice. Since we report a sensory deficit 
within dystrophic carotid bodies, it would be interesting to ascertain if sensory 
processing in the NTS is altered in mdx mice. Studies examining the motor 
pathways of accessory respiratory muscles in mdx mice are paramount to further 
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understand respiratory control and compensation in mdx mice. Of particular 
interest, the intercostal and abdominal muscles should be examined to determine 
the putative compensatory role that they play in preserving ventilatory capacity in 
mdx.  
 
Given the prevalence of sleep disordered breathing and obstructive sleep apnoea in 
DMD, studies are required to determine if motor control of the upper airway is 
affected by dystrophin deficiency. EMG recordings of the genioglossus muscle 
(pharyngeal dilator) or hypoglossal nerve activity would help determine if neural 
drive to the upper airway is altered in mdx mice. Moreover, an examination of the 
hypoglossal motor nucleus for neuroinflammation and monoamine concentrations 
is required. It is necessary to reveal if there are deficits or compensation in the 
motor control of the upper airway in mdx mice, to fully reveal all consequences of 
dystrophin deficiency on the control of breathing. Furthermore, since sleep 
disordered breathing and hypoxaemic periods occur in patients, it would be 
interesting to examine the consequences of intermittent hypoxia (modelling sleep 
disordered breathing) on respiratory control and respiratory muscle form and 
function in mdx mice. Such studies would draw focus to the potential concern that 
sleep disordered breathing exacerbates respiratory morbidity in DMD. It is also 
important in future work to determine if low dose therapeutic intermittent hypoxia 
is efficacious in boosting respiratory motor outputs facilitating breathing in mdx 
mice with potential application to DMD. 
 
Given that deficits are present at multiple sites within the respiratory control 
network, there is an argument in support of the pharmacological use of respiratory 
stimulants to enhance ventilation and potentially alleviate respiratory dysfunction 
in mdx mice. There is a remarkable capacity for plasticity within the respiratory 
control system. Studies exploring if there is a capacity for plasticity within the 
respiratory control network of mdx mice are necessary. Harnessing respiratory 
plasticity and motor facilitation in animal models of motor neuron disease and 
spinal cord injury have proved beneficial for improving ventilatory capacity. Motor 
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facilitation of the diaphragm and accessory respiratory muscles may have potential 
for enhancing ventilation in animal models of DMD. 
 
Although the mdx mouse has had a fundamental role in understanding the 
pathophysiology of DMD and the assessment of therapeutic interventions, studies 
in models closer to human DMD are required, such as the golden retriever and 
porcine models. This is of particular importance for the clinical translation of 
therapeutic interventions. 
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8.3 Conclusion 
We conclude that respiratory control is altered in mdx mice – a murine model of 
Duchenne muscular dystrophy. Dystrophin deficiency in mdx mice results in deficits 
in respiratory muscle, breathing and sensory control. Compensation within the 
respiratory control system includes altered neuromechanical control of breathing 
which facilitates greater inspiratory pressure generation in mdx mice during near 
maximal ventilatory behaviours, despite profound diaphragm muscle weakness. A 
combinational drug therapy targeting anti-inflammatory and anti-stress pathways 
improves respiratory performance in mdx mice. These data have relevance for the 
development of interventional strategies in DMD.  
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